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Inflammatory bowel disease (IBD) causes inflammation in any part of 
gastrointestinal (GI) tract and the main reason for the occurrence of this disease is not still 
known. The main obstacle with the drug therapy for IBD is the dependency of the treatment 
to the severity of the disease and drug targeting which make the drug therapy controversial. 
Cell-based systems have been proposed to improve the drug targeting and release while 
healing the damaged epithelium in IBD. Organoids have been proposed in this study as 
source of cells that can facilitate regeneration and entrap drugs. Organoids are bud-like 
structure that are formed from intestinal stem cells (ISCs) and can target the inflamed area 
while releasing the drug at the site of action and regenerating the inflamed tissue. The focus 
of this dissertation is the evaluation of the organoid ability to entrap the drug-loaded 
nanoparticles and the organoid’s ability to heal the inflammation. 
It was shown that organoids can entrap PLGA nanoparticles in a timely manner and 
pump out the nanoparticles after a certain time. Negatively charged 5-ASA loaded PLGA 
nanoparticles coated with alginate were made. It was shown that mixing nanoparticles with 
organoid suspension and Matrigel could enhance the nanoparticle entrapment.  It was also 
confirmed that PLGA nanoparticles did not impose any harmful effect on the organoid’s 
viability and growth.  Moreover, the effect of differently-charged particle surface on the 
entrapment have been evaluated using negatively charged alginate and positively charged 
chitosan coated PLGA nanoparticles. It was shown that organoids had more affinity to 
positively charged particles resulting in more particle entrapment. Neither alginate nor 
chitosan coating were harmful for the organoids in terms of growth and viability.   
 
xiv 
Based on what has been observed in these studies, more attempt was directed 
towards in vivo evaluation of the delivery system and the systems application to treat 
inflammation. To apply this system rectally, distal colon was the target and thus, colonic 
organoids needed to be developed. Colonoids with different media were cultured and 
none of the media formulations supported promising growth. Thus, intestinal homogenate 
was added to the system to provide enough growth factors for Wnt signaling. Colonoids 
grown with homogenate could grow into a 3-dimensional structure and showed enough 
proliferation and differentiation. Colonoids could survive for more than 6 passages while 
staying functional. As the next step, In vivo experiments using colonoids were performed. 
Mice were treated with 3% dextran sodium sulfate (DSS) for 5 days and 1.5% DSS for 2 
days and this treatment provided lesions of distal colon. colonoids transplantation to 
inflamed colon tissue was evaluated as the next experiment and to determine the effect of 
IL-10 (interleukin-10) on healing after inflammation, IL-10 positive and IL-10 negative 
colonoids were transplanted to inflamed tissue. Colonoid infused mice showed superior 
epithelial regeneration compared to DSS treated mice without colonoid infusion showed 
in colonoscopy images. Moreover, IL-10 positive colonoids significantly increased 
healing and it was a confirmation of the effect of IL-10 on healing. Despite the great 
findings, there are still many quantitative analyses need to be performed to confirm the 
qualitative results attained from colonoscopy.
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 INTRODUCTION 
Drug therapy for the treatment of inflammatory bowel disease (IBD) has not been 
efficient due to the dependency of the treatment to the severity of the disease as well as the 
problems with drug targeting. Cell-based treatments have been proposed in order to improve 
the tissue regeneration, drug targeting, and drug release. Organoids have been proposed in this 
study as a source of cells for healing after regeneration and a drug delivery carrier. The focus 
of this dissertation is the evaluation of the organoid ability to entrap the drug-loaded 
nanoparticles while healing the damaged tissue. 
The fundamentals behind the organoids, the source of organoids and the structure of 
epithelial layers have been discussed. Moreover, the organoid formation as well as the different 
pathways for stem cell homeostasis have been delineated. IBD as a prevalent gastrointestinal 
(GI) disease has been presented and its different categories, symptoms and treatments have 
been discussed in detail. 
 Cell-based treatments as a new technology for IBD has been discussed. Organoids 
were introduced as a new candidate for cell-based targeting and regeneration in IBD. 
Organoids due to their ability to entrap small particles (scale of nanometer), target to the 
inflamed region, and stem cell proliferation were selected and discussed in IBD condition. 
Gastrointestinal tract 
GI tract is a complex organ extending from mouth to anus composed of different parts 
with diverse functions including ingestion (food is consumed), digestion (food is broken by 
chemical and mechanical mechanisms), nutrient absorption (digested food is distributed to the 
cells via cardiovascular and lymphatic systems), and excretion of waste (indigestible food is 
removed from body).(1, 2) Foods are passing the hollow core or the lumen of GI tract which 
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is covered by a layer of epithelium.(2) Beneath the mucosal layer of the epithelium are two 
muscle layers, inner and external, both containing smooth muscle cells (SMCs), albeit in 
different orientation. Their main function is the support of intestinal peristaltic function.(3)   
The small intestine and colon are two major sections of the intestinal tract, and form 
the lower part of the GI tract.(1) The epithelial structure and cellular composition are different 
in small intestine and colon.(4)  
Small intestinal structure 
Because of its finger-shaped villi structures, the small intestinal epithelium has a large 
surface area (Figure 1.1A). This enlarged surface facilitates absorption of great quantities of 
substances such as nutrients, electrolytes and water.(5, 6) Colon lacks villus and is composed 
of a flat mucosal surface which facilitates the stool excretion from large intestine.(4) A layer 
of differentiated epithelium covers the villus in small intestine or flat surface of colon, 
extending over blood and lymph vessels that absorb the nutrients. The cavities between villi  
or alternatively between flat surfaces in colon are called crypts of Lieberkühn and lie beneath 
the mucus layer.(6) Intestinal epithelium has the highest self-renewal rate among all the tissues 
because of stem cells that are located at the bottom of the crypts. The villus-crypt structure of 
the small intestine and the presence of crypt alternatively in colon act in an orderly manner to 
impart different functions onto the differentiated cells. Stem cells residing at the bottom of the 
crypts constantly proliferate into daughter cells, then differentiate, and migrate to the top of 
the villus or to the flat surface in colon case, then die and are shed.(7)  
Various types of differentiated cells exist in the small intestine each having a distinct 
functionality. Absorptive enterocytes, monolayer polarized epithelial cells, comprise most of 
the brush border structure of the gut epithelium. It takes ~3–4 days for the absorptive cells to 
migrate from the crypt to the villus tip before they can reach the tips of the villi.(8) Enterocytes 
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are responsible for the release of digestive enzymes as well as controlled antigen uptake and 
processing by endocytosis. They act as a diffusion barrier, with the help of mucus layer 
secreted by Goblet cells, the second category of differentiated intestinal epithelial cells.(1, 9) 
The volume density of goblet cells in the villi increases in the small intestine, from the 
duodenum to the distal ileum, although it is constant in crypts across the entire length of the 
intestine. As a result, mucin (mucus glycoprotein) secretion differs in different parts of the 
intestine.(10) Enteroendocrine cells are differentiated cells that are located in deeper half of 
the mucosa. They are sparse and, therefore, are isolated from one other.(11) Their most 
important function is the secretion or export of hormones such as serotonin or somatostatin.(1, 
9, 11) Tuft cells are the next type of cells that are detected by their long and blunt microvilli 
on their surface as well as numerous vesicles in their apical cytoplasm.(12) Tuft cells are 
chemosensory cells that are defending against helminths (worm-like parasites).(4) M cells are 
located between enterocytes. As an epithelial cell type, M cells have role in transcytosis of 
microorganisms, macromolecules, and particles from the lumen into the Peyer's patches. The 
M cell’s apical surface facilitates endocytosis, and the invagination of their basolateral surface 
shortens the distance that transcytosis vesicle needs to travel. Invagination of the M cells results 
in the epithelial pocket formation which is the location for immune cells deployment. (13) 
Thus, luminal antigens can be delivered to the immune system by M cells.(4)  Paneth cells 
comprise the last important type of differentiated cells. They are different from the other groups 
in that upon differentiation they migrate downward to the crypt, where they can remain for 
almost 23 days before removal by phagocytosis.(9) Many important roles are attributed to 
Paneth cells, with secretion of antimicrobial peptides helping body’s defense system as the 
most significant one. Maintaining the intestinal microbiota homeostasis and nourishing stem 
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cells of the small intestine are their other important functions.(14) The structure of the small 
intestinal and colonic epithelium are shown in Figure 1.1. 
 
Figure 1.1 (A) Scanning electron micrograph of small intestine (left panel). Villis-crypt 
structure is shown in the picture. The right panel represents the schematic of finger like 
structured human intestinal tissue containing stem cells and paneth cells residing at the bottom 
of the crypt and differentiated cells (Enterocytes, Goblet cells and enteroendocrine cells) 
locating at the epithelium of villus. Stem cells by proliferating and migrating upward, 
differentiate into intestinal differentiated cells.(15) (B) Scanning electron micrograph of colon 
(left panel). The right panel represents the schematic of flat surface of colon to facilitate waste 
excretion and alternative valley of crypts. The colon epithelium includes stem cells at the 
bottom of the crypt and daughter cells which differentiate into absorptive enterocytes 
(colonocytes), enteroendocrine cells, tuft cells, and goblet cells.(15) 
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Colon structure 
The majority of the colonic epithelium cells are the same as small intestine (Figure 
1.1B). Enterocyte also called colonocytes, goblet cells, enteroendocrine cells and tuft cells are 
existed in colon epithelium with almost the same function. The colonic epithelium, however, 
lacks Paneth cells and M cells.(4) The number of goblet cells are higher in colon compared to 
small intestine to facilitate the rapid excretion of stool.(15) In both small intestine and colon, 
intestinal stem cells (ISCs) play an important role in proliferation and differentiation into the 
epithelial cells.  
Intestinal stem cells and organoid structure 
As has been illustrated (Figure 1.1 and Appendix A), tissue-specific stem cells reside 
in most tissues and are recognized by their ability of self-renewal and differentiation into 
particular cells in that organ.(16) High turnover rate of the small intestinal epithelium (~3–4 
days) in comparison with other mucous layers encourages researchers to consider the existence 
of a source of stem cells with an ability to differentiate into all types of intestinal epithelial 
cells.(17, 18) Cheng and Leblond first proposed the existence of stem cells at the base of the 
crypts and introduced the term Crypt-Based Columnar (CBC) stem cells.(7) CBC cells are at 
the origin of the differentiating process. As is shown in Figure 1.1A, CBC cells residing among 
Paneth cells start to divide into daughter cells (TA cells) which progressively transit into 
differentiated cells. As the cells move upward through the crypt, their modality changes from 
progenitor to differentiated cells until the crypt-villus junction where two major categories of 
epithelial lineage cells, absorptive and secretory lineages, exist. Enterocytes are included in the 
absorptive lineage, and goblet, enteroendocrine cells and tuft cells belong to the secretory 
lineage. Paneth cells are also members of the secretory lineage, however, they are located at 
the bottom of the crypt.(16) Hans Clevers was the one who in 2007 recognized G protein-
6 
coupled receptor with leucine rich-extracellular domain (LGR5) as a marker of CBC cycling, 
and LGR5+ CBC cells as small intestinal stem cells.(19) Moreover, it has been speculated that 
in addition to LGR5+ CBC and TA amplifying cells, a specific type of stem cells is located at 
+4 position (shown in Figure 1.1A) above the Paneth cells, that is entirely different from 
LGR5+ CBC cells.(19) These +4 cells are also known as DNA label-retaining cells ( after 
irradiation and pulse labeling with 5-bromodeoxyuridine (BrdU)) with several markers 
attributed to them including Bmi-1, Hopx, mTert, and Lrig1.(7, 20-23) Actually, little 
information is available concerning their culture and microenvironment, but more focus is on 
LGR5+ CBC cells.(7)  
 
Figure 1.2 Major pathways necessary for the homeostasis of LGR5 Crypt-Based Columnar 
cells (CBCs). Wnt, Notch and epidermal growth factor (EGF) signaling, which are originated 
from Paneth cells, by affecting their receptors maintain the stemness of LGR5 CBC. Bone 
morphogenetic protein (BMP) located at the surrounding environment and the effect of Wnt 
signaling. 
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It has been reported that ~15 LGR5+ CBC cells are present in every murine crypt, and 
that within a timescale of 24 h, each LGR5+ CBC cell differentiates into 16–32 epithelial cells, 
via TA cells.(7) The homeostasis and fate of LGR5+ CBC cells are directly related to their 
niche or microenvironment.(16) Some major pathways that regulate the stemness or 
differentiation of stem cells will now be briefly delineated (Shown in Figure 1.2). One of the 
most significant pathways is Wnt signaling that plays an important role in maintaining the 
undifferentiated state of stem cells.(24) Wnt signaling is amplified by R-spondin family 
proteins (Wnt agonists) that themselves are activated by LGR5.(16) When Wnt signaling is on, 
Wnt ligands attach to the receptors of Frizzled family and a member of the LDL receptor 
family, Lrp5/6 which leads to accumulation of β-catenin inside the nucleus as a result of an 
intracellular signaling cascade.(25) T-cell factor (Tcf)/β-catenin transcription is a significant 
element of stemness maintenance. Moreover, Wnt signal is also responsible for the terminal 
differentiation of Paneth cells.(24)  
A second major pathway is the Notch pathway. Notch signaling plays two important 
roles in the intestine. First, it affords negative regulation that inhibits differentiation of stem 
cells and, as a result, maintains their stemness. Second, it promotes unidirectional cell 
differentiation, controlling the absorptive to secretory lineage ratio. This regulation occurs 
because of cell-to-cell signaling. Delta-like or Notch ligands of Paneth cells (DLL1 and DLL4) 
receive Notch signal from the adjacent CBC cells and bind to the Notch receptor on the cell 
surface. Upon this binding, proteolytic cleavage results in shedding of extracellular domain of 
receptor and the release of Notch intracellular domain (NICD), NICD translocation to the 
nucleus and mediates subsequent gene expression in collaboration with the transcription 
factors CSL and Hif1a, with cell differentiation, proliferation or maintenance of stemness and 
8 
survival as the final outcome. This process may inhibit differentiation of CBC cells.43 Loss of 
contact between DLL1 ligand-containing Paneth cells and daughter cells results in daughter 
cell differentiation.(7) It can be noted that lateral inhibition is responsible for this type of 
differentiation. As a result of lateral inhibition, Notch activation leads to Notch ligand 
production. Thus, lower Notch activity accompanies higher Notch ligand concentrations, and 
higher ligand concentrations lead to increased Notch signaling in proximal cells and, 
subsequently, reduce the amount of neighboring cell ligands. Decreasing the neighboring cell 
ligands leads to increase in the original cell ligands to a greater extent than upon initial 
activation and thus, the differentiation fate of two neighboring cells are different. Notch-high 
progenitor cells differentiate into enterocytes and, therefore, their neighboring cells will 
become secretory cells.(16)  
Bone morphogenetic protein (BMP) signaling comprises another regulatory pathway 
in differentiation of stem cells to epithelial layers. By binding to type-II receptor, BMP recruits 
type-I receptor that transfers signal to the nucleus by Smad transcription factors and has a role 
in differentiation. However, Noggin (Nog), an extracellular protein, antagonizes the BMP 
signal and inhibits its activity, leading to the formation of crypt like-structures among villi.(17)  
Epidermal growth factor (EGF) is activated upon binding to its receptors on the cell 
surface, normally EGFR (epidermal growth factor receptors), enhancing cell proliferation.(26) 
Thus, EGF binds EGFRs of ISCs and TA cells and causes them to divide into the same stem 
cells.(7) 
Considering the fact that stemness of LGR5+ CBC cells strongly depends on the niche, 
there should be an element in the intestine that controls the microenvironment and accordingly 
manages the signaling pathways. Researchers have demonstrated that the presence of Paneth 
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cells adjacent to LGR5+ CBC cells is of great importance for maintaining CBC cell’s proper 
condition to stay undifferentiated. Paneth cells secrete EGF and Wnt3 in addition to their 
bactericidal peptides. Production of Notch ligands Dll1 and Dll4 comprises another role of 
Paneth cells. To conclude, Paneth cells are considered a niche-controlling element and the 
interaction between Paneth and LGR5+ CBC cells is critical for cell fate. Moreover, in order to 
gain the full characteristics of stem cell niche, BMP and R-spondin, are provided by non-
Paneth cells sources.(7)   
Understanding stem cell homeostasis, the effect of different elements on their 
differentiation, and, generally, stem cells biology, as well as their potential therapeutic 
applications require long term ex vivo culturing. However, it is generally agreed that 
conventional long-term culture of adult tissues is not feasible.(24) Although a lot of effort has 
been dedicated toward identifying culture conditions appropriate for ISC culture, only short 
term maintenance of cells, ~2–4, weeks could be achieved.(27-29) Finally, in 2009, Sato 
succeeded in developing a culture system for maintaining viable cells for over 1.5 years.(30) 
Sato simply assumed that inclusion of all the elements important for stemness maintenance in 
the culture system, i.e., Wnt signaling, R-spondin-1 (Wnt agonist), EGF, and Nog (BMP 
inhibitor) would aid cellular survival and prepare similar condition to natural biology of human 
intestine for stem cell maintenance. Moreover, cell detachment from their extracellular matrix 
(ECM) may results in lack of proliferation. Therefore, a similar matrix to the ECM was 
designed for the cells to reside in. Because of a high laminin (α1 and α2) content of the crypt 
base, laminin-rich Matrigel was proposed as a matrix.(30) Under the stated conditions, a single 
LGR5+ stem cell of small intestine can be used to generate intestinal epithelium that would 
mimic normal intestinal epithelium. The resulting organoid structure consists of several crypts, 
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presented as buds around a hollow cyst, and villus like epithelium located between the crypts. 
The crypts contain LGR5+ stem cells in addition to adjacent Paneth cells and TA proliferating 
cells that are located at crypt necks. Over the course of 5 days, stem cells at the bottom of the 
crypts differentiate, move towards the cyst, and finally shed into the hollow cyst.(24) The 
organoid structure is shown in Figure 1.3. Upon culturing a stem cell, a symmetric cyst 
containing stem cells forms. After 2–3 days, by the effect of Paneth cells, Wnt signaling is 
initiated and  the presence of R-spondin make the signaling focal.(7) It is interesting that just 
as in a normal crypt-villus structure, EphB/EphrinB interaction underlies bud formation in 
organoid structures. Eph receptors are a family of tyrosine kinase receptors that specifically 
bind Ephrin ligands. Repulsion is a consequence of Eph-Ephrin interaction in cell-cell 
interactions. Paneth cells express EphB3, a Wnt target gene. When TA cells differentiate, they 
travel upstream of Wnt gradient from the crypt to the villus and, therefore, express 
EphrinB1.(31)  
 
Figure 1.3 Organoid structure containing all types of differentiated cells in addition to Crypt-
Based Columnar cells (CBCs). CBCs located at the buds of organoid. At the end of the 
differentiated cell life span, cells shed off into the lumen of organoid (process called 
Anoikis).(24) (Reproduced with permission from M. Leushacke, et al., Gut, 2014, 63, 1345–
1354. Copyright 2014: BMJ Publishing Group Ltd and the British Society of Gastroenterology) 
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Regarding focal Wnt signaling and the subsequent Eph/EphrinB repulsion, crypts 
containing stem and Paneth cells are repelled from the cyst and buds are generated (Figure 
1.4).(7)  
 
Figure 1.4 Bud formation in the organoid structure. Focal Wnt signaling by Paneth cell (blue 
parts) results in EphB expression and bud formation because of the repulsion between EphB 
and EphrinB ligand.(7) (Reproduced with permission from T. Sato, et al., Science, 2013, 340, 
1190–1194. Copyright 2013: American Association for the Advancement of Science) 
 
There were some important findings in Sato’s experiment.(30) First, although LGR5+ 
cells are not dependent on the submucosal layer beneath the epithelial layer, some important 
growth factors were required for cell survival. Furthermore, it is possible to prevent cell 
apoptosis (anoikis) by using Rho-associated protein kinase (ROCK).(30) Despite the 
conclusion of Garabedian in 1997 that Paneth cells are not needed in a stem cell niche, Sato 
did not focus on the effect of Paneth cells on LGR5+ cell culture in 2009.(30, 32) Nevertheless, 
in 2010 Sato proved that a direct physical contact between Paneth cells and stem cells initiates 
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Notch signaling.(33) Moreover, Paneth cells are responsible for EGF and Wnt3 support. It is 
true that Wnt may originate in cells other than Paneth cells, however, it has been confirmed 
that R-spondin amplifies Paneth cell’s local Wnt signaling. Localized Wnt signaling of Paneth 
cells also affects the asymmetrical crypt-villus construction in organoids.(33) In comparison 
with 15 LGR5+ stem cells, there are ~10 Paneth cells in each crypt. Therefore, because of the 
fewer number of Paneth cells, stem cells should compete for their niche, and, according to the 
“neutral competition model”, the number of stem cells remaining in the crypt is related to the 
size of Paneth cell surface area.(6) It has been observed that the lack of Notch signaling leads 
to the formation of Paneth cells capable of Wnt signaling and to the production of more Paneth 
cells and stem cells. Therefore, this would be a positive feedback loop for increasing the 
number of stem and Paneth cells.(6) However, this signaling pathway should be balanced to 
prevent the ever-expanding cryptal growth. An investigation by Koo (2012), showed that 
RNF43 and ZNRF3, Wnt signaling inhibitors, limit the crypt size by affecting Frizzled 
receptors (G protein-coupled receptors in Wnt signaling pathway).(34) Other reports also 
demonstrated the effect of Lrgi1 (leucine-rich repeats and immunoglobulin-like domains 
protein 1), a +4 stem cell marker, on stem cell proliferation and crypt homeostasis. Lrgi1 was 
inversely related to the amount of protein and the activity of receptors like Erb B family and 
prevented ISC over-expansion by interacting with them.(35) Long-term organoid culture, with 
some alterations, was also successfully conducted with human GI epithelium.(36, 37)  
In conclusion, culturing ISCs for long-term use as organoids has been successful. 
Therefore, there is great hope in the application of ISCs for different medical purposes 
including microbial experiments and toxicological investigations of different GI tract diseases 
and, employing organoids as disease models.(37) There is also a great potential for using 
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organoid structures in the pharmaceutical field, for instance, for drug screening and drug 
targeting to treat specific diseases of the GI tract.(15) Moreover, mild GI tract biopsy and 
culturing of the extracted tissues would render organoids an effective tool to be used in 
regenerative medicine.(38)  
Inflammatory bowel disease 
Inflammatory bowel diseases (IBDs) belong to a group of diseases that result in the 
inflammation of any part of the GI tract.(39) In some conditions, IBD is diagnosed while 
distortion in tissue architecture or single inflammatory cells in gut is observed but, 
distinguishing between healthy and inflamed gut is not always easily achievable. Normally, 
inflammation in healthy intestine is a response to pathogens and intestine can enter the 
tolerance phase after resolving inflammation. However, in IBD condition, gut is unable to 
down-regulate the inflammatory responses and causes dysregulated immune inflammatory 
responses.(40) By different triggers, neutrophils, via diapedesis, move from the circulation 
system to the damaged tissue. They start releasing antimicrobial peptides degradative enzymes, 
chemokines, and reactive oxygen intermediates and causing more damage to the tissue. By 
activating and recruiting other immune cells, neutrophils initiate the secretion of chemokines 
and pro-inflammatory cytokines. Thus, inflammation enters more serious stage.(40) 
Ulcerative colitis (UC) and Crohn’s disease (CD) are considered as two major types of 
IBD.(40) UC refers to the relapsing non-transmural inflammation in colon that occurs in the 
inner layer of large intestine. Severity of UC can be categorized as mild, moderate, and severe 
inflammation. Bloody diarrhea, pus, and mucus movement as well as abdominal cramp are 
clinical signs of UC. Severity of disease is highly depended on the frequency and intensity of 
the symptoms.(41) CD is a relapsing transmural inflammation occurs in any part of the GI 
tract. The location of the disease highly affects the presentation of the disease.(41) In general,  
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diarrhea, fever, abdominal pain, bowel obstruction and the presence of mucus and blood are 
the clinical signs of the disease.(41, 42) Diarrhea as one of the main signs is highly detected in 
UC patients because of the leakiness of tight junctions (TJs). The connection between 
enterocytes in epithelial layers are called TJs that play a key role in paracellular transfer of 
molecules.  Tight junction proteins are subdivided into “tightening” TJs, responsible for 
intensification of the epithelial layer, and “leaky” TJs, responsible for regulating paracellular 
transfer. Inflammation highly affects cell-to-cell adhesion by disruption of epithelial barrier 
and results in loose TJs via inflammatory processes. Leakiness of epithelial barrier is a result 
of upregulation of leaky TJ proteins (such as claudin-2) and down regulation of tightening TJ 
proteins (such a claudins-3, -5, and -8). Moreover, excess number of oxidants compared to 
antioxidants results in impairment of epithelial TJs and as a result, the water flows to the lumen 
and diarrhea occurs. Neutrophils that are recruited to the inflamed region by cytokines can 
attack the microbes translocating across the leaky epithelium and simultaneously cause the 
tissue damage in IBD. (43)  
The underlying cause of IBD is still unknown. However, genetic and environmental 
factors, such as infection, smoking, stress, pollution, and diet are considered as important IBD-
predisposing factors.(42, 44) The genes that are associated with IBD mostly include NOD2, 
CARD9, and IFN-γ-regulated leucine-rich repeat kinase 2 (LRRK2), MHC, and MST1 
3p2.(45, 46) 
No cure for IBD exists. All the used agents are able to induce remission but do not cure 
the disease. The present agents can facilitate mucosal healing, decrease the oxidative agents, 
or inhibit the TJ structural changes.(43) 5-aminosalicylic acid (Mesalazine) is the most 
prominent therapy in UC. All oral and rectal Masalazine formulations and prodrugs such as 
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sulfasalazine, olsalazine and balsalazide as anti-inflammatory agents have the same effect but, 
different mechanisms in inflammation suppression. Corticosteroids such as hydrocortisone, 
budesonide, and beclomethasone can also suppress inflammation when administered rectally. 
In moderate to severe cases of UC, infliximab, a monoclonal antibody to tumor necrosis factor 
(TNF) α, can be added to the conventional treatments. In the most severe condition, which 
none of the treatments remit the inflammation, patient needs to be hospitalized and get 
intravenous corticosteroids. The worst case scenario of UC treatment is surgical resection of 
colon.(41) 
In CD treatment, however, sulfasalazine is the first therapeutic agent for mild to 
moderate cases. Mesalazine is not fully efficient in this disease treatment. Budesonide as a 
corticosteroid has shown to be effective in severe cases with less systematic side effects 
compared to oral corticosteroid formulations. Infliximab can also be used for moderate to 
severe conditions in conjunction with anti-inflammatory agents and corticosteroids.(41)  
Prescribed anti-inflammatory and immunosuppressive agents, Removal of inflamed 
intestinal tissue section and, drug delivery systems are not fully effective as treatment methods 
respectively because of dependency of curative capability related to the intensity of disease, 
imposed inconvenience to patient and obstacle of direct transport to inflamed region.(42, 47, 
48)  
Organoids in IBD 
In order to improve the drug therapy for IBD, cell-based delivery can significantly 
improve targeting at the site of inflammation with a superior controlled release.(49) Scientists 
could either attach the active agent on the surface of cells or encapsulate the drug inside the 
cells.(50) Cell-carrier would be loaded with the drug and release the drug systematically or at 
the site of action.(49) Bacteria and animal cells have been used as the carrier for drugs.  
16 
Stem cells are a category of the cells that have been used as the carrier for drug delivery. 
Stem cells with their ability of “homing” or migrating to specific areas via chemical signals 
attracts attention in targeted delivery.(51) Most of the studies on stem cells focus on the gene 
delivery ability.(52) However, there are still some research on the application of stem cells as 
the carrier without genetically modifying the cells. Marrow-isolated adult multilineage 
inducible (MIAMI) cells as a subpopulation of mesenchymal stem cells (MSCs) have been 
used to deliver the internalized poly-lactic acid (PLA) nanoparticles and lipid nanocapsules 
(LNCs) loaded with coumarin-6.(53) It has been hypothesized that MSCs can target brain 
tumors. It was demonstrated that nanoparticles and nanocapsules were successfully 
internalized by MSCs and the MSCs was distributed around brain tumor after direct injection 
to the tumor. However, the interaction between MIAMI cells and tumor cells was not 
investigated. (53) Neural stem cells (NSCs) have also been used as the oncolytic virus carrier 
in order to migrate to the brain and target the tumor tissue of gliomas. Oncolytic virus is 
engineered to replicate in tumor cells and destroy the tumor tissue. In this system, the median 
survival using the delivery system was considerably higher than using virus alone and that the 
adenovirus infected NSCs could migrate to the tumor better than unloaded NSCs due the 
increased expression of chemoattractant receptors and ability to cross the midline and migrate 
towards the tumor implanted hemisphere. However, the effect of delivery system when 
administered in a far distance from tumor has not been evaluated in this research.(54) More 
than drugs, stem cells have been widely used as the carrier for tracking and imaging agents.(55-
57) 
As intestinal organoids are initially isolated from host intestine, it would be a wonderful 
option for cell-based treatments. The lumen of the organoid is a great option for drug 
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entrapment. Organoid structure have previously been used as the carrier for nanoparticles.(58) 
Intestinal organoids have been isolated from intestinal fragments and loaded with DNA-
functionalized gold nanoparticles (GNPs) in order to investigate the entrapment of small gold 
nanoparticles (~10 nm) inside the lumen of organoids.(58) Moreover, It has been shown before 
that LGR5+ cells of organoids have the ability to target the inflammation site in dextran sulfate 
sodium (DSS) induced mouse models which makes them an ideal carrier.(38) 
Moreover, cell-based therapy can be achieved considering organoid’s LGR5+ stem 
cells. Once implanted in the tissue, stem cells present in an organoid structure can proliferate 
and differentiate which facilitates healing as a treatment for IBD. Moreover, the lesions 
associated with IBD often result in glandular dropout which indicates that there are no ISC in 
the area of the lesion.  This would make the use of organoids to deliver ISCs to the lesion 
promising. Several studies have used this ability of organoids to develop a method of treatment. 
It was shown that the transplanted colonic enteroids adhered and covered the inflamed tissue 
and after 4 weeks terminally differentiated cell types were detected in the colon of DSS treated 
mice (inflammation formed) while the epithelial barrier was maintained.(38) In a different 
study, fetal enterospheres (FEnS) were transplanted in mouse colon to induce more 
proliferation  and differentiation and start maturation in vivo. FEnS has shown to be attached 
to denuded regions of colonic epithelium and incorporated into epithelium after inflammation 
with no tumor formation while forming differentiated cells.(59) These results confirms the 
competence of ISCs in organoid structure as a candidate for helping regeneration in IBD 
condition. 
The main focus of this study is using organoids as an element that helps IBD treatment. 
First goal was using organoids as the carrier for drugs and drug loaded nanoparticles with the 
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hope of targeting to the inflamed tissue and release the drug. Two separate articles are 
presented in CHAPTER 2 and CHAPTER 3 to show the ability of intestinal organoids for 
PLGA nanoparticle entrapment. Different parameters affecting organoid entrapment have been 
discussed and tested. Nanoparticle tracking and organoid viability in contact with nanoparticles 
as well as the organoids growth over time have been detected. It is shown that nanoparticles, 
mixing with Matrigel and organoids suspension, could diffuse through the organoids after 3 or 
4 days and they were desorbed from organoids afterwards. Moreover, the surface charge of 
particles has been shown to affect the nanoparticles entrapment. Positively charged 
nanoparticles could diffuse efficiently inside the organoids. The fluorescent quantity for 
comparison of the absorbed nanoparticles inside the organoids has also been provided.  
The second goal was evaluating the healing properties of organoids. As the treatment 
area for transplantation of organoids were distal colon, colonic organoids were developed in 
CHAPTER 4. Colonic organoids were grown using intestinal homogenate and the functionality 
of cultured colonoids were tested with different functionality experiments. Colonoids that were 
grown with homogenate showed 3-dimensional structure even after six passages and functional 
by testing different transporters and tight junctions leakiness. Finally, the cultured colonoids 
were used for in vivo transplantation in CHAPTER 5. Colonoids were isolated from IL-10 
(interleukin-10) positive and IL-10 negative mice and infused into the inflamed colon of IL-
10 deficient mice to check the effect of IL-10 on epithelial regeneration in IBD condition. It 
was shown that while regeneration was occurred in transplanted tissues, IL-10 had 
considerable effect on healing properties of colon tissue. As a conclusion, using organoids can 
be helpful for IBD treatments and a combination of different directions in this study can be a 
promising finding for further research. 
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Introduction 
Tissue engineering (TE) refers to an interdisciplinary field of science that employs 
biological and engineering sciences with the aim of replacing or repairing a malfunctioning, 
missing, or injured organ.1 This approach has been proposed as an alternative to autologous or 
allogeneic grafts when these cannot be used, e.g., because of a lack of donor tissues and 
potential transmission of disease such as infection, or triggered immune response, 
respectively.2,3 Cells and scaffolds play the most significant roles in designing a tissue-
engineered organ. TE uses different cells and different scaffold materials to regenerate vital 
tissues.4 Employment of different cells is associated with different advantages. Two basic types 
of cells are being considered, parenchymal or tissue-specific cells, and progenitor cells or stem 
cells.5 On the other hand, scaffolds provide an appropriate structure for cell growth and act as 
extracellular matrix (ECM) for the incorporated cells until the formation of innate ECM by 
these cells.6–8 Moreover, scaffolds have a role in maintaining and delivering biological 
components requisite for tissue growth, such as growth factors or cytokines. 9 Therefore, 
selection of the appropriate scaffold material is essential. In addition, great effort is dedicated 
to designing 3D-structured scaffolds instead of the typical 2D scaffolds because of their 
superior capability of mimicking ECM structure.2,10  
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The engineered tissue should display the highest possible similarity to the original 
organ and, more importantly, proliferate and grow into the regenerated tissue. In order to 
improve the function of a tissue-engineered organ, different capabilities, such as gradual 
degradation and angiogenesis, added to the designed scaffold.11 Different organs are currently 
under investigation for TE, including the skin, bladder, the liver, the heart, bones, the pancreas, 
cornea, etc. 4 
 
Figure S 1.1(A) Hematoxylin and eosin staining of the human intestinal epithelium. The 
location of Stained differentiated cells (Goblet cells, Enteroendocrine cells, Paneth cells and 
Enterocytes) are highlighted.14 (Reproduced with permission from H. Clevers, Cell, 2013, 
154, 274–284. Copyright 2013: Elsevier).  (B) Schematic of finger like structured human 
intestinal tissue containing stem cells and paneth cells residing at the bottom of the crypt and 
differentiated cells (Enterocytes, Goblet cells and enteroendocrine cells) locating at the 
epithelium of villus. Stem cells by proliferating and migrating upward, differentiate into 
intestinal differentiated cells.106 (Reproduced with permission from A. J. Carulli, et al., Integr. 
Biol., 2014, 6, 243–257. Copyright 2014: The Royal Society of Chemistry). 
Gastrointestinal (GI) tract is a complex organ composed of different parts with diverse 
functions, including ingestion, digestion, nutrient absorption, and excretion of waste. The small 
intestine and colon are two major sections of the intestinal tract, and form the lower part of the 
GI tract.12 Because of its finger-shaped villi structures, the small intestinal epithelium has a 
large surface area (Figure 12.1). This enlarged surface enables it to absorb great quantities of 
substances such as nutrients, electrolytes and water.13,14 A layer of differentiated epithelium 
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covers the villus, extending over blood and lymph vessels that absorb the nutrients. The 
cavities between villi are called crypts of Lieberkühn and lie beneath the mucus layer.14 Small 
intestinal epithelium has the highest self-renewal rate among all the tissues because of stem 
cells that are located at the bottom of the crypts. The villus-crypt structure of the small intestine 
acts in an orderly manner to impart different functions onto the differentiated cells. Stem cells 
residing at the bottom of the crypts constantly proliferate, differentiate, and migrate to the top 
of the villus, then die and are shed.15 
Various types of differentiated cells exist in the intestine each having a distinct 
functionality. Absorptive enterocytes, monolayer polarized epithelial cells, are in charge of the 
brush border structure of the gut epithelium. It takes ~3–4 days for the absorptive cells to 
migrate from the crypt to the villus before they can reside at the mucus intestinal layer.16 
Enterocytes are responsible for digestion of nutrients as well as controlled antigen uptake. They 
act as a diffusion barrier, with the help of mucus layer secreted by Goblet cells, the second 
category of differentiated intestinal epithelial cells.12,17 The volume density of goblet cells in 
the villi increases in the small intestine, from the duodenum to the distal ileum, although it is 
constant in crypts across the entire intestine length. As a result, mucin (mucus glycoprotein) 
secretion differs in different parts of the intestine.18 Enteroendocrine cells are differentiated 
cells that are located in deeper parts of the mucosa. They are sparse and, therefore, localized 
far from one other.19 Their most important function is the secretion or export of hormones.12,17 
Paneth cells comprise the last important type of differentiated cells. They are different from 
the other three groups in that upon differentiation they migrate downward from the villus to 
the crypt, where they can remain for almost 23 days before removal by phagocytosis.17 Many 
important roles are attributed to Paneth cells, with secretion of antimicrobial peptides helping 
28 
body’s defense system as the most significant one. Maintaining the intestinal microbiota 
homeostasis and nourishing stem cells of the small intestine are their other important 
functions.20 The structure of the intestinal epithelium is shown in Figure 12.1. Beneath the 
mucosa layer of the small intestine are two muscle layers, inner and external, both containing 
smooth muscle cells (SMCs), albeit in different orientation. Their main function is the support 
of intestinal peristaltic function.21 
Because of the broad functionality of the intestinal tissue, its defects may compromise 
the operation of the entire body. The intestine may be affected by grave diseases. Inflammatory 
bowel disease (IBD), colorectal cancer (CRC), and short bowel syndrome (SBS) are the three 
major intestinal diseases. IBDs belong to a group of diseases that result in the inflammation of 
any part of the GI tract, including the small intestine.22 Genetic and environmental factors, 
such as infection, smoking, stress, etc., are now considered as important IBD-predisposing 
factors.23,24 Diarrhea, fever, abdominal pain, vomiting, and weight loss are diagnosed as 
clinical signs of IBD.24 No definite permanent cure for IBD exists. Prescribed anti-
inflammatory and immunosuppressive agents, Removal of inflamed intestinal tissue section 
and, drug delivery systems are not fully effective as treatment methods respectively because 
of dependency of curative capability to intensity of disease, imposed inconvenience to patient 
and obstacle of direct transport to inflamed region.24–26   CRC is another serious and 
unfortunately common disease of the GI tract.27 Environmental and genetic factors both lead 
to CRC development. CRC can be inherited, familial, or sporadic.28 Chemotherapeutic agents 
remain as the only traditional treatment, but molecular targeting agents are also being 
developed to substitute these agents to eliminate their side effects.29 SBS results from 
insufficient intestine length, as a consequence of surgical resections (e.g., tumor), neonatal 
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condition, trauma, or IBD.11,30 Intestine is the major organ of nutrient absorption and therefore, 
losing intestine during SBS results in insufficient absorption area, leading to malnutrition and, 
subsequently, weight loss. Diarrhea, electrolyte imbalance, and vitamin deficiency are other 
SBS symptoms.31 Transplantation is considered as a common method to improve the life 
expectancy in SBS patients Which is challenging because of lack of donor, low compatibility 
between the donor and the acceptor, requirement for immune suppression, high cost, and 
complexity.11 Binachi method (longitudinally dividing the bowel into two tubes) and parenteral 
nutrition are also accounted as the treatment methods. However, the efficacy of these 
approaches is disputed.11,32–34 
Different methods of curing the intestinal diseases are available, with their own 
shortcomings. To avoid surgical interventions and the risk of side effects of conventional drug 
administration, a great need exists for tissue replacement and this requirement should be met 
with the help of new methods of TE.21,34 Employing a tissue-engineered intestine would 
circumvent the disadvantages of other therapies and be a conclusive method to cure intestinal 
diseases. However, in order to prepare an effective intestine by TE, certain obstacles should 
first be overcome, including identification of the appropriate source of cells and materials.35 
An appropriate cell source should be considered before a useful tissue-engineered intestine can 
be created. Furthermore, the complicated anatomy of the small intestine renders intestinal TE 
complex.21 A thorough understanding of the different elements of intestinal TE is of great 
importance and will be required before the scientists will be able to design an appropriate 
tissue-engineered small intestine (TESI). In this chapter, different TESI components are 
described and Intestinal stem cells (ISCs) are introduced as a unique cell source for TESI. 
Moreover, as ISCs should be employed in an appropriate environment in order to regenerate 
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into the intestinal tissue, elements contributed to an efficient environment or niche of ISCs 
should be studied. The second major focus of this chapter is assigned to the two substantial 
environments that should be prepared for the ISCs in order for them to have their complete 
functionality. Two of the most significant environments, specifically chemical and mechanical 
environments, are further discussed and the connectivity between ISCs and environmental 
elements in TESI is highlighted. 
Tissue engineered intestine Components 
Cells 
Different types of cells can be used to seed the intestinal TE scaffolds (Shown in Figure 
12.2). In general, we can categorize these cells into two distinct classes: differentiated cells 
and stem cells. The most used differentiated cells possess characteristics most similar to the 
intestinal epithelial cells. Caco-2 cell line, which is derived from GI tumors, is being employed 
as the intestinal epithelial cell model in many in vitro experiments examining cell attachment, 
differentiation, and proliferation on different scaffolds36. Sposito and his research group used 
Caco-2 cells as a tool to investigate biocompatibility of hyaluronic acid (HA) ester groups as 
epithelial cell scaffolds. This resulted in greater differentiation of Caco-2 cells on 2D scaffolds 
in comparison with 3D scaffold, considering the similar surface chemistry.37 Caco-2 cell 
attachment and penetration of a composite scaffold has been reported to enhance by increasing 
the amount of HA (Figure 12.2B).37 SMCs have also been used as a differentiated cell type for 
TESI38 (Figure 12.2A) because, despite the fact that SMCs are present in different organs, their 
functionality differs depending on the tissue.39 Therefore, Nakase attempted to extract SMCs 
from the stomach wall to use as an autologous seed for collagen sponge scaffold to dampen 
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the immune reaction to tissue-engineered intestine.39 The development of a muscle layer in 
addition to a well-developed epithelial layer is a positive effect of SMC use.39  
Other promising cell sources are undifferentiated or stem cells.40 The two main 
characteristics of stem cells are their prolonged proliferation as well as their capacity to 
differentiate into one, multiple, or several cell types.41 Adult tissue-specific or organ-specific 
stem cells are multi-potent cells that can differentiate into multiple cell types. Mesenchymal 
stem cells (MSCs) are a specific type of adult stem cells which are normally present in 
connective tissues.40 The ability of MSCs to differentiate into multiple types of cells and easy 
culture render them a remarkable cell resource for TE.42 For these reasons, researchers have 
been investigating the formation of muscle layers by seeding autologous MSCs onto collagen 
sponge scaffolds (Figure 12.2C). However, the outcome of long-term use of such tissue-
engineered organs in Beagles was not satisfactory. In the study, lack of muscle layer recovery 
was attributed to the inadequate cell seeding or lack of pre-induction.34 Thus, the demand for 
a promising cell source still exists. Researchers have suggested another type of cells, called 
ISCs, which in addition to retaining their ability to differentiate into various types of cells, are 
more specific to the intestinal tissue (Figure 12.2D).  
Intestinal Stem Cells 
As has been illustrated, tissue-specific stem cells reside in most tissues and are 
recognized by their ability of self-renewal and differentiation into particular cells in that 
organ.43 High turnover rate of the intestinal epithelium (~3–4 days) in comparison with other 
mucous layers encourages researchers to consider the existence of a source of stem cells with 
an ability to differentiate into all types of intestinal epithelial cells.44,45 Cheng and Leblond first 
proposed the existence of stem cells at the base of the crypts and introduced the term Crypt-
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Based Columnar (CBC) stem cells.15 CBC cells are at the origin of the differentiating process. 
As is shown in Figure 12.1B, CBC cells residing among Paneth cells start to proliferate into 
daughter cells (TA cells) which progressively transfer into differentiated cells. As the cells 
move upward through the crypt, their modality changes from progenitor to differentiated cells 
until the crypt-villus junction where two major categories of epithelial lineage cells, absorptive 
and secretory lineages, exist. Enterocytes are included in the absorptive lineage, and goblet 
and enteroendocrine cells belong to the secretory lineage. Paneth cells are also members of the 
secretory lineage, however, they are located at the bottom of the crypt.43 Hans Clevers was the 
one who in 2007 recognized G protein-coupled receptor with leucine rich-extracellular domain 
(LGR5) as a marker of CBC cycling, and LGR5+ CBC cells awntwns small intestinal stem 
cells.46 Moreover, it has been speculated that in addition to LGR5+ CBC and TA amplifying 
cells, a specific type of stem cells is located at +4 position (shown in Figure 12.1B) above the 
Paneth cells, that is entirely different from LGR5+ CBC cells.46 These +4 cells are also known 
as DNA label-retaining cells with several markers attributed to them including Bmi-1, Hopx, 
mTert, and Lrig1.15,47–50 Actually, little information is available concerning their culture and 
microenvironment, and more focus is being placed on LGR5+ CBC cells.15  
It has been reported that ~15 LGR5+ CBC cells are present in every murine crypt, and 
that within a timescale of 24 h, each LGR5+ CBC cell differentiates into 16–32 epithelial cells, 
via TA cells.15 The homeostasis and fate of LGR5+ CBC cells are directly related to their niche 
or microenvironment.43 Some major pathways that regulate the stemness or differentiation of 
cells will now be briefly delineated (Shown in Figure 12.3). One of the most significant 
pathways is Wnt signaling that plays an important role in maintaining the undifferentiated state 
of stem cells.51 Wnt signaling is amplified by R-spondin family proteins (Wnt agonists) that 
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themselves are activated by LGR5 stem cell marker.43 Wnt ligand binding leads to 
accumulation of β-catenin inside the nucleus as a result of an intracellular signaling cascade. 
T-cell factor (Tcf)/β-catenin transcription is a significant element of stemness maintenance. 
Moreover, Wnt signal is also responsible for the terminal differentiation of Paneth cells.51 
 
Figure S 1.2 Different cells that can be used in TESI. (A) Isolated smooth muscle cells seeded 
on the PCL scaffold. Laser cut pores which are shown with arrows are responsible for vascular 
and cellular penetration into the scaffold.38 (Reproduced with permission from C. M. 
Walthers, et al., PLoS One, 2014, 9, 1–20. Copyright 2014: Walthers et al). (B) Attachment of 
Caco-2 cells on HYAFF 3D (Hyaluronic acid scaffold).37 (Reproduced with permission from 
A. Esposito, et al., J Mater Sci Mater Med, 2006, 17, 1365–137. Copyright 2006: Springer 
Science + Business Media, LLC). (C) Microscopic picture of regenerated intestine, 16 weeks 
after implantation of collagen sponge scaffold seeded with MSC in beagle dogs.34 (Reproduced 
with permission from Y. Hori, et al., J. Surg. Res., 2002, 102, 156–160. Copyright 2001: 
Elsevier Science). (D) ISC. Epithelium formation in Polyglycolic acid scaffold seed with 
organoids 6 weeks after implantation in mouse model.70 (Reproduced with permission from 
Rosa S. Choi, et al., J Pediafr Surg, 1998, 33, 991–997. Copyright 1998: Saunders Company) 
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A second major pathway is the Notch pathway. Notch signaling plays two important 
roles in the intestine. First, it affords negative regulation that inhibits differentiation of stem 
cells and, as a result, maintains their stemness. Second, it promotes unidirectional cell 
differentiation, controlling the absorptive to secretory lineage ratio. This regulation occurs 
because of cell-to-cell signaling. Delta-like or Notch ligands of Paneth cells (DLL1 and DLL4) 
receive Notch signal from the adjacent CBC cells and bind to the Notch receptor on the cell 
surface. Upon this binding, proteolytic cleavages result in shedding of extracellular domain of 
receptor and the release of Notch intracellular domain (NICD), NICD translocation to the 
nucleus and subsequent gene expression, with cell differentiation or proliferation as the final 
outcome. This process may inhibit differentiation of CBC cells.43 Loss of contact between 
DLL1 ligand-containing Paneth cells and daughter cells results in daughter cell 
differentiation.15 It can be noted that lateral inhibition is responsible for this type of 
differentiation. As a result of lateral inhibition, Notch activation leads to Notch ligand 
production. Thus, lower Notch activity accompanies higher Notch ligand concentrations, and 
higher ligand concentrations lead to increased Notch signaling in proximal cells and, 
subsequently, reduce the amount of neighboring cell ligands. Decreasing the neighboring cell 
ligands leads to increase in the original cell ligands to a greater extent than upon initial 
activation and thus, the differentiation fate of two neighboring cells are different. Notch-high 
progenitor cells differentiate into enterocytes and, therefore, their neighboring cells will 
become secretory cells.43 
Bone morphogenetic protein (BMP) signaling comprises another regulatory pathway 
in differentiation of stem cells to epithelial layers. By binding to type-II receptor, BMP recruits 
type-I receptor that transfers the signal to the nucleus and has a role in differentiation. 
35 
However, Noggin (Nog), an extracellular protein, antagonizes the BMP signal and inhibits its 
activity, leading to the formation of crypt like-structures among villi.44 
Epidermal growth factor (EGF) is activated upon binding to its receptors on the cell 
surface, normally EGFR (epidermal growth factor receptors), enhancing cell proliferation.52 
Thus, EGF binds EGFRs of ISCs and TA cells and causes them to divide into the same stem 
cells 15. 
Considering the fact that stemness of LGR5+ CBC cells strongly depends on the niche, 
naturally, there should be an element in the intestine that controls the microenvironment and 
accordingly manages the signaling pathways. Researchers have demonstrated that the presence 
of Paneth cells adjacent to LGR5+ CBC cells is of great importance for maintaining their proper 
condition to stay undifferentiated. Paneth cells secrete EGF and Wnt3 in addition to their 
bactericidal secretions. Production of Notch ligands Dll1 and Dll4 comprises another role of 
Paneth cells. To conclude, Paneth cells are considered a niche-controlling element and the 
interaction between Paneth and LGR5+ CBC cells is critical for cell fate. Moreover, in order to 
gain the full characteristics of stem cell niche, BMP and R-spondin, are provided by non-
Paneth cells sources.15   
Understanding stem cell homeostasis, the effect of different elements on their 
differentiation, and, generally, stem cells biology, as well as their potential therapeutic 
applications require long term ex vivo culturing. However, it is generally agreed that 
conventional long-term culture of adult tissues is not feasible.51 Although a lot of effort has 
been dedicated toward identifying culture conditions appropriate for ISC culture, only short 
term maintenance of cells, ~2–4, weeks could be achieved.53–55 Finally, in 2009, Sato 
succeeded in developing a culture system for maintaining viable cells for over 1.5 years.56 Sato 
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was simply assumed that inclusion of all the elements important for stemness maintenance of 
stem cells in the culture system, i.e., Wnt signaling, R-spondin-1 (Wnt agonist), EGF, and Nog 
(BMP inhibitor) would aid cellular survival and prepare sImilar condition to natural biology 
of human intestine for stem cell maintenance. Moreover, cell detachment from their 
extracellular matrix (ECM) may results in lack of proliferation. Therefore, an appropriate 
matrix, as similar to the crypts as possible, was designed for the cells to reside in. Because of 
a high laminin (α1 and α2) content of the crypt base, laminin-rich Matrigel was proposed as a 
matrix.56 Under the stated conditions, a single LGR5+ stem cell can be used to generate 
intestinal epithelium that would mimic normal intestinal epithelium. The resulting organoid 
structure consists of several crypts, presented as buds around a hollow cyst, and villus like 
epithelium located between the crypts. The crypts contain LGR5+ stem cells in addition to 
adjacent Paneth cells and TA proliferating cells that are located at crypt necks. Over the course 
of 5 days, stem cells at the bottom of the crypts differentiate, move towards the cyst, and finally 
shed into the hollow cyst.51 The organoid structure is shown in Figure 12.4. Upon culturing a 
stem cell, a symmetric cyst containing stem cells forms. After 2–3 days, by the effect of Paneth 
cells, Wnt signaling is initiated and  the presence of R-spondin make the signaling focal.15 It 
is interesting that just as in a normal crypt-villus structure, EphB/EphrinB interaction underlies 
bud formation in organoid structures. Eph receptors are a family of tyrosine kinase receptors 
that specifically bind Ephrin ligands. Repulsion is a consequence of Eph-Ephrin interaction in 
cell-cell interactions. Paneth cells express EphB3, a Wnt target gene. When TA cells 
differentiate, they travel upstream of Wnt gradient from the crypt to the villus and, therefore, 




Figure S 1.3 Major pathways necessary for the homeostasis of LGR5 CBCs. Wnt, Notch and 
EGF signaling, which are originated from Paneth cells, by affecting their receptors maintain 
the stemness of LGR5 CBC. BMP located at the surrounding environment and the effect of 
BMPR is blocked by Noggin inside CBC that results in the maintaining of CBC 
undifferentiated state. R-spondin amplify the effect of Wnt signaling. 
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Regarding focal Wnt signaling and the subsequent Eph/EphrinB repulsion, crypts part 
of organoid region containing stem and Paneth cells is repelled from the cyst and creates 
buds (Figure 12.5).15 
There were some important attainments in Sato’s experiment.56 First, although LGR5+ 
are not dependent on the submucosal layer beneath the epithelial layer, some important growth 
factors were required for cell survival. Furthermore, it is possible to prevent cell apoptosis 
(anoikis) by using Rho-associated protein kinase (ROCK).56 Despite the conclusion of 
Garabedian in 1997 that Paneth cells are not needed in a stem cell niche, Sato did not focus on 
the effect of Paneth cells on LGR5+ culture in 2009.56,58 Nevertheless, in 2010 Sato proved that 
a direct physical contact between Paneth cells and stem cells initiates Notch signaling.59 
Moreover, Paneth cells are responsible for EGF and Wnt3 support. It is true that Wnt may 
originate in cells other than Paneth cells, however, it has been confirmed that R-spondin 
amplifies local Wnt signaling of Paneth cells. Localized Wnt signaling of Paneth cells also 
affects the asymmetrical crypt-villus construction in organoids. It has been demonstrated that 
touching Paneth cells are vital for stem cell maintenance.59 In comparison with 15 LGR5+ stem 
cells, there are ~10 Paneth cells in each crypt. Therefore, because of the fewer number of 
Paneth cells, stem cells should compete for their niche, and, according to the “neutral 
competition model”, the number of stem cells remaining in the crypt is related to the size of 
Paneth cell surface.14 It has been observed that the lack of Notch signal leads to the formation 
of Paneth cells capable of Wnt signaling and to the production of more Paneth cells and stem 
cells. Therefore, this would be a positive feedback loop for increasing the number of stem and 
Paneth cells.14 However, this signaling pathway should be balanced to prevent the ever-
expanding cryptal growth. An investigation by Koo (2012), showed that RNF43 and ZNRF3, 
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Wnt signaling inhibitors, limit the crypt size by affecting Frizzled receptors (G protein-coupled 
receptors in Wnt signaling pathway).60 Other reports also demonstrated the effect of Lrgi1 
(leucine-rich repeats and immunoglobulin-like domains protein 1), a +4 stem cell marker, on 
stem cell proliferation and crypt homeostasis. Lrgi1 was inversely related to the amount of 
protein and the activity of receptors like Erb B family and prevented ISC over-expansion by 
interacting with them.61 Long-term organoid culture, with some alterations, was also 
successfully conducted with human GI epithelium.62,63  
 
Figure S 1.4 Organoid structure containing all types of differentiated cells in addition to CBCs. 
CBCs located at the buds of organoid. At the end of the differentiated cell life span, cells shed 
off into the lumen of organoid (process called Anoikis).51 (Reproduced with permission from 
M. Leushacke, et al., Gut, 2014, 63, 1345–1354. Copyright 2014: BMJ Publishing Group Ltd 
and the British Society of Gastroenterology) 
In conclusion, culturing ISCs for long-term use in the form organoids has been 
extremely successful. Therefore, there is great hope in the application of ISCs for different 
medical purposes, including microbial and toxicological investigations of different GI tract 
diseases and, employing organoids as disease models.63 There is also a great potential for 
using organoid structures in the pharmaceutical field, for instance, for drug screening and 
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drug targeting to treat specific diseases of the GI tract.64 Moreover, mild GI tract biopsy and 
culturing of the extracted tissues would render organoids an effective tool to be used in 
regenerative medicine.65 
 
Figure S 1.5 Bud formation in the organoid structure. Focal Wnt signaling by Paneth cell (blue 
parts) results in EphB expression and bud formation because of the repulsion between EphB 
and EphrinB ligand.15 (Reproduced with permission from T. Sato, et al., Science, 2013, 340, 
1190–1194. Copyright 2013: American Association for the Advancement of Science) 
Environmental factors 
Due to the fact that each type of cell need a specific environment to fulfill its 
requirement, niche of each cell should be evaluated individually. ISCs environment as the 
focus of this chapter is delineated. The combination of ISCs that form epithelial layers of the 
small intestine with an appropriate environment for maintaining stem cell niche and organ 
structure results in TESI. TESI can grow into the intestinal tissue to treat or improve intestinal 
function. The important point in designing a TESI is the selection of appropriate factors 
required for stem cell growth. These important factors can be divided into two major groups: 
mechanical factors, or the environment, and chemical environment. 
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Mechanical Environment 
Mechanical environment refers to all the factors that are mechanistically required for 
stem cell growth and generally, are known as scaffolds.  
TESI was first introduced in 1988 by Vacanti group that designed different scaffolds 
(polyglactin, polyorthoesters, and polyanhydride) to be loaded with parenchymal intestinal 
cells as a substitute of transplantations with surgical implications, or cell suspension injected 
into the tissue.66 The rate of cellular scaffold attachment and survival was acceptable and 
differentiated epithelium cells were arising on the scaffolds.66 
After Hans et al. developed organoid units, Vacanti group used this source of cells as 
seeds in polyglycolic acid (PGA) fiber scaffolds in intestinal TE in Lewis rats.53,67 PGA is a 
polyester, and polyesters are a group of synthetic biodegradable polymers .68 PGA undergoes 
bulk degradation that leads to decrease in its molecular weight even in the first days post 
implantation.69 Biocompatibility of its degradation product, glycolic acid, renders it 
appropriate for use in medical fields.68 In Vacanti’s report, PGA was shown as a promising 
organoid-supporting scaffold. Beyond survival, organoids supported by PGA were 
proliferating and differentiating into columnar epithelium, goblet cells, Paneth cells, and crypt-
villus structures typical for the intestinal tissue, that were all surrounded by vascularized tissue, 
fibroblast Extracellular matrix (ECM) SMCs, and polymer degradation products. Moreover, it 
was noted that increasing implant length resulted in larger cysts with more natural crypt-villus 
structures.67 
To illustrate the morphological and functional aspect of tissue-engineered neointestine, 
non-woven tubular PGA sprayed with PLLA (poly-l-lactic acid) and coated with type I 
collagen was prepared, seeded with organoids, and implanted in Lewis rats.70 PLLA is an 
42 
isomeric form of poly-lactic acid and a member of polyester group of compounds. PLLA is 
more hydrophobic than PGA and, therefore, it shows less degradation .68 It was concluded that 
the presence of PLLA on the surface of a degradable tubular scaffold results in lower scaffold 
degradation rate.70 Collagen is a biomolecule that can be extracted from different sources, e.g., 
bovine skin and tendons, porcine skin, and murine tails. This highly compatible polymer is 
mainly produced by fibroblasts and forms the organic part of the ECM.71,72 The presence of 
collagen on the surface of PGA/PLLA scaffolds resulted in better engraftment and larger cysts. 
The resulting neointestine mimicked the intestine in the formation of polarized epithelium 
layer with differentiated cells, basement membrane, and brush border enzymes. It has been 
also shown that epithelial maturation occurred over 2–6 weeks, including increased crypt and 
villus formation, numerous differentiated cells, and more mature columnar epithelium. 
Subepithelial layer containing a fibrous layer similar to lamina propria and SMC layers of 
different thicknesses in different regions were also obtained. It was also discovered that 
transepithelial resistance of the neointestine was similar to the intestine, which indicated that 
epithelial permeability of the neointestine was the same as in the intestine. However, lesser 
maturation of the neointestine compared with the intestine resulted in decreased ion movement 
across the epithelial layer.70 Other reports presented the formation of complete neomucosa and 
immune system in tissue-engineered neointestine.73,74 These investigations confirmed the 
existence of B cells, T cells, and Natural killer (NK) cells in the neointestine, following a period 
of time of ~20 weeks after anastomosis. Without luminal stimuli or within a shorter timeframe 
(~10 weeks), the numbers of some immune cells were lower with respect to 20 weeks time 
scale.73 It has been also shown that TESI can greatly improve the functionality and regeneration 
of the intestine after small bowel resection. TESI-exerted positive effects included decreased 
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recovery time, improved absorptive function, and creation of muscular, vascular, and neural 
components, and a thicker muscularis mucosae layer. An attractive insight gained from this 
experiment was that small bowel resection positively affected cell differentiation.75 A 
perfusion bioreactor has been designed for the same system to render stem cell environment 
more similar to natural in vivo conditions in order to make long term ex vivo culture feasible. 
Constant oxygen exposure of cells increased cellular survival, proliferation, and 
differentiation. The possibility of investigating the effect of different factors on TESI and 
dynamic seeding thus constituted the advantages of bioreactor use. However, these 
experiments were performed for just 2 days and applicable results have not been obtained.76 
Sala et al. (2011) succeeded in establishing a multicellular approach of cell extraction and 
seeded the cells onto collagen-covered PGA/PLLA scaffold.11 The method involved extracting 
full-thickness sections of mouse intestine and saving the mesenchymal components (muscle 
and nerve), instead of extracting low quantities of single cells for long-time culturing with 
subsequent cell transformation. Fully-differentiated epithelium, in addition to other vital 
components of TESI, including muscularis layer, nerves, and blood supply, was thus obtained. 
Immediately after implantation, vast amounts of differentiated cells from the full-thickness 
intestine were dying and the neointestine was only generated from the stem cells presented. 
This may have also been caused by lack of oxygen supply and nutrition in the bulk scaffold. 
Wound healing had just started upon implant insertion, by forming undifferentiated flat 
epithelium at the scaffold ends. It was concluded that “mesenchymal-epithelial cross-talk” 
results in tissue repair and regeneration.11  
To decrease the immune response of body to TESI, it is vital for the donor and the host 
to be the same. Since the ultimate aim of TESI is its employment as a substitute of the human 
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intestine, extracting organoids from human intestine is a step in the right direction. One of the 
major problems necessitating the use of TESI in human is SBS and SBS usually occurs in 
newborns. Levin used postnatal human intestine as a source for organoid derivation.77 
Postnatal organoids were seeded onto collagen-coated PGA/PLLA scaffold and inserted into 
the omentum of adult Non-Obese Diabetic/Severe Combined Immuno Deficiency 
(NOD/SCID) gamma chain-deficient mice. Cluster of cells were extracted from fresh postnatal 
small intestine to add intestinal subepithelial myofibroblasts (ISEMF) and differentiated 
epithelial cells to the intestinal cells, with the goal of a fully-functional neointestine. Increased 
absorptive area associated with the presence of enterocytes and flat epithelium, assumed to 
have the ability to develop into crypt-villus structures, was the results of this arrangement. In 
addition, all secretory cell lineages, including goblet cells, enteroendocrine cells, and Paneth 
cells, were detected. This TESI also comprised mesenchymal and nerve components in 
addition to adjacent ISEMF and epithelial layers. Neurovascular components were also 
confirmed in that experiment. The existence of all types of differentiated cells is an indication 
of similarity between a normal intestine and TESI. Presence of all intestinal factors is an 
indicator of the full-thickness TESI achievement using postnatal organoids. 77. It was expected 
that if TESI containing human postnatal organoids placed in a murine omentum has the same 
functional profile as mouse TESI in a mouse, autologous human TESI (hTESI) will be 
practically achievable. It has been reported that mouse TESI (mTESI) and hTESI result in a 
formation of a fully differentiated epithelium, containing fully functional secretory cells. Well-
polarized epithelium determined the ion flux potential of both types of TESI. Actin localization 
resulting in tight epithelial junctions was observed in both TESIs. High expression of Cell 
division control protein 42 homolog (Cdc42) in secretory cells was related to tissue 
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development and normal homeostasis, confirming the notion of identical function of TESI and 
normal intestine. It was also shown that mTESI and hTESI expressed enough ion and water 
transporters and channels to act as a normal intestine. Sodium-glucose linked transporter 
(SGLT-1) TESI localization was similar to a control, confirming adequate nutrient absorption. 
Strong intestinal alkaline phosphatase (IAP) activity in mTESI and hTESI indicated the 
integration of the gut barrier properties   and increase in food digestion. It can be concluded 
that satisfactory functional properties were achieved by both kinds of TESI and both had 
similar characteristics, which gives hope for using TESIs to treat deficiencies such as SBS in 
human. However, engineering of extensive injury treatment remains difficult.78 
Matrigel is a soluble extract of basement membrane that converts to gel at 37 °C.79 The 
principal components of Matrigel are laminin, collagen IV, and enactin. Matrigel is widely 
used in cell culture and it is believed that cell responses change after the cells are inserted into 
Matrigel. This is believed to be associated with the presence of growth factors, such as basic 
fibroblast growth factor (bFGF), EGF, insulin-like growth factor1 (IGF-1), transforming 
growth factor β (TGF-β), platelet-derived growth factor (PDGF), and nerve growth factor 
(NGF) inside a standard Matrigel.80 Engelbreth-Holm-Swarm (EHS) tumor (murine tumor 
with high ECM content) is the source of Matrigel.79 Because of its unique properties, Matrigel 
can maintain cell progeny and pluripotency. Thus, it is widely used as ECM in stem cell 
culture.80 Matrigel is also common in intestinal organoid unit culture. However, because of its 
origin, it may provoke foreign body response and thus might not be useful in regenerative 
applications.81  
Collagen has been introduced as a 3D substitute of Matrigel in Ex vivo culture of ISCs.10 
Although the combination of collagen and laminin showed lower ISC proliferation than 
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Matrigel, Multilineage differentiation and longtime proliferation of ISCs are the indicatives of 
collagen ability as a 3D matrix for ISC culture.10  In vitro culture and in vivo implantation of 
collagen-coated PGA organoid scaffolds were also evaluated to determine the effect of 
collagen presence instead of Matrigel.81 In vitro culture revealed different organoid 
morphology on Matrigel and collagen structures. As anticipated, crypts displayed bud-
surrounded lumen on Matrigel substrate. However, a smooth structure without buds arose on 
collagen matrix. Moreover, a differentiated epithelium monolayer emerged in culture when 
collagen matrix was used. This was not observed with Matrigel. Cells could survive on both 
matrices and fully differentiated cells, including enterocytes, goblet cells, enteroendocrine 
cells, and Paneth cells, in addition to stem cells were observed as enteroid structures on 
Matrigel and monolayers on collagen. However, LGR5 expression was noticeably higher on 
Matrigel than on collagen matrix because of its similarity to intestine crypt-like structure. Co-
culture of organoids and ISEMFs, combined with either collagen or Matrigel, was applied to 
scaffolds and implanted in wild-type mice. Cells within both matrices, having been provided 
the appropriate niche, proceeded through the growth process and the presence of 
myofibroblasts aided scaffold engraftment. Interestingly, collagen-containing scaffolds 
regained bud structure in vivo, which may be associated with the cellular microenvironment.81 
The different scaffolds used in ISC TE are summarized in Table 12.1. 
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Effect of the scaffold 
 
Reference 
PGA1 Lewis rats Lewis rats Organoid survival, proliferation, and 
differentiation to columnar epithelium; 





















































































Decreased degradation rate, better 
engraftment and larger cysts; formation 
of columnar epithelial layer, 
differentiated cells, basement 
membrane, and enzyme brush border; 
similar transepithelial resistance to the 




Formation of immune system. 
 
Formation of neomucosa. 
 
Formation of differentiated epithelium; 
formation of muscular, vascular, and 
neural components; formation of 
thicker muscularis mucosae layer; 
decreased recovery time after massive 
resection; increased differentiation. 
 
Mesenchyme-epithelial cross-talk; 
formation of fully differentiated 
epithelium, muscularis, nerves, and 
blood vessels; death of large numbers 
of original cells; formation of flat 
epithelium at the ends of scaffold. 
 
Presence of all types of differentiated 
epithelial cells (enterocytes, goblet 
cells, enteroendocrine cells, and Paneth 
cells); appearance of mesenchymal and 
nerve components, muscularis, and 
neurovascular components. 
 
Fully differentiated cells, fully 
functional secretory cells, ion fluxes; 
tight junctions of the epithelium; 
developed TESI; adequate channels for 
ion-water transport; adequate nutrient 
absorption and integrated gut barrier 
properties. 
 
Fully differentiated cells, fully 
functional secretory cells, ion fluxes; 
tight junctions of the epithelium; 
developed TESI; adequate channels for 
ion-water transport, adequate nutrient 














































Wild-type mice Recapitulates stem cell niche; regained 
crypt-like structure and growth of 
organoids; better engraftment because 
of ISEMF cells. 
81 
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Table S 1.1 (continued) 
 
Chemical Environment 
Chemical environment encompasses all factors that are chemically required for ISC 
function maintenance, as a TE cell source. Growth factors play the most important role here. 
Several reports on the effect of different growth factors on the proliferation and growth of 
epithelium layer have been published, concerning specific disease treatment or renewal of the 
intestinal organ.82–84  
Circulating growth hormone (GH) binds cellular GH receptors, which leads to IGF-1 
production. Both GH and IGF-1 are responsible for somatic growth.85 Inconsistencies in 
clinical results regarding the administration of recombinant GH (rhGH) are considered to be 
associated with the methods used, patient diet, and diet supplements.86,87 IGFs can improve the 
growth of small bowel, where their receptors are expressed.88 Factors, such as bFGFs and IGFs, 
are responsible for proliferative characteristics of crypts in gut.89 Glucan-like peptide-2 (GLP-
2), a PGDP (peptide derived from post  translational processing of proglucagons), has the 
ability to regulate epithelial cell proliferation.90 GLP-2s are peptides that are secreted from 
enteroendocrine cells that, because of their location, can affect the entire length of the intestinal 
epithelium.91 It has been reported that, unlike IGFs, the increase of cell proliferation by GLP-
2 is “tissue specific only in the intestine”.90,92 Decreased cell apoptosis, increased crypt cell 














Wild-type mice Recapitulates stem cell niche; regained 
crypt-like structure and growth of 
organoids; better engraftment because 




3 Non-Obese Diabetic/Severe Combined ImmunoDeficiency 
4 C57 black 6 
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administration of GLP-2 is controversial because of its short half-life, and use of Teduglutide, 
GLP-2 analog resistant to enzymatic degradation, is more common. However, the variability 
of results of Teduglutide adminstration should be resolved by a comprehensive study.87 
Administration of EGF as another growth factor can also enhance the proliferation rate and 
absorptive properties of the intestine by binding to enterocyte receptors.93,94 EGF has been 
successfully used in the treatment of different GI tract diseases.87 EGF stimulatory role has 
also been considered in epithelial growth. PDGFs are also regarded as stimulatory growth 
factors.95 Similarly, TGF-α exerts a stimulatory effect on proliferation of stem cells in crypts, 
while TGF-β is mostly known for its inhibitory function.89 By decreasing the duration of the 
stem cell mitotic cycle, subsequently increasing the number of dividing cells, EGF and TGF-
α increase cell proliferation rate in the crypt region. However, TGF-β prevents cell 
proliferation in 50–75% crypt region.89 It is worth noting that different tissue reactions would 
be expected because of different cell responses to TGF-β. Time-related inhibition or 
stimulatory TGF-β effects can be seen on different time scales. Hepatocyte growth factor 
(HGF), a protein synthesized in digestive tissues, is responsible for epithelium repair, and 
mucosal regeneration and recovery.96 Interestingly, none of these factors can perform their 
roles in their entirety individually and only their combination leads to an appropriate tissue 
response.89  
The brief summary above described the most important growth factors in the GI tract, 
however, not all of these elements are useful in TE.97 Some practical examples of their 
employment in TE will now be delineated. 
GLP-2 has been subcutaneously administered as a growth factor to enhance the 
functionality of TESI formed by a PGA scaffold with PLLA surface layer seeded with organoid 
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units in adult rats.98 Different aspects of the effect of GLP-2 on TESI were then investigated. 
First, endogenous regulatory effects of GLP-2, including increased villus length and crypt 
depth, increased crypt cell proliferation, and decreased apoptosis, were successfully observed. 
Moreover, GLP-2 increased nutrient absorption of neointestine epithelium by increasing 
SGLT-1 expression and its distribution along the entire villus length. Furthermore, GLP-2 
affected the expression of sucrase but not GLUT2, suggesting different regulation mechanisms. 
These experiments confirmed subepithelial layer localization of GLP-2R.98 
In 2011, Wulkersdorfer and his colleagues used locally-delivered growth factors (GLP-
2, HGF, and transferrin) on PGA felt disks to increase growth factor bioavailability in target 
tissue and decrease growth factor requirement. The simplicity and lack of protein degradation 
in this method were apparent when compared with microsphere delivery method.99 Seeded 
growth factor-containing scaffolds were used and tested in Lewis rats. The effect of Matrigel 
was also investigated, by suspending the PGA scaffolds in a Matrigel solution. Although, since 
Matrigel was used, the distinct effects of growth factors in all samples that contained them 
were not obvious, comparisons of TESIs with and without growth factors helped in 
understanding of some of their effects. Matrigel results in “complex neomucosal structure and 
increased surface area” (Shown in Figure 12.6C).99 However, increased cyst numbers were 
attributed to GLP-2. GLP-2 did not affect the diameter of the neomucosal area but GLP-2 
effects described in Ramsanahie report were also observed.98 It was concluded that the 
localized GLP-2 effects were identical to the effects generated by systematic administration. 
No significant HGF effects were observed, which was related to its low dose in TESI (Shown 
in Figure 12.6A). However, transferrin samples displayed a more complex structure in addition 
to higher neomucosal surface area(Shown in Figure 12.6D).99 
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Figure S 1.6 Different chemical elements used for TESI improvement. (A) Using HGF on PGA 
scaffolds seeded with organoids showed no significant differences in neomucosal structure 
after 4 weeks implantation in Lewis rat.99 (Reproduced with permission from B. 
Wulkersdorfer, et al., J. Surg. Res., 2011, 169, 169–178. Copyright 2011: Elsevier) (B) Crypt-
villus structure formed by TESI containing organoid unit seeded collagen coated PGA/PLLA 
scaffold and Fgf10 overexpression.100 (Reproduced with permission from Y. Torashima, et al., 
J Tissue Eng Regen Med, 2016, 10, 132–139. Copyright 2013: John Wiley & Sons, Ltd.) (C) 
Complex mucosal structure formed by implanting PGA scaffolds seeded with organoids and 
treated with Matrigel after 4 weeks implantation in Lewis rat.99 (Reproduced with permission 
from B. Wulkersdorfer, et al., J. Surg. Res., 2011, 169, 169–178. Copyright 2011: Elsevier) 
(D) Complex cyst morphology obtained from using holo-Transferrin in PGA scaffolds seeded 
with organoids implanted in Lewis rats for 4 weeks.99 (Reproduced with permission from B. 
Wulkersdorfer, et al., J. Surg. Res., 2011, 169, 169–178. Copyright 2011: Elsevier) (E) High 
level of Neointestinal capillary marked by CD31 (endothelial cell marker) in neointestine, 
formed by organoid seeded PGA/PLLA scaffold containing PLLA microspheres loaded with 
VEGF, after 4 weeks implantation in Lewis rats.102 (Reproduced with permission from F. G. 
Rocha, et al., Biomaterials, 2008, 29, 2884–2890. Copyright 2008: Elsevier) 
Fgf10 is a fibroblast growth factor that has been used in intestinal TE of extensive 
injuries or deficiencies on account of its attractive GI tract properties, such as controlling 
epithelium proliferation, differentiation, survival, and expression inside the GI tract. It is 
assumed that Fgf10 overexpression may improve TESI formation. Therefore, organoids were 
extracted from transgenic mice with inducible Fgf10 overexpression. Organoids were seeded 
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on PLLA-coated PGA scaffolds and implanted in mice. As expected, Fgf10 overexpression 
resulted in greater villus length and deeper crypts, which consequently improved the absorptive 
area (Shown in Figure 12.6B). Proliferation of epithelial in Fgf10-overexpressing TESI was 
higher than in the control sample. However, the amount of epithelial proliferation is not enough 
to consider it as an appropriate TESI. Cells should sufficiently differentiate and distribute along 
the epithelium before TESI can be considered suitable for mimicking small intestine. Fgf10-
overexpressing TESI contained completely differentiated cells of all kinds, reminiscent of a 
normal intestine.100 
In order to provide TESI with nutrients and oxygen, Rocha et al. used PLGA 
(poly(lactic-co-glycolic acid)), biodegradable and biocompatible polymer101, microspheres 
containing VEGF (Vascular endothelial growth factor) as an angiogenesis factor.102 
PLGA/VEGF microspheres were loaded onto PLLA-coated PGA scaffolds that were 
afterwards seeded with organoids and implanted in adult Lewis rats. VEGF-containing TESIs 
showed increased construct size and weight, which has been related to TESI VEGF delivery. 
Higher capillary network density in comparison with control samples was observed (Shown in 
Figure 12.6E). Epithelial cell proliferation increased in response to higher amounts of nutrients 
and oxygen supply, as a result of increased vascularity. Apoptosis rates were similar to the 
control sample and it thus can be concluded that degradation of PLGA does not exert any 
harmful effects on the TESI function. TE system mimicking the natural intestine was thus 
obtained.102 
Considering the probability of microsphere degradation and also the inability to control 
the villus-crypt height, researchers have devised another method of VEGF application.103 
Instead of microspheres, VEGF overexpression was used in the Rocha system described 
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above.102,103 Triple transgenic CMVCre-rtTAflox/ flox -tet(o)-VEGF mouse was selected as the 
donor of organoids and the host of TESI because of its ability to induce VEGF overexpression 
upon doxycycline treatment. A sustained VEGF expression was thus attained, unaffected by 
polymer degradation. Complete neovascularization was achieved and nutrient transport to the 
bulk scaffold resulted in mucosal layer growth. Increased crypt cell proliferation may also be 
attributed to sufficient nutrition. Complete differentiation of intestinal epithelial cells without 
inhibition took place in TESI. Fully-developed mucous layer, in addition to different types of 
differentiated intestinal cells, was assumed to be associated with the presence of Flt-1 and Flk-
1 (VEGF receptors) and their signaling in the epithelium layer. High villi and deep crypts were 
observed in VEGF overexpression system at a higher density  compared with the control 
system.103 
It is crucial that, as mentioned before, elements required for stem cell niche 
maintenance should be included in TESI. In addition to growth factors, other factors facilitate 
acceptable TESI generation. Matrigel is an important factor facilitating the formation of more 
complex TESI structure resembling the naturally occurring crypt-villus structures. Increased 
mucosal surface area and cyst formation was obtained after using Matrigel on PLGA scaffolds. 
Improved differentiation of cells on Matrigel is regarded as an effect of cell-cell interaction on 
or in the Matrigel matrix, and, in consequence, differentiated cells similar to those naturally 
occurring in the organs are formed.79 The complexity of tissue-engineered structure of the 
intestine is thus explained. Longer, narrower, and densely spaced villi were observed when 
using Matrigel on PLGA scaffolds, as compared with PLGA suspended in Hanks’ buffered 




Figure S 1.7 Different steps in a long term culture of human ISCs and the future of making a 
transplantable epithelium to regenerate intestinal tissue.63 
Some growth factors are also required for preparing the important signaling pathways 
to maintain the stem cell nature of cells in culture and for long-time maintenance, which seems 
necessary for long-term usage of these cells. In small intestinal murine cultures, ENR (murine 
EGF, murine Nog, and human R-spondin-1) are essential for differentiation of stem cells to all 
types of intestinal cells.56,63,65 Addition of Wnt3 to the culture medium results in generation of 
cells that are mostly undifferentiated. Even though the specified chemical condition favored 
mouse crypt formation, such was not the case for human intestinal culture and 7 days was the 
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maximum lifespan of human stem cells under these conditions. To improve the efficiency of 
culture, gastrin (neoendocrine hormone secreted by G-cells in the stomach 104) and 
nicotinamide (a form of vitamin B3 or niacin 105) was added to the system. Gastrin does not 
play a major role in culture systems and does not intervene with differentiation but, it was 
preferred to use gastrin in all human culture systems.  In contrast, nicotinamide increased the 
lifespan of cells to 1 month. After 1 month, the organoids converted from bud-like structures 
to cystic structures and their proliferation decreased significantly. By adding a combination of 
A83-01 (Alk4/5/7 inhibitor) and SB202190 (p38 inhibitor) the viable culture period was 
increased to 6 months. Differentiated cells did not arise under these conditions. Wnt3, 
SB202190, and nicotinamide were considered as differentiation-inhibiting factors. 
Differentiation was achieved by eliminating these factors.63 Single biopsy of a patient and 
culturing organoid units of the intestinal tract under the specified chemical conditions can lead 
to generation of a “transplantable epithelium” for treating intestinal organ malfunction.63 All 
steps of human ISC culture is shown in (Shown in Figure 12.7). A summary of all chemical 
factors required for TE is presented in Table 12.2. 
Conclusions and Future Perspectives 
Intestinal TE, as an alternative approach circumventing the limitations of other 
techniques like, drug therapy, chemotherapy and, surgical methods, will help patients to regain 
their health more easily. However, because of the complex intestine structure and functionality, 
detailed investigations of various components of TESI have to be undertaken. TESI 
components can be divided into two distinct categories, cells and cellular growth environment. 
Although, different types of cells have been used in TESI design, a cell source that meets all 
the requirements of intestinal structure and also affords all functionalities is the best choice. 
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Stem cells comprise a promising cell source as they can convert into differentiated cells with 
the ability to perform an intended role in an organ. ISCs, residing at the bottom of intestinal 
crypts, appear to be the best option because they can proliferate into identical stem cells and 
can also differentiate into all cell lineages of the intestinal epithelium. The obstacle in their 
application is that ISCs do not survive under conventional cell culture conditions. Therefore, 
an environment has to be created that would simulate the niche that they occupy, similarly to 
biological microenvironments. Stem cells convert into crypt-villus–like structures termed 
organoids. Organoids, or mini-guts, contain differentiated epithelium-forming cells as well as 
ISCs that can renew the entire organ. The key point here is that organoids should be provided 
with a proper surrounding environment to enable them to grow into a whole organ. Chemical 
and mechanical aspects of the environment should be fulfilled. Chemical environment 
encompasses all the chemical components, such as proteins, growth factors, etc., that are 
necessary to aid organoid proliferation and differentiation into intestinal cells capable of 
carrying out all the necessary intestinal epithelial functions, including nutrition, absorption, 
lubrication, and barrier function. Mechanical environment encompasses supporting materials 
required for the organoids to act as an ECM for the cells. This chapter presented a 
comprehensive overview of every concept of ISC TE, including organoids as the cell source; 
such chemical elements as GLP-2, FGF, and VEGF; and scaffolds, e.g., PGA and collagen-
coated PGA/PLLA.  
Despite the great effort in ISC TE, there are still some sections of this topic that are not 
evaluated or need further investigations. One of the first attempts of future work should be 
directed towards the culture condition of human ISCs. Since a working human intestine is the 
ultimate goal of TESI, further studies should focus on more effective culture conditions to 
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maintain long-term human organoids in a more controlled manner and make the ISCs able to 
proliferate constantly and differentiate into epithelial cells.  More operative factors should be 
investigated and added to the culture system that have positive effects on maintaining the 
normal niche of ISCs. The other area of future research should be assigned to involve polymer 
technologies in manufacturing and chemical processes of scaffold preparation in order to 
provide scaffolds with the highest similarity to the human intestine. Subsequently, mimicking 
the intestinal structure and complete organ functionality can be expected from TESI. Similarity 
of scaffold and intestine should be achieved in diverse aspects including shape and size 
(possess the most similar shape to the finger like structure of small intestine), materials used, 
and surface and bulk properties.  These strategies will facilitate engineering of a regenerating 
intestine to replace the native intestine during disease. 






















Increased villus height and crypt depth; increased 
crypt cell proliferation; decreased apoptosis; 
increased nutrient absorption; expression of 
sucrase and absence of GLUT2 expression; 
location of GLP-2R in the subepithelial layer. 
Elevated cyst numbers, increased villus height, 






















Increased villus height, increased crypt depth, 
increased cell proliferation; fully differentiated 









CMV Cre rtTAflox/ 
flox -tet(O)-VEGF 
mice7 
 Increased size and weight of TESI; increased 
vascularity and epithelial proliferation, no change 
in apoptosis. 
Increased villus height and crypt depth, increased 
crypt cell proliferation, increased mucous 











Model Effect of the growth factor Reference 
Matrigel Lewis rats Lewis rats Greater surface area and cyst diameter, more 
complex neomucosal structure (longer, 




















































Crypt hyperplasia; Wnt activation. 56,63,65 




human - Improved culture efficiency, prolongation of 
culturing period, differentiation inhibition. 
63 
Wnt3 human - Differentiation inhibition. 
63 
A83-0110 human - Synergic effect with SB202190 in prolonging 
the culture period. 
63 
SB20219011 human - Synergic effect with A83-01 in prolonging the 
culture period; differentiation inhibition. 
63 
1 Glucan-like peptide-2 
2 Hepatocyte growth factor  
3 Fibroblast growth factor 
4 fibroblast growth factor 10; transgene insertion 24, Margaret E Buckingham 
5 r26rtTA: gene trap ROSA 26, Philippe Soriano; targeted mutation 1, Anton Wutz- 
6 Vascular endothelial growth factor 
7 CMV Cre : transgene insertion 1, University of Cologne 
8 Epidermal growth factor 
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Abstract 
Inflammatory bowel disease (IBD) causes inflammation to the Gastrointestinal (GI) 
tract. Local administration of Anti-inflammatory drugs such as 5-aminosalysilic acid (5-ASA) 
can alleviate the symptoms of IBD. The application of nanoparticles for IBD treatment in direct 
rectal administration showed high drug availability and treatment efficacy. However, relying 
on size-dependent adsorption of smaller particles is not sufficient for making the formulation 
capable of targeting. Intestinal organoids can improve the functionality of the nanoparticles 
due to their ability to adsorb small nanoparticle inside the lumen and attach to the damaged 
area. In this study, intestinal organoids were used as carriers of 5-ASA-loaded PLGA 
nanoparticles. The nanoparticle sizes, confirmed by scanning electron microscopy, were 200–
300 nm and the zeta potential were negative. The nanoparticles did not have any noticeable 
pernicious effect on organoid growth and viability. After mixing the nanoparticles with 
Matrigel and organoids, Rhodamine B (RhodB) loaded inside the nanoparticles was highly 
detected inside the organoid’s lumen after 3 days by confocal fluorescent microscopy and no 
longer detected in the lumen after day 4. It may be attributed to the ability of the lumen to 
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digest particles. Thus, the organoid Trojan horse system is a possible approach for delivering 
drugs to inflamed areas. 
 
Keywords: 
Inflammatory bowel disease, PLGA, nanoparticles, organoids, intestinal stem cells. 
Introduction 
Gastrointestinal (GI) tract is a complex organ composed of different parts with diverse 
functions, including ingestion, digestion, nutrient absorption, and excretion of waste.(1) 
Because of the broad functionality of the intestinal tissue, defects in its structure may affect 
the operation of the entire body. Severe diseases may negatively impact the intestine, with one 
such example being inflammatory bowel disease (IBD), a group of diseases that result in 
inflammation in any part of the GI tract.(2) IBD affects approximately 1.6 million people in 
the U.S.(3), and the number of people affected has increased by approximately 200,000 from 
2011 to 2014, resulting in an unmet clinical need requiring of innovative and effective 
treatment.(3) To date, no permanent cure for IBD exists. Anti-inflammatory drugs such as 5-
Aminosalicylic acid (5-ASA) or Mesalamine and immunosuppressive agents are prescribed, 
but their curative ability is highly dependent on the degree and intensity of the disease.(4, 5) 
5-ASA can ameliorate the symptoms of IBD by locally affecting the inflamed area.(6, 7) Drug 
targeting has become a potential means to improve the local effectiveness of the prescribed 
drugs by inhibiting the major disadvantages of the systematic delivery including the 
nonselective distribution of the drugs throughout the body, wasted drugs in normal tissues, and 
negative side effects of the drug molecules.(8)  
Different delivery strategies for targeting have been proposed, such as bioadhesion, 
nanoparticles, liposomal drug carriers, and bacteria-based drug delivery.(4, 9) Nanoparticle- 
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and microparticle-based delivery is regarded as one of the most promising methods of IBD 
treatment that can provide sustained drug release at the desired location with decreased side 
effects. In mice models, orally administered dexamethasone-loaded Poly(DL-lactic acid) 
(PDLLA) microspheres have been shown to preferentially distribute in inflamed regions of 
colon affected by Ulcerative colitis (UC), a chronic and relapsing type of IBD, by targeting 
immune-regulating cells such as macrophages. Compared to the models treated with free 
dexamethasone, no signs of side effects were observed.(10) Microspheres resulted in lessened 
inhibitory effects on epithelium regeneration and inflammation.(11) In 2001, Lamprecht 
demonstrated that the smaller the particle size, the higher the accumulation of particles in both 
inflamed and healthy regions of the colon.(12) However, the deposition of smaller particles 
was noticeably increased in ulcerated regions and was correlated with increased penetration of 
the smaller particles into the mucus membrane rather than internalization by phagocytic 
cells.(12) Nanoparticles have since become one of the most prevalent research topics in IBD 
drug delivery. 
Polymers have been widely used in biomedicine for drug delivery and regenerative 
medicine(13, 14) and different types of polymer have been used to make nanoparticles for IBD 
treatment.(15) Poly(lactic-co-glycolic acid) (PLGA) nanoparticles demonstrated ideal 
characteristics, including high deposition on the inflamed region, enough biodegradability to 
prevent polymer deposition in inflamed tissue, and avoidance of adverse effects because of the 
negligible amount of drug release in other tissues. These proper characteristics make them a 
promising carrier system for IBD treatment.(16)  Scientists have been conducting research on 
drug-related strategies and approaches to improve their effectiveness through rectal, oral, or 
parenteral delivery routes.(3) Despite the superior properties of orally delivered nanoparticles, 
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rectally delivered nanoparticles showed desirable therapeutic efficiency, they have been shown 
to help drug absorption through Peyer’s patch and lessened the drug’s enzymatic 
degradation.(17) The direct transport and delivery of a drug to the inflamed area is still a great 
obstacle.(18) In addition, human administration of micro and nanoparticles by colonoscopy 
showed that size-dependent adsorption is not the most reliable and applicable method for 
colonic drug delivery.(19) A more advanced drug delivery technology should accompany 
particulate delivery in order to achieve better rectal delivery properties. 
Cell-mediated drug delivery brings numerous advantages, including targeted drug 
delivery to the inflamed, injured, or tumor sites, controlled drug release, and lowered or no 
drug immunogenicity or toxicity owing to the homing properties of cell carriers.(20) However, 
there are also some disadvantages in these systems, such as low drug loading, lack of complete 
drug detachment from cell carriers, earlier release of loaded drug, and harmful effects of the 
drug on the cell carrier.(20) Many of these drawbacks can be mitigated using cell carriers 
containing drug-loaded nanocarriers.(20) Trojan horse systems are those in which a drug is 
entrapped or concealed into the host cells. Passive diffusion, exocytosis, and efflux are 
regarded as the three major phenomena of drug release from cell carriers in Trojan horse 
systems.(21)  
Cheng and Leblond first proposed the existence of intestinal stem cells (ISCs) at the 
base of the crypts and introduced the term crypt-based columnar (CBC) stem cells.(22) The 
high turnover rate of the intestinal epithelium (~3–4 days) in comparison with other mucous 
layers encouraged researchers to consider the existence of a source of stem cells with an ability 
to differentiate into all types of intestinal epithelial cells.(23, 24) CBC cells are at the origin of 
the differentiating process. Although it is theoretically applicable to use CBCs as an 
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appropriate source of cells for drug delivery, it is generally agreed that conventional long-term 
culture of adult tissues is not feasible.(25)  
To solve this problem, in 2009, Sato succeeded in developing a culture system to 
maintain viable cells for over 1.5 years.(26) With the use of a 3D culture system with Matrigel 
instead of 2D systems(27) to achieve previous memory of the cells(28-30) and employing 
necessary elements to prepare the natural biology of the intestine(26), a single LGR5+ stem 
cell can be used to generate intestinal epithelium called an organoid structure that would mimic 
normal intestinal epithelium. The resulting organoid structure consists of several crypts, 
presented as buds around a hollow cyst, and villus-like epithelium located between the 
crypts.(25)  
The hollow cyst of the organoids seems to be ideal to encapsulate the particles due to 
the organoids numerous characteristics. First, it can be loaded with nanoparticles. Previous 
work has reported the successful encapsulation of small nanoparticles without therapeutic 
agents inside the lumen of the organoids.(21) In 2015, Wang’s research group worked on 
organoid Trojan horses loaded with DNA-functionalized gold nanoparticles (GNPs).(21) The 
ultimate goal was to evaluate the possibility of loading gold nanoparticles within the lumen of 
the organoids and to assess the toxicity of nanoparticles to the host cells. It was assumed that 
because of the high positive charge of the inflamed tissue, DNA-functionalized GNPs can 
easily attach to the inflamed mucosa owing to their high negative charge.(21) Moreover, it was 
shown that transplanted organoids can preferentially target the inflamed area.(31) Thus, a 
Trojan horse system of ISCs can be attained by loading particles inside the hollow cyst of 
organoids with the aim of targeting the inflamed region. In addition, the anti-inflammatory 
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effect of drugs, which will be loaded inside the particles, as well as the organoids regeneration 
into the intact epithelium(31, 32) can facilitate the tissue healing.  
So far, ISCs have been successfully cultured as carriers of cell delivery(26) and 
organoid structures capable of particle encapsulation have been formed.(26) Furthermore, 
organoids have been used as carriers for small nanoparticles.(21) Despite the remarkable 
improvements in making organoid Trojan horses, the system is still lacking a therapeutic agent 
that can be applicable in IBD treatment. Furthermore, the effectiveness of the system as well 
as its adverse effects have not been evaluated.  
Therefore, it is hypothesized that the addition of encapsulated nanoparticles with 
therapeutic agents to the organoid Trojan horse structure will be a great step in IBD treatment 
because of its direct action on the inflamed area and low immunogenic properties. The aim of 
this study is to investigate the effect of PLGA nanoparticle loaded with 5-ASA as a model drug 
on the organoid structure and assessing the organoid ability to entrap the nanoparticles.  
Materials and methods 
Materials  
Matrigel was purchased from Corning Inc (NY, USA). Epidermal growth factor (EGF), 
noggin, and R-spondin-1 (RS-1) were purchased from PeproTech Inc (Rocky Hill, NJ, USA). 
Poly(lactic-co-glycolic acid) (PLGA) was purchased from Evonik Industries (Essen, Germany) 
(5050 DLG 2A). 5-Aminosalicylic acid (5-ASA), alginic acid sodium salt, dichloromethane 
(DCM), latex beads, and green and red fluorescent nucleic acids were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Rhodamine B (RhodB) was purchased from Acros (Geel, 
Belgium). All other materials were purchased from Life Technologies (Carlsbad, CA, USA). 
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Nanoparticle preparation 
PLGA nanoparticles loaded with 5-ASA or RhodB were prepared by a double-
emulsion (water/oil/water)-based solvent evaporation/extraction method.(33) To achieve 
different drug and dye concentrations, four different 5-ASA-to-polymer ratios (0%, 2.5%, 5%, 
and 7.5% (w/w)) and four different RhodB-to-polymer ratios (0%, 1%, 2.5%, and 5% (w/w)) 
were prepared. The weighed drug (or dye) and PLGA were dissolved in 0.5 mL of nano-pure 
water and 5.5 mL of DCM, respectively. The drug (or dye) solutions were added to the polymer 
solutions and sonicated for 30 cycles (1 s each with a duty cycle of 80%). To obtain the 
negative charge required for the attachment of nanoparticles to the inflamed area, alginate, a 
negatively charged natural biopolymer(34, 35), was chosen as the surfactant to coat the drug 
molecules. The sonicated PLGA/5-ASA and PLGA/RhodB primary emulsions were quickly 
poured into 25 mL of 1% (w/v) alginate solution and sonicated for 30 cycles (1 s each with a 
duty cycle of 80%). The double emulsions were poured into 150 mL of 0.2% (w/v) alginate 
solution and the mixture w78 
as stirred for 2h at room temperature. Afterwards, the suspensions were centrifuged at 
10,000 rpm at 4°C and resuspended three times. The final suspensions of nanoparticles were 
analyzed to evaluate the properties before being loaded inside the organoid units.  
Stem cell isolation and culture 
Organoids were extracted based on previously reported methods.(21, 36) Briefly, 
primary ISCs were extracted from C57BL/6 (B6) mice donated by the College of Veterinary 
Medicine of Iowa State University. All animal procedures were conducted with the approval 
of the Iowa State University Institutional Animal Care and Use Committee. All methods and 
procedures in the experiments were performed in full compliance with the committee's 
guidelines and regulations. The small intestine of the mice was cut horizontally and vertically 
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into small pieces. The small pieces were washed with PBS several times. After washing, the 
upper solution was removed and 30 mL of Ethylenediaminetetraacetic acid (EDTA) was added 
to the small intestine pieces. The tube containing the pieces was placed on ice and after 30 min 
of shaking, the EDTA solution was sucked out. To remove the remaining EDTA, the pieces 
were washed with PBS. Thereafter, PBS was added to the pieces and by pipetting up and down, 
the final solution was achieved. The final solution was filtered and after centrifugation for 5 
min at 1400 rpm and 4°C, the final crypts will appear. 
Extracted cells will be suspended with Matrigel, a soluble extract of basement 
membrane,(37) and applied on a pre-warmed 24-well plate. Culture medium was prepared by 
adding 0.5 mL of N2, 50 µL of RS-1, 1 mL of B27, 100 µL of N-acetyl-l-cysteine (NALC), 50 
µL of EGF, and 50 µL of noggin to 50 mL of basal medium and was added after gel formation 
in the wells.  
Nanoparticle characterization 
In order to use the nanoparticles, it is necessary to analyze the different characteristics 
of the nanoparticles before loading them inside the organoids. The encapsulation efficiency 
(EE) of the RhodB loaded PLGA nanoparticles was calculated using the following equation 
(λmax of 555). 
%𝐸𝐸 = [
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑅ℎ𝑜𝑑𝐵 − 𝑢𝑛𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑅ℎ𝑜𝑑𝐵
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑅ℎ𝑜𝑑𝐵
] × 100 
 The size of the particles was determined using the Zetasizer (Nano-Zs 90). To confirm 
the results of the Zetasizer, the particle size was also evaluated by scanning electron 
microscopy (SEM, FEI Quanta 250 FE-SEM). The zeta potential of the particles was 
investigated by Zetasizer (Nano-Zs 90). 
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Microscopy 
In order to track the particles, 40 μL or 400 µL of the nanoparticle suspensions (2 
mg/ml) containing 0%, 1%, 2.5%, and 5% RhodB were added directly to the cell culture 
medium after culturing the organoids, and fresh culture medium was added to the system every 
two days. A control organoid culture without nanoparticles was also prepared. The images 
were recorded by a Leica DMi1 inverted microscope to show the rate of organoid growth. The 
organoids were chosen from the middle of each well. To track the presence of nanoparticles 
inside the lumen, images were taken by confocal fluorescent microscopy (Olympus IX2). To 
evaluate the effect of chemical structures on the nanoparticle diffusion, latex beads were added 
to the system. 
The second method of adding nanoparticles to the system was to mix the nanoparticle 
suspension with the cell suspension and subsequently adding obtained suspension to the 
Matrigel in the passage step of organoid culture. After resuspension, the resultant mixture was 
applied onto the plate and culture medium was added after gel formation. To test this method, 
10 µL of 2.5% RhodB nanoparticles (2 mg/ml) was tested. Moreover, 200-nm latex beads, 
200-nm and 400-nm polyanhydride (PA) nanoparticles (donated by the Narasimhan group) (2 
mg/ml) were also tested to check the effect of chemical structure on the nanoparticle absorption 
inside the organoid. 
Live-dead cytotoxicity test 
After 7 days, the medium of the cells was removed and replaced with Hank's Balanced 
Salt Solution (HBSS) for 2–3 min. Green (SYTO® 10) and red (DEAD REDTM) florescent 
nucleic acid stain (1 µL) was added to 500 µL of HBSS and the covered HBSS layer of the 
cells was replaced with the new solution. The cells were incubated in the dark for over 15 min. 
Then, the dye solution was replaced with fresh HBSS. The next step was fixation with 4% 
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paraformaldehyde for 1 h, and the organoids were then observed with confocal fluorescent 
microscopy.  
 
Figure 2.1(A) The trend of nanoparticle size changes with different 5-ASA loading ratios. 
(B) The trend of nanoparticle zeta-potential changes with increasing the 5-ASA loading 
ratios. * significant at p<0.05. 
Results 
Size and zeta potential of the nanoparticles 
The EEs for 1%, 2.5% and 5% RhodB loaded nanoparticles were 32.8%±11.1, 
45.5%±7.1 and 44.7%±9.6, respectively. The recorded sizes of the particles were 
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approximately 259 ± 10.58, 255 ± 6.4, 240 ± 6.5, and 256 ± 8.6 nm for 5-ASA/PLGA ratios 
of 0%, 2.5%, 5%, and 7.5% (w/w), respectively, as shown in Error! Reference source not f
ound.A. The zeta potentials of the particles were -33 ± 3.65, -34.9 ± 2.73, -33.6 ± 4.09, and -
33.2 ± 3.74 mV for 5-ASA/PLGA ratios of 0%, 2.5%, 5%, and 7.5% (w/w), respectively, as 
shown in Error! Reference source not found.B. The SEM images are shown in Figure 2.2B. 
Particles were approximately 250 nm in the SEM images, which verifies the results from the 
Zetasizer.  
 
Figure 2.2 SEM of the nanoparticles with different 5-ASA loading ratios. 
Microscopy 
Figure 2.3 shows the growth of the crypts within a 6-day timescale. Much like the 
control sample, none of the samples containing nanoparticles showed unusual growth behavior. 
As a confirmation, Figure S 2.1 shows that the size of organoids in all samples increased after 
6 days. Moreover, Figure 2.4 shows the effect of nanoparticles on organoids after 7 days. The 
green fluorescent nucleic acid stain is a membrane-permeable dye and a marker of live and 
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dead cells. The red fluorescent nucleic acid stain only labels dead cells. As shown in Figure 
2.4, none of the control samples showed red dots in the organoid area. Samples containing 
nanoparticles showed only two or three dead cells inside the organoid, the organoid structure 
was maintained, and the organoid was still healthy. 
 
Figure 2.3 Organoid's growth in 6-day time scale using inverted microscope. The 
magnification is 10X. Scale bars represent 200 µm. 
 Figure 2.5 shows the absorption of 40 µL of nanoparticle solution containing 0%, 1%, 
2.5%, and 5% the tracer dye RhodB inside the organoid’s lumen in a 7-day experiment. Red 
fluorescence is an indicator of the presence of RhodB in the system. The test was performed 
on the border of Matrigel for the sample containing 5% dyed nanoparticles and is shown in 
Figure 2.6. To evaluate the effect of larger amounts of nanoparticles on the diffusion, 400 µL 
of nanoparticle solution containing 2.5% RhodB was added to the cell culture medium. Thus, 
the volume of the particle solution was 10 times higher than that in the first experiment. The 
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picture of the system in z-direction is shown in Figure S 2.2. To assess the effect of chemistry 
on the diffusion, polystyrene (PS) nanoparticles with the same size as PLGA nanoparticles 
were tested. The fluorescent pictures are shown in Figure S 2.3A-C. 
 
Figure 2.4 Live (SYTO® 10) /dead (DEAD REDTM) cytotoxicity test recorded by confocal 
fluorescent microscope. Green fluorescent nucleic acid labels all live and dead cells. Red 
fluorescent nucleic acid labels the dead cells with compromised membrane. The magnification 
is 20X. Scale bars represent 100 µm. NP stands for nanoparticle. 
To assess the second method, Figure 2.7 shows the effect of mixing PLGA 
nanoparticles containing 2.5% RhodB with the organoids and Matrigel suspension on the 
diffusion of particles. The live/dead cytotoxicity test was performed without RhodB to observe 
the harmful effect of nanoparticles on the viability of the organoids (Figure 2.8). To quantify 




Figure 2.5 Bright field, DSU RFP and merged pictures of the organoids exposing 40 µl of (A) 
0% RhodB (B) 1% RhodB (C) 2.5% RhodB (D) 5% RhodB loaded PLGA nanoparticles in the 
cell culture medium using confocal fluorescent microscope within one week of experiments.  
Red areas are the indicators of the RhodB loaded inside the PLGA nanoparticles.. The 
magnification is 10X. Scale bars represent 200 µm. 
To find out the exact time of nanoparticle disappearance, the daily trend of nanoparticle 
tracking is shown in Figure 2.10. Moreover, the chemical structure and the size of the 
nanoparticles are of great importance in the organoid absorption. Thus, 200-nm latex beads 
loaded with FITC and 200-nm and 400-nm PA nanoparticles loaded with RhodB were tested 
to check the effect of size and chemical structure. The daily trends of tracking these 
nanoparticles in a 1-week time scale are shown in Figure S 2.4-6. 
Discussion 
The nanoparticle sizes are close to those found in the literature for PLGA nanoparticles 
with alginate as a surfactant.(33) As it is shown in Figure 2.1A, the size of nanoparticles is all 
in range. The zeta potential of the nanoparticles prepared by the double-emulsion method 
(Figure 2.1 B) is similar to those of the nanoparticles previously attained by solvent 
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diffusion.(38) These numbers show that the zeta potential is stable with changing 5-ASA ratios 
and that the overall charge of the particles is negative. Thus, the particles may easily attach to 
the positively charged inflamed region and release the drug there. 
 
Figure 2.6 Bright field, DSU RFP and merged pictures of the organoids exposing 40 µl of 5% 
RhodB loaded PLGA nanoparticles suspension at the border of Matrigel using confocal 
fluorescent microscope within one week of the experiments. Red areas are the indica tors of 
the RhodB loaded inside the PLGA nanoparticles. The magnification is 10X. Scale bars 
represent 200 µm. 
As seen in Figure 2.3, the normal growth of the organoids in samples containing 
nanoparticles compared to the control sample can be an indicator of the harmless 
characteristics of PLGA nanoparticles on the growth of organoids. This test can be verified as 
shown in Figure S 2.1, which quantifies the growth rate. All samples showed a progressive 
growth rate after 6 days. Live/dead cytotoxicity testing (Figure 2.4) confirmed this conclusion 
by showing the small number of dead cells inside the organoid area, which is comparable to 
that in the control sample without nanoparticles. As it is shown in Figure 2.4, the nanoparticles 
did not cause considerable cell death compared to the control sample and the major cell death 




Figure 2.7 Bright field, DSU RFP and merged pictures of the mixture of 10 µl of  2.5% RhodB 
loaded PLGA nanoparticles suspension, Matrigel and Organoids using confocal fluorescent 
microscope within one week of experiments. Red areas are the indicators of the RhodB loaded 
inside the PLGA nanoparticles. The magnification is 20X. Scale bars represent 100 µm. 
The EEs for 1%, 2.5% and 5% RhodB loaded nanoparticles were 32.8%, 45.5% and 
44.7%, respectively. Due to the higher loaded RhodB inside the nanoparticles by increasing 
the loading ratio, higher red color is expected in the lumen of the organoids. By increasing the 
amount of RhodB in the nanoparticle formulation, the red dye was more pronounced in the 
lumen of organoids (Figure 2.5A–C). However, this trend was not confirmed by 5% RhodB 
(Figure 2.5D). One possibility was the presence of nanoparticles at the border of the Matrigel 
and the lack of permeation inside the Matrigel. Figure 2.6 confirms the higher amount of 
RhodB in the lumen in response to the higher EE and shows a strong red color at the border of 
the Matrigel and the culture media. This figure confirms that the dyed particles did not enter 
the Matrigel.  
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Figure 2.8 Live (SYTO® 10)/ dead (DEAD REDTM) cytotoxicity test of the mixture of 10 µl 
0% RhodB loaded nanoparticles, Matrigel and Organoids recorded by confocal fluorescent 
microscope. Green fluorescent nucleic acid labels all live and dead cells. Red fluorescent 
nucleic acid labels the dead cells with compromised membrane. The magnification is 20X. 
Scale bars represent 100 µm. 
The red color in Figure 2.5A–C can be explained as either single dye molecules, which 
were present in the nanoparticle solution individually, or dye molecules that were already 
released from the nanoparticles. Three possible reasons can be considered in this case. First, 
the volume of nanoparticle solution added to the system was too small and hence, the amount 
of nanoparticles present in the solution was too small to penetrate the gel. Second, the chemical 
structure of PLGA does not allow the particles to penetrate the Matrigel. The third explanation 
may relate to the larger size of particles. As shown in a previous study, gold nanoparticles with 
a size of around 13 nm easily diffused inside the Matrigel.(21)  
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Figure 2.9 Comparison of organoids sizes without nanoparticle, with 0% RhodB and with 2.5% 
RhodB loaded nanoparticles in a one-week experiment. 
 The first explanation is rejected based on Figure S 2.2, where the volume of 
nanoparticles added to the system was 10 times higher than that used previously. The dyed 
nanoparticles accumulated on the upper curved side of the Matrigel and could not penetrate 
the gel. It is interesting that the organoids present in the Matrigel were also dyed, which is a 
confirmation of the presence of single RhodB molecules inside the gel. Evidently, there are no 
sharp red dots inside the entire Matrigel. Furthermore, the second explanation is not acceptable. 
As observed in Figure S 2.3A-C, the PS nanoparticles were all populated at the border of the 
Matrigel and could not penetrate the gel. Thus, the chemical structure is not the obstacle at the 
present stage of project but may need to be evaluated further. 
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Figure 2.10 Bright field, DSU RFP and merged pictures of the mixture of 10 µl 2.5% RhodB 
loaded nanoparticles, Matrigel and Organoids using confocal fluorescent microscope within 
one week of experiments. Red areas are the indicators of the RhodB loaded inside the PLGA 
nanoparticles. The magnification is 20X. Scale bars represent 100 µm. 
The only remaining explanation that needs to be investigated is the particle size. To 
correct for the failure of the nanoparticles to penetrate the Matrigel, a condition should be 
prepared in which organoids can be contacted without the diffusion requirement. As mentioned 
before, in the passage step of organoid culture, the nanoparticle suspension was mixed with 
the cell solution and subsequently with the Matrigel. After resuspension, the resultant mixture 
was applied onto the plate. Therefore, the Matrigel was seeded with crypts and nanoparticles 
that were located around the crypts. When the organoids grew, they were in close contact with 
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the nanoparticles and absorbed them. As a result, there was no need for nanoparticle 
penetration into the Matrigel. It is shown in Figure 2.7 that the nanoparticles were all absorbed 
into the lumen after 3 days. The red dots representing PLGA nanoparticles loaded with 2.5% 
RhodB at day 0 are seen all around the lumen. The red color inside the lumen at day 0 can be 
attributed to the free RhodB in the nanoparticle suspension. At day 3, there were no 
nanoparticles around the organoid, but they were all absorbed into the lumen. The sharp red 
color is an indicator that supports this theory. High EE of 2.5% loaded RhodB results in the 
high amount of RhodB entrapped inside the lumen. In contrast to the method of adding 
nanoparticle suspension to the culture medium, high EE of 2.5% loaded RhodB nanoparticles 
is completely sensible in the lumen of the organoids. Figure 2.8 shows that after 7 days of 
adding nanoparticles, no considerable harmful effect was observed compared to that in the 
control sample and the organoid growth rate was comparable to that of the control sample 
(Figure 2.9). However, the main challenge is the phenomenon that was observed after day 3 in 
Figure 2.7, when no RhodB was detected. To explain this phenomenon, tracking was 
performed every day for 7 days. 
Figure 2.10 shows the same phenomenon. No red indicator was observed after day 3, 
which can be correlated to the ability of the organoids to digest the particles. Furthermore, no 
red indicator was observed in the lumen after day 3. Another possibility is the degradation of 
the particles due to the enzymatic activity of the organoids, which results in the absorption of 
free RhodB inside the lumen and its desorption out of the lumen after day 4. To test this 
hypothesis, RhodB-loaded PA nanoparticles were tested. As Figure S 2.5 and 6 show, the 
RhodB-loaded PA nanoparticles showed the same trend. For larger nanoparticles, fewer 
nanoparticles can be absorbed inside the lumen, but for both samples, the RhodB was not active 
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after day 4, confirming the conclusion from Figure 2.10. As the absorption mechanism of 
organoids is not fully understood, it can be implied that the loaded organoids are mostly 
applicable in day 3. In day 3, the drug in fully absorbed inside the lumen and the organoid is 
ready to release the drug into the surrounding tissue. By complete release of the drug from 
organoid to the tissue, the drug molecule can locally affect the inflamed region. Latex bead 
nanoparticles could not diffuse inside the lumen and the FITC remained around the organoid 
for 7 days (Figure S 2.4). Latex beads are more stable, and less free FITC can be released from 
the nanoparticles. Moreover, the rate of degradation was lower in latex beads, which can 
confirm the second hypothesis that the released RhodB diffused inside the lumen.  
Conclusion 
IBD is a group of diseases that result in inflammation in any part of the GI tract. No 
permanent cure for this disease exists. The high number of people suffering from this disease 
all over the world leads to the design and production of different drug formulations to alleviate 
the symptoms. Trojan horse systems using ISCs seems to have promising potential in the 
pharmaceutical field. In this research, cell delivery treatments using 5-ASA-loaded PLGA 
nanoparticles have been proposed. It was hypothesized that loading nanoparticles containing 
drugs inside the lumen of intestinal organoids have highly appropriate characteristics that 
would be helpful in IBD treatment. 
PLGA nanoparticles were made by a double-emulsion (water/oil/water) method and 
tested to determine the characteristics. The size of nanoparticles containing 0, 2.5%, 5%, and 
7.5% (w/w) 5-ASA was in the range of 200–300 nm, and the data was confirmed with SEM 
images. The zeta potentials of the samples were all approximately -30 to -40 mV, which makes 
the particles completely ideal for attaching to the inflamed area. 
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As observed, the nanoparticles did not have a considerable harmful effect on the 
viability of the organoids, and they exhibited normal growth with or without the presence 
PLGA nanoparticles. It was also concluded that because of the large size of the nanoparticles, 
they could not diffuse into the Matrigel as they were. As the nanoparticles could not cross the 
border of the Matrigel, a new technique was proposed to improve the loading efficiency of the 
organoids. Nanoparticle suspension was mixed with the organoid suspension and Matrigel, and 
finally applied on the well. It was demonstrated that the nanoparticles were absorbed into the 
lumen and digested after 3 days. Furthermore, the PLGA nanoparticles mixed with organoids 
and Matrigel did not exhibit any negative effect on the organoids after 7 days, and the organoid 
growth rate was not significantly different compared to that of the control sample. It was 
interesting that the same trend of penetration was observed even after changing the 
nanoparticles to PA or changing the size of the nanoparticles from 200 nm to 400 nm. 
Therefore, this technique affirms the penetration of the nanoparticles inside the lumen without 
considerable negative effect on organoid growth. 
Despite the great development of nanoparticle-loaded organoids, much needs to be 
done to make the system more applicable. The insertion of a delivery system inside the colon 
and the assurance of its accuracy and operation in mice are necessary goals for this field. Thus, 
immunohistochemistry is of great help in determining the functionality and effectiveness of 
the system. Moreover, a method of checking the functionality of the system in mice (in vivo) 
must be designed. However, for the periodic evaluation, some external factors such as weight 
loss, food and water uptake, and the color of excrement can be monitored. It is worth noting 
that these tests are not generally precise because of the influence of various factors, including 
stress or infections.(39) Colonoscopy of mice is useful in achieving this goal. Based on the 
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advances made,(40) it can be helpful to apply the delivery system to the colon and monitor the 
colon constantly. Future goals will be to determine the effect of the treatment on mouse health. 
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Appendix: Supplementary figures 
 
Figure S 2.1 Comparison of organoids sizes containing different 5-ASA loading ratios at day 
0 and day 6. There is no nanoparticle in the well plate containing the control sample. 
 
Figure S 2.2 DSU RFP side view picture of 400µl of 2.5% 5-ASA loaded nanoparticle 
suspension addition into the cell culture media after 24h. Red areas are the indicators of the 





Figure S 2.3 (A) Bright field (B) DSU RFP and (C) Merged pictures of organoids seeded with 
dyed Polystyrene nanoparticles (latex beads) after 5 days. Red areas are the indicators of the 
RhodB loaded inside the Polystyrene nanoparticles.  The magnification is 20X. Scale bars 
represent 100 µm. 
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Figure S 2.4 Bright field, DSU RFP and merged pictures of the mixture of 10 µl latex beads, 
Matrigel and Organoids using confocal fluorescent microscope within one week of 
experiments. Green areas are the indicators of FITC. The magnification is 20X. Scale bars 
represent 100 µm. 
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Figure S 2.5 Bright field, DSU RFP and merged pictures of the mixture of 10 µl 400 nm 
polyanhydrides nanoparticles, Matrigel and Organoids using confocal fluorescent microscope 
within one week of experiments. Red areas are the indicators of the RhodB loaded inside the 
PA nanoparticles. The magnification is 20X. Scale bars represent 100 µm. 
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Figure S 2.6 Bright field, DSU RFP and merged pictures of the mixture of 10 µl 200 nm 
polyanhydrides nanoparticles, Matrigel and Organoids using confocal fluorescent microscope 
within one week of experiments. Red areas are the indicators of the RhodB loaded inside the 
PA nanoparticles. The magnification is 20X. Scale bars represent 100 µm. 
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Intestinal organoid can be used as an ex vivo epithelial model to study the effect of 
different drug delivery to the luminal surface of epithelial cells. In this study, the effect of 
surface charge on the delivery of 5-ASA loaded PLGA nanoparticle into the lumen of 
organoids was investigated. Alginate and chitosan were used to coat the nanoparticles and 
provide negative and positive charges on the particles, respectively. The organoid growth and 
viability was not affected by the presence of either alginate- or chitosan-coated nanoparticles. 
It was shown that nanoparticles could be transported from the serousal side of the organoids to 
the lumen as the dye gradually accumulated in the lumen by day 2-3 after adding the 
nanoparticles to the matrigel. By day 5, the dye was eliminated from the lumen of the 
organoids. It was concluded that the positively charged nanoparticles were more readily 
transported across the epithelium into the lumen. It may be attributed to the affinity of epithelial 
cells to the positive charge. Thus, the organoid can be utilized as an appropriate model to mimic 
the functions of the intestinal epithelium and can be used as a model to evaluate the benefits 




Inflammatory bowel disease, Nanoparticles, Alginate, Chitosan, Organoids. 
Introduction 
Inflammatory bowel disease (IBD) refers to a group of diseases that cause chronic 
inflammation in the small and large intestines of unknown etiology. Crohn’s disease and 
Ulcerative colitis are the two major classifications of IBD. Crohn’s disease occurs along the 
full length of the alimentary tract – esphogus to rectum - and involves the full thickness of 
mucosa; while ulcerative colitis which primarily involves the epithelial layer of rectum and 
colon is characterized by inflammation of the superficial mucosa.(1, 2) Genetic and 
environmental factors are regarded as the primary cause of IBD.(3) IBD patients encounter 
severe symptoms such as diarrhea, abdominal pain, rectal bleeding and, fever during 
inflammatory episodes(4) One common intervention  for  IBD  is  administration of 5-
aminosalicylic acid (5-ASA) or mesalazine to suppress inflammation.(4) However, the need 
of continual administration of 5-ASA at high dosages may result  in adverse  effects when used 
for extended periods of time.(5) 
Drug encapsulation inside  nanoparticles has attracted attention to decrease side effects 
resulting from the high dosage of active agent.(6, 7) Poly-lactic-co-glycolic acid (PLGA) as a 
biodegradable and biocompatible polymer has attracted attention in the field of drug 
delivery.(8-10) PLGA is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) 
and by changing the ratio of PLA to PGA in PLGA diverse physicochemical properties such 
as solubility, crystallinity and mechanical strength can be obtained from this polymer.(11) This 
polymer has also been used as a carrier for active agents to treat IBD. Lamprecht et al. used 
PLGA as the carrier of Rolipram and concluded that the system had superior targeting and 
accumulation in the site of inflammation and the prolonged drug release at the site of 
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action.(12) Moreover, PLGA has been proved to have high encapsulation efficiency and the 
ability to target sites of inflammation compared to free drug formulations or drug-loaded 
liposomes.(13) It was even shown that compared to pH sensitive nanoparticles, PLGA 
nanoparticles have more selective accumulation and higher drug concentration at the site of 
inflammation.(7)  However, Schmidt et al. by using PLGA nanoparticles in human models 
showed that using small sized nanoparticles for targeting is not always reliable.(14)  The study 
showed that smaller sized nanoparticles mostly appeared into blood system which increases 
the risk of systematic delivery.(14) To overcome this problem, some studies used other 
methods to improve targetting, such as coated PLGA nanoparticles or combining PLGA with 
other polymers.(15, 16)  
Intestinal organoid units are finger-like structures that result from the leucine rich-
extracellular domain (LGR5+) crypt based columnar (CBC) cells located at the bottom of the 
crypts.(17) In 2009, Sato et al. by developing a culture medium mimicking the stemness 
pathway, could culture organoids from small intestinal cryptal units.(18) Organoid units mimic 
the intestinal epithelium by having all the differentiated and undifferentiated cells of 
epithelium including enterocytes, goblet cells, Paneth cells and enteroendocrine cells 
surrounding the lumen.(19) Organoids can be passaged for more than 1.5 years and stay 
functional using proper growth factors.(17) Referring to the literature, organoid units have the 
ability to regenerate into functional intestinal tissue as a result of its stem-cell derived lineages 
and also applies as a model of intestinal epithelium.(20, 21) Our lab has previously suggested 
using organoids to facilitate nanoparticle delivery to IBD sites of intestinal inflammation.(22, 
23) 
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It was shown that small (13 nm) DNA-functionalized gold nanoparticles (GNPs) could 
be loaded efficiently inside the hollow lumen of organoids.(22) In other study, it was shown 
that intimate contact of alginate-coated PLGA nanoparticles, with a considerable larger size 
(~250 nm) compared to GNPs, resulted in nanoparticle uptake by the organoids.(23) PLGA 
nanoparticles did not impose any harmful effect to the organoid viability, cellular proliferation, 
or differentiation.(23) Alginate is a natural polymer produced by brown algae which is 
commonly used in biomedical applications because of its biocompatibility, low cost, and low 
cytotoxicity.(24) Alginate is composed of  (1,4) linked β-D-mannuronate (M) and α-L-
guluronate (G) which are connected in blocks of M, G, or MG.(25, 26) Deprotonated 
carboxylic acid groups on the backbone of alginate results in high negative charge of this 
polymer.(27) Based on the previous literature,  it was assumed that due to the abundance of 
cationic proteins in inflamed region, alginate-coated nanoparticles possessing a considerable 
negative charge would readily  absorb to the site of inflammation.(23, 28-31)  
However, in some studies, it has been mentioned that positively charge molecules have 
the ability to interact with the anionic components of the epithelial cells, such as glycoproteins. 
As a consequence of charge neutralization, a differential opening takes place and positively 
charged molecules are transported through the tight junctions.(32-34) Cationic polymers can 
grant positive charge to the nanoparticles. Chitin is a natural mucopolysaccharide which is 
composed of 2-acetamido-2-deoxy-β-d-glucose by a β (1→4) linkage. Chitosan is N-
deacetylated derivative of chitin and because of its natural origin, it too has superior 
biocompatibility, biodegradability, and low cytotoxicity to synthetic polymers.(35, 36) 
Chitosan is insoluble in neutral and basic pH but, forms salt in acidic conditions. By dissolution 
of chitosan, its amino groups become protonated and results in the overall positive charge of 
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the polymer. Moreover, chitosan exhibits diverse molecular weights, gelation and film forming 
properties and control over release rate which make it an ideal option in pharmaceutical 
industry.(37) Chitosan has been used as the coating for PLGA nanoparticles to make the 
particles mucoadhesive and increase the pharmaceutical properties of nanoparticles.(38) 
Chitosan coated PLGA nanoparticles loaded with nuclear factor kappa B (NF-κB) decoy 
oligonucleotide (ODN) has shown promising effect in the treatment of murine colitis  
models.(39) The positive charge of chitosan played the key role in this study as it interacted 
with the negatively charged cell membrane and resulted in the higher cellular uptake of 
nanoparticles coated with chitosan.(39)  
The research described herein focused on the application of murine-derived intestinal 
organoids as the epithelial platform to evaluate the potential of using different nanoparticles as 
a drug delivery vehicle for IBD treatment. Specifically, the effect of particle charge on PLGA 
nanoparticle transport across the epithelial membranehas been emphasized in this study. PLGA 
nanoparticles loaded with 5-ASA were coated with two different surfactants: one with a 
negative charge and one with a positive charge. The nanoparticles characteristics were 
determined using zeta sizer and the entrapment efficiency of organoids were characterized 
using optical and confocal fluorescent microscopy. 
Materials and Methods 
Materials 
Matrigel was purchased from Corning Inc (NY, USA). Epidermal growth factor (EGF), 
noggin, and R-spondin-1 (RS-1) were purchased from PeproTech Inc (Rocky Hill, NJ, USA). 
Poly (lactic-co-glycolic acid) (PLGA) was purchased from Evonik Industries (Essen, 
Germany) (5050 DLG 2A). 5-Aminosalicylic acid (5-ASA), alginic acid sodium salt, low 
molecular weight Chitosan (mol wt 50,000-190,000 Da), dichloromethane (DCM), and green 
106 
and red fluorescent nucleic acids were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Rhodamine B was purchased from Acros (Geel, Belgium). Advanced DMEM/F12, HEPES, 
Glutamax, Penicillin/Streptomycene, ProLong™ Glass Antifade Mountant, Alexa FlourTM 647 
phalloidin, and SYTOTM 9 green fluorescent nucleic acid stain were purchased from 
Thermofisher scientific/Invitrogen (OR, USA). All other materials were purchased from Life 
Technologies (Carlsbad, CA, USA). 
Nanoparticles preparation 
PLGA nanoparticles were prepared using single oil-in-water (o/w) emulsion/solvent 
evaporation method.(40) 5-ASA to PLGA ratio was measured as 0%, 1%, 2.5% and, 7.5% w/w 
when the total solid mass (PLGA and 5-ASA) was considered 100 mg. PLGA and 5-ASA were 
dissolved in 9 mL DCM and 1 mL ethanol, respectively. 190 mL of 0.2% (w/v) alginate in 
Nanopure water and chitosan in 2% (v/v) acetic acid was prepared. 5-ASA solution was added 
to PLGA solution and the oil-phase solution was added to the 30 mL of the surfactant solution 
(alginate or chitosan) through a syringe pump at constant rate of 60 mL/h under constant 
stirring of 200 rpm. The oil-in-water solution was formed using sonicator for 60 cycles (1 s 
each with a duty cycle of 80%) on ice bath. The solution was then added to 160 mL of the 
surfactant solution under stirring overnight at 200 rpm. The nanoparticles were collected by 
centrifugation at 10000 rpm and 4°C for 10 minutes and re-suspended twice. For tracking the 
nanoparticles, the 5-ASA was replaced with 2.5% (w/w) RhodB.  
Crypt isolation and culture 
Crypts were isolated from C3H/HeN wild type mouse using previously reported 
method.(22, 23)  All animal procedures were conducted with the approval of the Iowa State 
University Institutional Animal Care and Use Committee IACUC 9-04-5755-M. NIH 
guidelines for the care and use of laboratory animals (NIH Publication #85-23 Rev. 1985) have 
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been observed. The mouse small intestine was cut horizontally and washed thoroughly with 
PBS (pH=7.2). It was then cut vertically into small pieces and after several washing steps with 
PBS, 30 mL of ethylenediaminetetraacetic acid (EDTA) was added to the pieces. The test tube 
containing intestinal pieces and EDTA was placed in ice for 30 minutes. The supernatant 
EDTA was removed afterwards and the pieces were washed by PBS. At the next step, PBS 
was added to the pieces and by pipetting up and down, tissue pieces were allowed to settle and 
crypts were accumulated in the upper liquid. The supernatant was filtered using 70 µm Nylon 
cell strainer. The crypts were collected by centrifugation for 5 min at 1400 rpm and 4°C.  
The resultant crypts were suspended in Matrigel and applied on a 37 °C pre-warmed 
well plate. 500 µL primary culture medium containing 50 mL Basal medium (Advanced 
DMEM/F12, 1% V/V HEPES, 1% V/V Glutamax and 1% V/V Penicillin/Streptomycene), 0.5 
mL N2, 50 µl R-Spondin1, 1 mL B27, 50 µL NALC, 50 µl EGF, 50 µl Noggin and 50 µl R-
inhibitor was added to the well after gel formation. 
Nanoparticle characterization 
Nanoparticle size and zeta potential was measured by Zetasizer (Nano-Zs 90). In order 
to characterize the amount of dug loaded inside the nanoparticles, the solution after each step 
of washing was characterized using UV (SpectraMax M3) at λmax of 330 nm. The encapsulation 
efficiency ratio (%EE) was calculated using the following formulation.  
%𝐸𝐸 = [
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 5 − 𝐴𝑆𝐴 − 𝑢𝑛𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 5 − 𝐴𝑆𝐴
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 5 − 𝐴𝑆𝐴
] × 100 
Microscopy 
The growth rate of organoids was measured using Leica DMi1 inverted microscope for 
6 days. Nine different organoids were chosen from different plates and the area was measured 
using ImageJ. To quantitatively check the size of particles the area of the organoids in each 
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day was compared to its area at day 2 and the percentage of growth was calculated using 
following equation: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑔𝑟𝑜𝑤𝑡ℎ 
=  
(𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑜𝑟𝑔𝑎𝑛𝑜𝑖𝑑 ) − (𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑒 𝑜𝑟𝑔𝑎𝑛𝑜𝑖𝑑 𝑎𝑡 𝑑𝑎𝑦 2)
(𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑒 𝑜𝑟𝑔𝑎𝑛𝑜𝑖𝑑 𝑎𝑡 𝑑𝑎𝑦 2)
× 100 
To track the nanoparticles over time, 10 µl of nanoparticles suspension containing 2.5% 
RhodB (2 mg/mL) was added to the crypt-Matrigel suspension and mixed thoroughly. The 
mixture was applied on the pre-warmed well plate and culture medium was added after gel 
formation. The culture medium was added to the system every 4 days. The images were 
captured by confocal fluorescent microscopy (Olympus IX2) every day. To quantify the 
fluorescent of each organoid, the corrected total cell fluorescence (CTCF) was calculated using 
the following formulations. 
 𝐶𝑇𝐶𝐹 =  𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
− (𝐴𝑟𝑒𝑎 𝑜𝑓 𝑠𝑒𝑙𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙
×  𝑀𝑒𝑎𝑛 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑟𝑒𝑎𝑑𝑖𝑛𝑔𝑠) 
To ensure the nanoparticle entrapment inside the organoids, the staining and fixation 
used to check the lumen under high resolution laser microscope (Olympus FV1000). The 
mixture of organoids, Matrigel and 0% or 2.5% 5-ASA loaded nanoparticle coated with 
alginate and chitosan was applied on 8-well chamber slide and incubated for three days. At 
day three, 1µL of SYTOTM 9 (5Mm) was added to the culture medium of each chamber and 
incubated at 37 °C for an hour. The gel was then washed with PBS and left for 5 minutes (2-3 
times washing). The PBS was then removed and replaced with 4% paraformaldehyde (PFA) 
in PBS and incubated overnight in 37 °C incubator. The PFA was removed and the gel was 
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washed with PBS and left for 5 minutes. The next step was adding 500 μL of PBS to each 
chamber and adding 4 μL of phalloidin afterwards. The solutions were incubated in room 
temperature for an hour. After removing the solution and washing twice with PBS, the 
chambers were removed and antifade mountant was added to the samples. The coverslip was 
pressed on the chamber plate and stored for 24 to 48 h before images were captured by laser 
microscope. 
Live-dead cytotoxicity test 
The live/dead cytotoxicity was carried out at day 7. The culture medium of the samples 
having 0% 5-ASA nanoparticles coated with alginate and chitosan as well as the control 
samples were removed. 500 μl of Hank's Balanced Salt Solution (HBSS) was added to each 
well and left at room temperature for 2–3 min. Then the HBSS solution was replaced with 500 
µL of HBSS solution containing 1μl of Green (SYTO® 10) and red (DEAD REDTM) florescent 
nucleic acid stain. The cells were incubated in the dark for approximately 60 min and the dye 
solution was replaced with no phenol red HBSS afterwards. After staining step, the fixation 
step was initiated by replacing HBSS with 500 μl of 4% PFA. The cells were incubated in dark 
for another 1 h, and PFA was replaced with HBSS. The organoids were then observed with 
confocal fluorescent microscopy.  
Results 
Nanoparticle characterization 
The size of nanoparticle is an indication of appropriate synthesis of nanoparticles. Thus, 
nanoparticle’s size were evaluated in this study. As it is depicted in Figure 3.1, the 
nanoparticles coated with alginate have an average size of 228.6 ± 9.4, 229.0 ± 9.4, 232.1 ± 
7.5 and, 235.2  ± 8.6 for particles loaded with 0%, 2.5%, 5%, or 7.5% 5-ASA, respectively. 
For chitosan coated nanoparticles, the sizes were approximately 362.2 ± 49.3, 345.5 ± 23.02, 
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Figure 3.1 The mean size of the nanoparticles using different 5-ASA ratio for two different 
surfactants. Three separate batches of NPs were tested for each data point. 
 
Figure 3.2 The mean zeta potential of the nanoparticles using different 5-ASA ratio for two 
different surfactants. Three separate batches of NPs were tested for each data point. 
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The zeta potential of the nanoparticles is an indicator of surface charge of the particles. 
The zeta potential of the nanoparticles prepared by alginate surfactant are -41.31±10.36, -
52.07±5.3, -48.04±2.65 and, -46.89±4.7 for 0%, 2.5%, 5% and, 7.5% 5-ASA, respectively. 
Nanoparticles formed by using chitosan surfactant have the zeta potential of 53.63±10.2, 
47.91±4.51, 52.71±9.99, 46.49±4.13 for 0%, 2.5%, 5% and, 7.5% 5-ASA, respectively. The 
zeta potential of the samples is shown in Figure 3.2. 
Encapsulation efficiency of the nanoparticles coated with alginate were 50.6%±14.2, 
53.5±4.6, 73.9±4.2 for 2.5%, 5% and 7.5% 5-ASA, respectively. For the nanoparticles coated 
with chitosan, the encapsulation efficiencies were 32.7%±12.6, 67.5%±12.3 and 73.7%±3.4 
respectively for 2.5%, 5% and 7.5% 5-ASA. The  presentation of encapsulation efficiencies is 
shown in Figure 3.3. 
 
 
Figure 3.3 Encapsulation efficiency of 5-ASA loaded PLGA nanoparticles using alginate or 
chitosan as the surfactant. Three separate batches of NPs were tested for each data point. 
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Microscopy 
As previously discussed in the literature, 5-ASA affected proliferation and induced 
apoptosis in all of the cell lines that was tested.(41) In order to check the effect of 5-ASA on 
the proliferation and the fate of the cells presented in the organoid structure, organoids were 
incubated with nanoparticles loaded with different ratios of 5-ASA. The organoid’s growth in 
contact with alginate and chitosan coated PLGA nanoparticles were shown in Figure 3.4 and 
Figure 3.5, respectively. Moreover, the effect of different ratios of 5-ASA on organoid’s size 
is observable in the figures. The size of organoids at day-4 and day-6 is depicted in Figure 3.6. 
As it is shown the pictures, the size of the organoid’s exposed to either formulation of 
nanoparticles greater than that of the control organoids. The trend is observed in Figure 3.4 
and Figure 3.5. The quantitative results of organoid’s growth are presented in Figure S 3.1and 
Figure S 3.2. 
By using fluorescent microscopy, nanoparticles containing 2.5% (w/w) RhodB were 
tracked and the images from Day-0 to Day-6 are shown in Figure 3.7 and Figure 3.8. The 
nanoparticles are clearly detectable inside the lumen. The maximum activity of nanoparticles 
was observed on days 3-4. The fluorescent measurement of the nanoparticles is shown in the 
column bars of Figure 3.9. This figure showed the same trend that was mentioned in Figure 
3.7 and Figure 3.8. The maximum detection of fluorescent is observed in day-3 and day-4 and 




Figure 3.4 The trend of organoid's growth made by Alginate surfactant and different ratios of 
5-ASA using optical microscopy over 6-days (1:4 V/V Nanoparticle: Matrigel suspension). 
The magnification is 10X. The scale bar represents 200 µm. 
To check the loading properties of organoids, the organoids in contact with 
nanoparticles were checked by laser microscopy. As it is shown in Figure 3.10, Syto 9 could 
completely stain the cells and phalloidin could stain the actin filaments of the organoids. 
Moreover, RhodB is observable in samples containing RhodB loaded nanoparticles. RhodB is 
more detectable in the chambers having chitosan coated nanoparticles compared to alginate 




Figure 3.5 The trend of organoid's growth made by Chitosan surfactant and different ratios of 
5-ASA using optical microscopy over 6-days (1:4 V/V Nanoparticle: Matrigel suspension). 
The magnification is 10X. The scale bar represents 200 µm. 
Live-dead cytotoxicity test 
Figure 3.11 represents the effect of nanoparticles on organoids. Compared to the 
control, samples containing 10 μl PLGA nanoparticles coated with alginate or chitosan 
surfactant did not show cytotoxic effect. Red fluorescent nucleic acid represents dead cells and 
green fluorescent nucleic acid represents live and dead cells. Samples containing nanoparticles 




Figure 3.6 The percent change in area of the organoids relative to day-2 (1:4 V/V Nanoparticle: 
Matrigel suspension). More than nine organoids were tested for each sample. 
Discussion  
IBD constitutes a chronic inflammatory disorder affecting the small and large 
intestines. Severity and location of the inflammation will determine the optimal disease 
treatment.(1, 2) Nanoparticles have been used to improve the targeting and increase drug 
delivery to the site of inflammation.(12) Dependency on the size of nanoparticles for drug 
delivery, however, is not reliable because of the discrepancies between different studies.(14) 
Coating the nanoparticles to effect differential surface charges can be a method to increase the 
likelihood of nanoparticle interaction with the epithelium. An organoid unit is a structure that 
contains intestinal epithelial cells while preserving their functionality.(19) Due to the similarity 
of its structure and functionality with that of in vivo intestinal epithelium, it can be used as a 
model to mimic the  delivery nanoparticles through the epithelia and into the lumen.(21) Our 
group has previously studied the role of intestinal organoids as a model for drug delivery with 
PLGA nanoparticles. To evaluate the benefits of nanoparticles with different surface charges, 
the current research used two different surfactants to coat nanoparticles. Alginate with a 
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negative charge and chitosan with a net positive charge were selected for this research. PLGA 
nanoparticles using two different surfactants was made using single oil-in-water (o/w) 
emulsion/solvent evaporation method.  
 
Figure 3.7 Bright field, DSU RFP and merged pictures of the mixture of 10 µl 2.5% Rhodamine 
B loaded nanoparticles made by alginate surfactant, matrigel and organoids using confocal 
fluorescent microscope (1:4 V/V Nanoparticle: Matrigel suspension). The experiment was 
performed for six days after the passage. Red areas are the indicators of the Rhodamine B 
loaded inside the PLGA nanoparticles. The magnification is 10X. Scale bars represent 200 µm. 
Also, samples made with alginate as the coating surfactant are characterized by a 
negative surface charge while samples containing chitosan possess a positive surface charge. 
This phenomenon relates to the surface charge of each surfactant. Alginate has overall negative 
charge which results from deprotonated carboxylic acid on its backbone.(27) However, 
chitosan is known as a positively charged polymer due to the protonation of its amino groups 
while dissolved.(37) As surfactant is covering the nanoparticle, the charge of surfactant has 
direct effect on the overall nanoparticle zeta potential. Furthermore, increasing the loading 
percentage of 5-ASA in the NPs did not have any effect on the charge of nanoparticles. The 
surface charge of chitosan coated PLGA nanoparticles remained positive by increasing the 
ratio of 5-ASA and the surface charge of alginate coated PLGA nanoparticles remained 
negative by increasing the 5-ASA loading percentage (Figure 3.2). It can be confirmed that the 
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nanoparticles can be distinguished based on their charge for the rest of the study and the effect 
of different surface charges of the same nanoparticle on its intestinal delivery can be evaluated. 
 
Figure 3.8 Bright field, DSU RFP and merged pictures of the mixture of 10 µl 2.5% Rhodamine 
B loaded nanoparticles made by Alginate surfactant, Matrigel and Organoids using confocal 
fluorescent microscope (1:4 V/V Nanoparticle: Matrigel suspension). The experiment was 
performed for six days after the passage. Red areas are the indicators of the Rhodamine B 
loaded inside the PLGA nanoparticles. The magnification is 10X. Scale bars represent 200 µm. 
As it is shown in Figure 3.3, the encapsulation efficiency of the chitosan-coated or 
alginate-coated PLGA nanoparticles is not following any specific trend. However, they have 
almost the same range of encapsulation efficiency for different amounts of 5-ASA. Thus, we 
can conclude that effective dose of 5-ASA is successfully loaded inside the nanoparticles.  
Alginate-coated and chitosan-coated PLGA nanoparticles were mixed with Matrigel 
and organoid suspension to check the effect of those on organoid’s proliferation and growth. 
It was shown in Figure 3.4 and Figure 3.5 that compared to the control sample without any 
nanoparticles, the organoids in contact with nanoparticles show normal growth. This result 
confirms that neither alginate nor chitosan worsen the growth rate of organoids. It is assumed 
that alginate and chitosan surfactant, due to their natural sources, did not impose significant 
cytotoxicity on the epithelial cells.(42) Luciani et al reported that 5-ASA can decrease 
proliferation and induces cell apoptosis in all of the colonic cell lines that were tested by 
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keeping the cells in the S phase and inhibiting DNA synthesis.(41) It was mentioned that 5-
ASA intervention is independent of p53 mutation and thus the G1 arrest does not happen. It 
can be concluded that unlike G1 or G2 arrest in the case of S-phase inhibition, cell proliferation 
is delayed not inhibited.(41) In organoid structure, CBC cells are located at the bottom of the 
crypt and are surrounded by Paneth cells. After proliferation, they form daughter cells or transit 
amplifying cells. Daughter cells will differentiate into the differentiated epithelial cells and 
will shed of from the villus top into the lumen of the organoids. By increasing the proliferation, 
more daughter cells will form and consequently, more cells will be differentiated.(17) As a 
result, the size of the organoids will increase and thus, there is a direct relation between the 
size of the organoid and the proliferation of the cells. If the released 5-ASA decreases cell 
proliferation, it should be visible on organoid’s size. Based on the results in Figure 3.4 and 
Figure 3.5, by increasing the amount of 5-ASA no harmful effect threatens organoids compared 
to the control organoids. All samples present normal growth and by comparing the quantitative 
percent change of organoid’s area in Figure 3.9, organoids have positive increase in surface 
area at day-4 after culturing with or without nanoparticles. The percentage increased even more 
at day-6. The results were confirmed using Live/dead cytotoxicity test in Figure 3.11. SYTO® 
10 stains live and dead cells. Like control organoids, the organoids in contact with 
nanoparticles represents sharp green color. It confirms that most of the cells in an organoid 
stayed alive 7 days after adding nanoparticle to the mixture of organoids and Matrigel. DEAD 
REDTM stains dead cells. It is observed in Figure 3.11 that very few dead cells are detectable 
inside the organoids and most of the dead cells are out of the organoids area which may be the 
single cells remained inside the gel after passaging or the debris of the gel. The presence of 
dead cells cannot be attributed to the nanoparticle’s activity comparing the samples containing 
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nanoparticles with the control sample. The number of dead cells in control sample and samples 
containing nanoparticles with either alginate or chitosan as the surfactant is the same. 
 
Figure 3.9 Figure 3.9 Quantitative analysis of cell fluorescent recorded by confocal fluorescent 
microscope using alginate or chitosan as the surfactants for PLGA nanoparticles loaded with 
2.5% Rhodamine B. The nanoparticles were mixed with matrigel and organoid (1:4 V/V 
Nanoparticle: Matrigel suspension). More than nine organoids were measured for each sample. 
To check the nanoparticle entrapment, alginate or chitosan coated nanoparticles were 
loaded with 2.5% RhodB. Figure 3.7 and Figure 3.8 represents the daily tracking of 
nanoparticles using confocal fluorescent microscope. Much like the results from previous 
study(23), nanoparticles were accumulated into the lumen at a certain time point. Based on 
Figure 3.7 and Figure 3.8, the nanoparticles are randomly distributed around the organoid at 
day-0. Organoids start to uptake nanoparticles after that and day-4 was the day that maximum 
fluorescent was detected inside the lumen. It was assumed that after maturation of organoids 
and formation of absorptive cells, the organoids are able to absorb particles. The nanoparticles 
were all accumulated inside the lumen at day-4 which the organoid maturation in sufficient. 
Moreover, RhodB was not detected inside the lumen after day-4. It may be because of the free 
RhodB which is leaching out of the nanoparticles after day-4 or the degradation of 
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nanoparticles inside the lumen. Thus, the organoid pumps out the soluble RhodB through 
enterocytes and no more RhodB is detected afterwards.  
 
Figure 3.10 Laser microscopy of organoids after adding 2.5% loaded PLGA nanoparticles 
coated with Alginate and Chitosan (1:4 Nanoparticle: Matrigel). Green represents SYTOTM 
9, magenta represents phalloidin, and red represents Rhodamine B. The magnification of 
images is 40 X with digital zoom of 1.8 and scale bars represents 20 μm.  
Moreover, there is a difference between the detected fluorescent using two different 
surfactants. Comparing Figure 3.7 and Figure 3.8, it appears that the positive charge of the 
particles coated with chitosan had a greater effect on its transport through the epithelial layer. 
The data was confirmed quantitatively in Figure 3.9. Quantitative results of Figure 3.9 show 
that in the first three days, nanoparticles coated with chitosan as the surfactant may be more 
transported through the epithelial layer inside the lumen of organoids because the average of 
fluorescent in different organoids in contact with chitosan coated nanoparticles is higher than 
the organoids in contact with alginate coated nanoparticles. This trend is more pronounced at 
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day-4 which organoids represents their maximum fluorescence. This may be due to the higher 
affinity of epithelial cells to transfer positively charged particles because of their interaction 
with the negatively charged epithelial glycoproteins.(32-34) It was stated that there is a specific 
interaction between the chitosan and surface of epithelial layer. It seems that the positive 
charge of macromolecules such as chitosan enables them to interact with the negative charge 
of the epithelial layer’s anionic components such as sialic acid.(32) The PLGA nanoparticles 
coated with chitosan are also effluxed faster than alginate coated PLGA nanoparticles and less 
fluorescence is observed at day 5 and 6. 
 
Figure 3.11 Live (SYTO® 10)/ dead (DEAD REDTM) cytotoxicity test of organoids in contact 
with 10 μl PLGA nanoparticles coated with Chitosan and Alginate surfactant recorded by 
confocal fluorescent microscope (1:4 Nanoparticle: Matrigel). Green fluorescent nucleic acid 
labels all live and dead cells. Red fluorescent nucleic acid labels the dead cells with 
compromised membrane. The magnification is 20X and the scale bar represents 100 μm. 
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To eliminate the effect of free RhodB of the nanoparticle suspension, the organoids are 
in contact with 2.5% RhodB loaded PLGA nanoparticles coated with alginate or chitosan 
surfactant were fixed. The organoids were stained with Phalloidin and DAPI to investigate the 
cell viability and normal activity. Phalloidin is a representative of bicyclic heptapeptide family 
called Phallatoxins that are derived from poisonous mushrooms. Phalloidin is able to tightly 
bind to the actin filaments. Fluorescent derivatives of Phalloidin can visualize actin filaments 
in live and fixed cells.(43) F-Actin filaments have role in polarized cells growth, migration of 
the cells, and cytokinesis.(44) As it is shown in Figure 3.10, localization of F-Actin in the 
apical surface demonstrate that organoids polarization is preserved.(45) SYTO dye family can 
penetrate intact cells and thus, it can stain live cells.(46) SYTOTM 9 is a green stain that can 
permeate through the cell membrane and stains the nucleic acid of the cells.(47) SYTOTM 9 
has labeled the nucleic acid of the cell in the whole organoid in Figure 3.10. RhodB (red) is 
fully detectable inside the lumen at day-3 for nanoparticles coated with both charges. However, 
the red color is much more pronounced having chitosan surfactant. As it is detectable in Figure 
3.10, 2.5% RhodB loaded chitosan coated PLGA nanoparticles are more uptaken by organoids 
compared to the alginate coated nanoparticles with the same amount of dye.  This phenomenon 
is a confirmation of the idea that epithelial layers of small intestine is more prone to entrap 
positively charged nanoparticles.  
Conclusion 
IBD is characterized by chronic inflammation in the GI tract which is responsive to 
some drug therapy. 5-amino salicylic acid or 5-ASA has been used for the treatment. However, 
conventional drug therapies lack targeting to the inflammation site and, therefore, may have 
off-target effects. This research has been focused on using different particle charges for 5-
amino salicylic acid or 5-ASA encapsulated PLGA nanoparticles and using an in vitro model 
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to evaluate the affinity of epithelial layer to entrap nanoparticles with different surface charges. 
Small intestinal organoids were used as a model to evaluate the nanoparticles encapsulation.  
In this study, negatively charged alginate and positively charged chitosan have been 
used as the surfactant for making 5-ASA loaded PLGA nanoparticles. The nanoparticles coated 
with chitosan have slightly larger sizes compared to the alginate coated PLGA nanoparticles. 
The negative charge of alginate and the positive charge of chitosan result in the negative and 
positive overall charge of the PLGA nanoparticles, respectively.  
The organoids in contact with either alginate-coated or chitosan-coated nanoparticles 
show normal growth compared to the control sample. The rate of proliferation was not affected 
by adding nanoparticles or increasing the amount of loaded drug inside the nanoparticles. 5-
ASA did not impose any effect on hindering or delaying cell proliferation. As a conclusion, 
there is no threaten from nanoparticles, surfactants coating nanoparticle or 5-ASA side to the 
proliferation of the epithelial cells. 
The organoids entrapped nanoparticles gradually and there was a maximum entrapment 
at day-4 for both nanoparticles. Moreover, organoids may entrap the chitosan coated PLGA 
nanoparticles better than alginate coated nanoparticles. It was assumed that epithelial cells have 
more affinity to positively charged particles due to the interaction with negatively charged 
glycoproteins.  
This research focused on the effect of particle characteristics on their epithelial 
entrapment in organoid models. As a conclusion, using positively charged nanoparticles may 
significantly increase the amount of nanoparticle entrapment through the epithelium layer of 
intestinal tissue and this would be a huge understanding in using nanoparticles for IBD 
treatment. In case of IBD treatment, using positively charged particles will facilitate 
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entrapment. Increased entrapment results in a huge efficiency in targeting of 5-ASA to the 
inflammation cite and as a result more suppression in case of IBD can be expected. Moreover, 
this study confirms that organoids are a reliable model for nanoparticle delivery investigation 
in epithelial layer which decreases the number of animal scarification. In conclusion, this study 
brought up the idea of using organoids as the epithelial barrier model and positively charged 
nanoparticles loaded with 5-ASA has shown to be a better match for IBD treatment. 
References 
1. Michalčíková RB, Dryahina K, Španěl P. SIFT-MS quantification of several breath 
biomarkers of inflammatory bowel disease, IBD: A detailed study of the ion chemistry. 
International Journal of Mass Spectrometry. 2016;396:35-41. 
2. Ali H, Weigmann B, Collnot E-m, Khan SA, Windbergs M, Lehr C-m. Budesonide 
loaded PLGA nanoparticles for targeting the inflamed intestinal mucosa — 
pharmaceutical characterization and fluorescence imaging. Pharmaceutical Research. 
2015;33(5):1085-92. 
3. Neurath MF. Cytokines in inflammatory bowel disease. Nature Reviews Immunology. 
2014;14(5):329. 
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and 
established and evolving therapies. The Lancet. 2007;369(9573):1641-57. 
5. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best 
Practice & Research Clinical Gastroenterology. 2010;24(2):157-65. 
6. Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaïli L, et al. 5-amino 
salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. 
Journal of Controlled Release. 2007;123(3):211-8. 
7. Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: 
particle targeting versus pH-sensitive delivery. International Journal of Pharmaceutics. 
2006;316(1-2):138-43. 
125 
8. Chandra L, Borcherding DC, Kingsbury D, Atherly T, Ambrosini YM, Bourgois-
Mochel A, et al. Derivation of adult canine intestinal organoids for translational 
research in gastroenterology. BMC Biology. 2019;17(1):1-21. 
9. Omagari D, Iijima M, Suguro H, Sato I, Asano M, Moro I. Differential distribution of 
mouse polymeric immunoglobulin receptor (mpIgR): establishment of enzyme-linked 
immunosorbent assay system for mpIgR. Scandinavian Journal of Immunology. 
2008;68(5):543-51. 
10. Fair KL, Colquhoun J, Hannan NR. Intestinal organoids for modelling intestinal 
development and disease. Philosophical Transactions of the Royal Society B: 
Biological Sciences. 2018;373(1750):20170217. 
11. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable 
controlled drug delivery carrier. Polymers. 2011;3(3):1377-97. 
12. Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, et al. 
Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory 
bowel disease. Journal of Pharmacology and Experimental Therapeutics. 
2001;299(2):775-81. 
13. Leonard F, Ali H, Collnot E-M, Crielaard BJ, Lammers T, Storm G, et al. Screening of 
budesonide nanoformulations for treatment of inflammatory bowel disease in an 
inflamed 3D cell-culture model. ALTEX-Alternatives to Animal Experimentation. 
2012;29(3):275-85. 
14. Schmidt C, Lautenschlaeger C, Collnot E-M, Schumann M, Bojarski C, Schulzke J-D, 
et al. Nano-and microscaled particles for drug targeting to inflamed intestinal 
mucosa—A first in vivo study in human patients. Journal of Controlled Release. 
2013;165(2):139-45. 
15. Ali H, Weigmann B, Neurath M, Collnot E, Windbergs M, Lehr C-M. Budesonide 
loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in 
mouse models of inflammatory bowel diseases. Journal of Controlled Release. 
2014;183:167-77. 
16. Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Préat V. pH-sensitive 
nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. 
International Journal of Pharmaceutics. 2014;473(1-2):203-12. 
126 
17. Davoudi Z, Wang Q. Intestinal tissue engineering with intestinal stem cells.  Smart 
Materials for Tissue Engineering2017. p. 329-57. 
18. Sato T, Vries RG, Snippert HJ, Van De Wetering M, Barker N, Stange DE, et al. Single 
Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche. 
Nature. 2009;459(7244):262. 
19. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: 
mechanism and applications. Science. 2013;340(6137):1190-4. 
20. Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and 
regeneration. Nature Reviews Molecular Cell Biology. 2014;15(1):19. 
21. Date S, Sato T. Mini-gut organoids: reconstitution of the stem cell niche. Annual 
Review of Cell and Developmental Biology. 2015;31:269-89. 
22. Peng H, Wang C, Xu X, Yu C, Wang Q. An intestinal Trojan horse for gene delivery. 
Nanoscale. 2015;7(10):4354-60. Epub 2015/01/27. 
23. Davoudi Z, Peroutka‐Bigus N, Bellaire B, Wannemuehler M, Barrett TA, Narasimhan 
B, et al. Intestinal organoids containing poly (lactic‐co‐glycolic acid) nanoparticles for 
the treatment of inflammatory bowel diseases. Journal of Biomedical Materials 
Research Part A. 2018;106(4):876-86. 
24. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Progress in 
Polymer Science. 2012;37(1):106-26. 
25. Siew CK, Williams PA, Young NW. New insights into the mechanism of gelation of 
alginate and pectin: charge annihilation and reversal mechanism. Biomacromolecules. 
2005;6(2):963-9. 
26. Rowley JA, Madlambayan G, Mooney DJ. Alginate hydrogels as synthetic 
extracellular matrix materials. Biomaterials. 1999;20(1):45-53. 
27. Li M, Elder T, Buschle-Diller G. Alginate-based polysaccharide beads for cationic 
contaminant sorption from water. Polymer Bulletin. 2017;74(4):1267-81. 
127 
28. Jubeh TT, Barenholz Y, Rubinstein A. Differential adhesion of normal and inflamed 
rat colonic mucosa by charged liposomes. Pharmaceutical Research. 2004;21(3):447-
53. 
29. Dahan A, Amidon GL, Zimmermann EM. Drug targeting strategies for the treatment 
of inflammatory bowel disease: a mechanistic update. Expert Review of Clinical 
Immunology. 2010;6(4):543-50. 
30. Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A. Local prevention of oxidative 
stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide 
dismutase and tempamine. Molecular Pharmaceutics. 2005;2(1):2-11. 
31. Tirosh B, Khatib N, Barenholz Y, Nissan A, Rubinstein A. Transferrin as a luminal 
target for negatively charged liposomes in the inflamed colonic mucosa. Molecular 
Pharmaceutics. 2009;6(4):1083-91. 
32. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of 
monolayers of intestinal epithelial cells (Caco-2). Pharmaceutical Research. 
1994;11(9):1358-61. 
33. Hart MN, VanDyk LF, Moore SA, Shasby DM, Cancilla PA. Differential opening of 
the brain endothelial following neutralization of the endothelial luminal anionic charge 
in vitro. Journal of Neuropathology & Experimental Neurology. 1987;46(2):141-53. 
34. Bannunah AM, Vllasaliu D, Lord J, Stolnik S. Mechanisms of nanoparticle 
internalization and transport across an intestinal epithelial cell model: effect of size and 
surface charge. Molecular Pharmaceutics. 2014;11(12):4363-73. 
35. Kumar MNR. A review of chitin and chitosan applications. Reactive and Functional 
Polymers. 2000;46(1):1-27. 
36. Davoudi Z, Rabiee M, Houshmand B, Eslahi N, Khoshroo K, Rasoulianboroujeni M, 
et al. Development of chitosan/gelatin/keratin composite containing hydrocortisone 
sodium succinate as a buccal mucoadhesive patch to treat desquamative gingivitis. 
Drug Development and Industrial Pharmacy. 2018;44(1):40-55. 
37. Ilium L. Chitosan and its use as a pharmaceutical excipient. Pharmaceutical Research. 
1998;15(9):1326-31. 
128 
38. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive DL-
lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery 
of elcatonin. Pharmaceutical Development and Technology. 2000;5(1):77-85. 
39. Tahara K, Samura S, Tsuji K, Yamamoto H, Tsukada Y, Bando Y, et al. Oral nuclear 
factor-κB decoy oligonucleotides delivery system with chitosan modified poly (D, L-
lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials. 
2011;32(3):870-8. 
40. Wang Q, Wang J, Lu Q, Detamore MS, Berkland C. Injectable PLGA based colloidal 
gels for zero-order dexamethasone release in cranial defects. Biomaterials. 
2010;31(18):4980-6. Epub 2010/03/23. 
41. Schneeberger K, Spee B, Costa P, Sachs N, Clevers H, Malda J. Converging 
biofabrication and organoid technologies: the next frontier in hepatic and intestinal 
tissue engineering? Biofabrication. 2017;9(1):013001. 
42. Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. 
Advanced Drug Delivery Reviews. 2006;58(4):487-99. 
43. Cooper JA. Effects of cytochalasin and phalloidin on actin. The Journal of Cell 
Biology. 1987;105(4):1473-8. 
44. Hotulainen P, Paunola E, Vartiainen MK, Lappalainen P. Actin-depolymerizing factor 
and cofilin-1 play overlapping roles in promoting rapid F-actin depolymerization in 
mammalian nonmuscle cells. Molecular Biology of the Cell. 2005;16(2):649-64. 
45. Leslie JL, Huang S, Opp JS, Nagy MS, Kobayashi M, Young VB, et al. Persistence 
and toxin production by Clostridium difficile within human intestinal organoids result 
in disruption of epithelial paracellular barrier function. Infection and Immunity. 
2015;83(1):138-45. 
46. Serra D, Mayr U, Boni A, Lukonin I, Rempfler M, Meylan LC, et al. Self-organization 
and symmetry breaking in intestinal organoid development. Nature. 
2019;569(7754):66-72. 
47. Fujii M, Matano M, Nanki K, Sato T. Efficient genetic engineering of human intestinal 




Appendix: Supplementary figures 
 
Figure S 3.1 The area of the organoids in contact with PLGA nanoparticles using Alginate 
surfactants in a 6-day time scale. 
 
Figure S 3.2 The area of the organoids in contact with PLGA nanoparticles using Chitosan 
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There has been a great need in developing a 3-dimensional (3D) ex-vivo model on 
intestinal tissue. Development of 3D organoid of small intestine has been a great breakthrough 
in drug development and biological research. Mouse colonoid culture condition, however, has 
been challenging for a while. There were many proposed methods and lack of consistency 
hindered application of each model.  In this research a new easy and cost-effective method for 
colonoid culture has been proposed. Intestinal homogenate was introduced as the culture media 
in this research. The colonoids cultured using homogenate showed great proliferation and 
differentiation and could preserve their structure for more than 6 passages. There was enough 
similarity between these colonoids and colon tissue. In order to evaluate the functionality of 
colonoids, permeability with 4 kDa and 40 kDa were tested and neither of those could permeate 
through the epithelium barrier. P-glycoprotein receptor has shown to be functional and its 
inhibition by verapamil significantly decreased Rhodamin 123 fluorescence. Forskolin 
treatment resulted in swelling which confirmed the functionality of CFTR. This model showed 
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Introduction 
Intestinal tissue is one of the most prominent organs responsible for many vital 
functionalities. Two major parts of intestinal tissue are small intestine and colon. Small 
intestine comprises of three sections including duodenum, jejunum and ilium and contains 
highly folded epithelium with villi, microvilli, and crypts. This folding results in increased 
surface area which make it ideal for digestion and nutrient absorption. Colon also comprises 
of different regions including the ascending, transverse, descending and sigmoid colon. Colon 
has a fairly flat surface and lacks villi, but it still includes alternative crypts. The main function 
of colon is water, ion, and vitamins uptake.(1) 
The intestinal epithelium covers the intestinal lumen. Long lived intestinal stem cells 
(ISCs) are located at the bottom of crypt and reproduce progenitor cells called transit-
amplifying (TA) cells which will differentiate into differentiated epithelial cells. TA cells by 
proliferating migrate up and mature up into the differentiated epithelial cells. ISCs in small 
intestine differentiate into enterocytes, goblet cell, enteroendocrine cell and Paneth cells while 
colonic ISCs mature up into enterocytes, goblet cells and enteroendocrine cells.(2)  
There are many intestinal related biological researches in need of an exact model to 
simulate the intestinal condition ex vivo. Using the ability of long term self-renewal and multi-
potent differentiation of intestinal stem cells(2), Sato developed organoid structure in 2009.(3) 
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Organoids first developed from crypt part of small intestine and were grown into a three-
dimensional (3D) structure that simulated the intestinal epithelium. Key components of 
forming murine small intestinal organoids were a 3D matrix to form the ECM of the cells, 
agonists of Wnt (R-spondin1), epidermal growth factor (EGF), antagonists of bone 
morphogenetic protein (BMP) (Noggin), and notch signaling inhibitor (N-acetylcysteine).(4) 
Intestinal organoids have replicated many properties of small intestinal epithelium and many 
researchers have used this 3D model to improve their ex vivo research.(5-8)  
This rate of progress has been much limited for colonoids (organoids isolated from 
colon) of murine models compared to intestinal organoids. The main reason behind that lies in 
the lack of Paneth cells in colon. In small intestinal organoid the proximity of G protein-
coupled receptor with leucine rich-extracellular domain (LGR5+) Crypt-Based Columnar 
(CBC) stem cells to Paneth cells is regarded as the key element in maintaining the niche for 
stem cells. Paneth cells in small intestine are a great source of growth factors like Wnt, EGF, 
and Notch ligands (Dll1 and Dll4).(9, 10) It was shown that the interaction between Paneth 
cells and LGR5+ CBC cells provide the niche for functionality of CBC cells as Paneth cells 
provide essential niche signals and secret bactericidal products.(11) Thus, Paneth cells are 
considered a niche-controlling element. 
Wnt signalling is one of the most prominent pathways that determine the stem cell fate. 
In the presence of Wnt signaling, Wnt ligands attach to the receptors of Frizzled family and a 
member of the LDL receptor family, Lrp5/6. This process results in the interaction of axin with 
Lrp5/6 and detachment of β-catenin protein from scaffolding proteins called destruction 
complex (Tumor suppressors adenomatous polyposis coli (APC) and axin and also glycogen 
synthase kinase-3- β (GSK3-β) kinase). Wnt signaling results in decoupling of β-catenin from 
133 
destruction complex and its translocation to the nucleus of the cell. Finally, it will react with 
Tcf/Lef transcription factors and activating Wnt target genes. (12-14)  Wnt signaling can 
determine the cell fate according to β-catenin binding to the coactivators like Creb binding 
protein (CBP) or p300. p300/ β-catenin leads to more differentiation while CBP/ β-catenin 
binding maintain the stem cell potency.(14) In the case of lack of Wnt signaling, β-catenin will 
encounter phosphorylation and finally enter a destruction complex because of its attachment 
to APC, axin , and GSK-3β.(12, 13)  
As discussed earlier, colonoids lack Paneth cells which means lack of Wnt signaling 
and other growth factors. The source of stem cell niche is unclear in colon tissue.(15) Many 
studies have worked on finding the niche of stem cells in colon tissue. Some believes that due 
to lack of paneth cells, an actively cycling source of cells should be existed to serve as stem 
cells in case of regeneration.(16) Other studies suggested a source of crypt-base goblet cells 
that express cKit/CD117 act like Paneth cells. It was shown that these cKit+ goblet cells have 
some similar expression as in Paneth cells and were proposed as the niche for colon LGR5+ 
cells.(17) Despite these studies, mouse colonoids have shown to be dependent on exogenous 
Wnt for growth.(18) Some studies believed that mesenchymal Wnt may be the Wnt source 
necessary for colonic stem cell maintenance.(15, 19) Basler group assumed that GLI1+ 
mesenchymal cells are located close to the base of crypts and is a source of Wnt ligands for 
colonic stem cells homeostasis.(15) Given all the data here, there are still controversies on the 
source of Wnt ligands in colon but, the obvious point in all studies was using extra Wnt in 
culture media for colonoid growth. 
Clevers’ group by adding recombinant Wnt3A to organoid culture media for culturing 
murine colonoid were not successful in attaining enough differentiation.(18) Other groups also 
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tried to optimize the clevers’ culture condition by adding growth factors to the Matrigel or 
lowering down the amount of growth factors while culturing cells on different plates.(20) Some 
researchers also applied L-WRN cell media (conditioned media from L-WRN cells) 
supplemented with human epidermal growth factor to compensate lack of growth factors for 
colonoid growth.(21) Some studies also used the same idea but with different conditioned 
media such as separate Wnt3A-conditioned media and R-spondin-2 conditioned media 
accompanied with other growth factors and supplements.(22) Moreover, in order to grant the 
colonoids enough growth factors, some studies used co-culture techniques with subepithelial 
myofibroblasts cell line (WEHI-YH2).(23) Each of these methods have their advantages 
and disadvantages that needs to be considered. Moreover, not all of them have satisfactory 
properties and functionality. Thus, there is a need for a universal method that improve the 
mentioned protocols. 
In this research, we were looking for a simple and cost effective method of colonoid 
culture that can provide acceptable colonoid structure and functionality. We proposed a 
new homogenate culture media for mouse colonoid and evaluated the colonoids grown 
with these conditions. Moreover, some other methods from previous studies has been 
experimented to compare to the obtained results.  
Materials and Methods 
Colonoid isolation 
Colonoids were isolated from 129 altered Schaedler flora (ASF) mice at Iowa State 
University. All animal procedures were conducted with the approval of the Iowa State 
University Institutional Animal Care and Use Committee. All methods and procedures in the 
experiments were performed in full compliance with the committee's guidelines and 
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regulations. The colon of the mice was cut horizontally and vertically into small pieces and 
washed with PBS several times. After several washing steps, the upper PBS was removed and 
by addition of 30 mL of Ethylenediaminetetraacetic acid (EDTA), the system was left in ice 
and shacked for 30 minutes. Then, the EDTA solution was sucked out and the pieces were 
washed with PBS. Thereafter, by pipetting up and down with PBS, the final solution was 
achieved. The final solution was filtered and after centrifugation for 5 min at 1400 rpm and 
4°C, the final crypts were appeared. Extracted crypts were suspended with Matrigel and 
applied on a pre-warmed 24-well plate. 
Colonoid maintenance 
 500 μl of culture media was added to each well after gel formation. The final culture 
medium was a 1:1 mixture of Complete media with growth factor (CMGF+) and homogenate. 
CMGF+ includes CMGF- (1X Advanced DMEM/F12 (Gibco), 2mM Glutamax (Fisher), 
10mM HEPES (Fisher), and 100ug/ml Primocin (InvivoGen)), 1X N2 Supplement (Fisher), 
1X B27 supplement (Fisher), 1 mM N-acetylcysteine (Sigma-Aldrich),  50 ng/mL  EGF  
(PeproTech),  100 ng/mL Noggin (PeproTech), 500 ng/mL R-spondin-1 (Pepro-Tech), 100 
ng/mL Wnt 3a (PeproTech), 10 nM Gastrin(Sigma-Aldrich), 10 mM Nicotinamide (Sigma-
Aldrich), 5mM A83-01 (TGFβtype I receptor inhibitor; Tocris), 50μM SB202190 (P38 
inhibitor; Sigma-Aldrich), and 8% FBS  (Atlanta  Biologicals),  supplemented  with  10μM 
rho-associated kinase inhibitor (ROCKi) Y-27632 (Stem-Gent) and 2.5μM glycogen synthase 
kinase 3β (GSK3β) inhibitor CHIR99021 (StemGent). Murine culture media included Basal 
media (1X Advanced DMEM/F12, 2mM Glutamax, 10mM HEPES, and 1X Penstrep (Gibco)), 
1X N2 Supplement, 1X B27 supplement, 1 mM N-acetylcysteine,  50 ng/mL  EGF,  100 ng/mL 
Noggin, 500 ng/mL R-spondin-1, 100 ng/mL Wnt 3a. The conditioned media was extracted 
after L-WRN (ATCC® CRL-3276TM) culture and collecting the media. 
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For making homogenate, small intestine and colon of different mice strains were 
isolated after mice euthanization. Tissues were cut horizontally and washed with ice cold PBS 
three times and cut into small pieces. Basal media was added to the tissue with 1:20 W/V ratio 
and were homogenized with omni blender (OMNI TH (OMNI International)) for 2 minutes. 
The solution was then centrifuged at 4°C and 10000 rpm (15334 rcf) for 30 minutes. The 
supernatant was then sucked up and transferred to a new tube. 10% FBS was added to the 
solution and the solution was filter sterilized with 2.2 μm filter. The solution was frozen at -
20°C until utilization. 
Different passaging techniques used were physical passaging and chemical passaging. 
Physical passaging includes breaking the gel with pipette tip using basal media and collecting 
colonoids in a tube. After vigorous vortexing and pipetting up and down, colonoid suspensions 
were centrifuged at 4°C and 200 rcf for 5 minutes. New Matrigel was added to the pellet after 
centrifugation and re-plated. Gel was set for 10-20 minutes and culture media was added to 
each well. Chemical passaging was performed using TryplEEM express. After suspending the 
colonoids in basal medium and centrifuging them at 4°C and 200 rcf for 5 minutes, 1 ml of 
TrypLEEM express was added to the colonoid and left at 37°C for different amount of time. 
After dissociation and termination of reaction by adding 4 ml of basal medium, cells were 
centrifuged at 4°C and 200 rcf for 5 minutes. Matrigel was mixed with colonoids pelleted 
afterwards and they were re-plated. Gel was set for 10-20 minutes and culture media was added 
to each well. 
Tissue and enteroid characterization and fixation for histopathology 
The growth trend of colonoids was measured using Leica DMi1 inverted microscope 
for 6 days. More than nine colonoids were used for each group.  For histopathology (H&E) 
and immunohistochemistry (IHC), small intestine and colon tissue were incubated in 10% 
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formalin (Fisher) for 24h and then stored in 70% ethanol. 8-10 wells of organoids and 
colonoids were fixed in 10% formalin for 7 minutes and stored in 70% ethanol. Fixed tissues 
and enteroids were embedded in paraffin blocks and were cut into slides. Image were captured 
by optical microscopy (Olympus BX40). 
Immunostaining for pIgR 
After culturing colonoids for 5-7 days in 8-wells chamber slide, culture media was 
replaced with 250 μl of 4% PFA/PBS at room temperature for 40 minutes. Removing fixative 
was followed by washing each well with PBS and adding 200 μl of permeabilization buffer 
(0.5% Triton-X in PBS) for 30 minutes. After removing the solution, each well was washed 
with PBS and 200 μl of blocking solution (1% PBSA in PBS) was added to the system and 
incubated for an hour at room temperature. 10 μg/ml of mouse Polymeric immunoglobulin 
receptor (pIgR) antibody (R&D systems) was added to each well and incubated overnight at 
4°C while shaking. After 24h wells were washed with 200 μl of PBS for three times and left 
on the shaker for 5 minutes per wash. Then, wells were incubated with donkey anti-Goat IgG 
secondary antibody (Alexa Flour 594) for 2 hours. After incubation, wells were washed with 
PBS for three times and 20 μl of DAPI included mountant was added to each well. The wells 
were covered with coverslip and left for imaging after 24-48 hours. The images were 
captured by confocal laser scanning microscope. 
Functionality experiments 
Fluorescein isothiocyanate dextran (FITC-DEX) experiment 
1 mg/ml of FITC-DEX 4000 Da (Sigma) and FITC-DEX 40000 Da (Sigma) were 
added to each well. The wells were incubated in 37°C incubator for 2h and the media was 
removed afterwards. PBS was added to each well and incubated for 5 minutes before removing 
the PBS. These washing steps were performed 3 times. After all, images of colonoids from 
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each well were captured by confocal fluorescent microscopy (Olympus IX2) using bright field 
and DSU FITC channel. At least six colonoids were chosen for imaging in each group. Control 
wells without FITC-Dextran particles were used to adjust the brightness and contrast of the 
images. 
Transportation inhibition by Verapamil 
40 μM Verapamil hydrochloride (Across organics) was added to the wells and 1 μM of 
Rhodamine123 (Rhod123) (Sigma) was added to the wells. Some wells were just treated with 
1 μM (Rhod123) as the positive control. Wells were incubated in 37°C incubator and were 
imaged by confocal fluorescent microscopy (Olympus IX2) using bright field and DSU GFP 
channel at 0h, 3h, 6h and 24h after incubation. Seven to nine colonoids were chosen for 
imaging in each group. Control wells with neither dye nor verapamil were imaged to adjust the 
brightness and contrast. 
Cystic fibrosis transmembrane conductance regulator (CFTR) assay 
Two days after passage, 10 μM Forskolin (Tocris Bioscience) was added to the culture 
media of the cells. As a negative control the same amount of Dimethyl sulfoxide (DMSO) was 
added to some wells. Images were taken by Leica DMi1 inverted microscope and 10X 
magnification before treatment and after 1h, 4h and 24h of incubation. At least 9 colonoids 
were studied for this experiment. The area of the colonoids were calculated using Image J 
software and compared to the area of the control samples.  
Results 
Colonoids isolation was followed by adding different culture media to the cells to 
optimize the appropriate media for colonoid culture. Adding murine culture media and 
conditioned media are shown in Figure 4.1. Colonoids could not proliferate and the haziness 
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of the edges of colonoids showed that neither of the media could provide enough support for 
colonoid growth even for one day.  
 
Figure 4.1 Colonoid growth for 3 days under murine culture media and conditioned media. 
None of the culture media improved colonoid proliferation and differentiation. Scale bars 
represent 500 μm and the magnification is 5X. 
CMGF+ culture media was tested as the next candidate. Cells have been shown to grow 
with in a sphere structure until day 2 (Figure 4.2) but they could not differentiate into colonoids 
and they started apoptosis after day 4. However, using CMGF+, colonoids showed much better 
proliferation and differentiation compared to colonoid’s growth using the other two media. In 
Figure 4.2, the black accumulation of the cells can be observed at day 7 and it seems that 
colonoids could no maintain their healthy structure and proliferation rate after 4 days. 
In order to improve proliferation and give the colonoids more space to grow, gel was 
broken, and more gel was added to the cell suspension (cleaning). As it can be observed in 
Figure 4.3, cleaning did not help with colonoids growth and colonoids started to apoptosis even 
after 2 days.  
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The other parameter to improve the colonoids health was changing the passaging 
techniques. Different passaging techniques were used to obtain healthier colonoids as it is 
shown in Table 4.1.  Time of incubation, Dilution and different size of pipette tips were the 
three different defined elements. By changing each of those, one of the passage parameters 
were evaluated. Physical dissociation of colonoids’ tight junction by vortexing and harsh 
pipetting were the first method. As another physical parameter, pipette tips were changed to 
smaller ones to provide less surface area and more pressure to the cells. 
 
Figure 4.2 Colonoid growth for 3 days under Complete media with growth factor (CMGF+). 
Colonoids grew significantly for 4 days and stopped growing afterwards due to the lack of 
nutrients in media. Scale bars represent 500 μm and the magnification is 5X. 
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Using TrypleEEM express with different incubation times added a chemical element to 
the system for breaking the colonoids into smaller crypts. As the TrypleEEM express can be 
harsh to the system, a ½ dilution of that was used as a third parameter to the system. 
 
Figure 4.3 Colonoid growth for 2 days under Complete media with growth factor (CMGF+) 
after cleaning the gel. Scale bars represent 500 μm and the magnification is 5X. 
Based on Figure 4.4, none of the physical methods seems to show a good result in 
breaking the junctions and after 6 days of culture, the colonoids structure was just a black mass 
of dead cells. Unlike physical dissociation, it seems that chemical methods showed better 
results in breaking the structure and providing ready to grow colonoids. However, it seemed 
that by increasing the time of incubation in 37 °C, the breaking was severe and colonoids could 
not recover afterward. With 3 minutes incubation in TryplEEM express, more structures were 
preserved. Using lower concentration of TryplEEM express however was not as efficient as the 
higher concentration. 
Regarding Figure 4.4, although 3 min incubation with TryplEEM express sounded 
promising, there was not still enough proliferation and differentiation even after 6 days growth 
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and still a great number of dead colonoids were observed. Thus, another element was added to 
the system to improve the culture.  
Table 4.1 Passaging methods that were used in study 




Physical - - 1000 μl 
Physical - - 200 μl 
Chemical-TrypleE 3 min 1 X 1000 μl 
Chemical- TrypleE 5 min 1 X 1000 μl 
Chemical- TrypleE 7 min 1 X 1000 μl 
Chemical- TrypleE 10 min 1 X 1000 μl 
Chemical- TrypleE 5 min 0.5 X 1000 μl 
 
The culture media of the organoids were changed to 50% homogenate and 50% 
CMGF+. The images are shown in Figure 4.5. The colonoids grew significantly and 
proliferation and differentiation rate seemed normal. The colonoids after 8 days were fully 




Figure 4.4 Colonoids growth after passaging with different passaging techniques. The 
colonoids were grown for 6 days after passage. Chemical techniques could break the structure 
more efficiently. Scale bars represent 500 μm and the magnification is 5X. 
The colonoids were passaged afterwards and interestingly, it was shown that 
colonoids could grow healthily. Colonoids structure were maintained through different 
passages and colonoids were grew into a 3D structure. The colonoid’s proliferation and 
differentiation has been shown in Figure 4.6. 
 
Figure 4.5 Colonoids growth with 50/50 homogenate and Complete media with growth factor 
CMGF+) culture media. Acceptable colonoid structure was confirmed 8 days after the passage. 
Scale bars represent 200 μm and the magnification is 10X. 
The H&E staining of 129 ASF colonoids grown with 1:1 homogenate/CMGF+ has 
been shown in Figure 4.7 to check the colonoids structure. Colonoid structure looked like colon 
and it was completely different from organoid structure while organoid stimulated small 
intestine with their bud-like protrusions. Moreover, the structure of colonoid at different 
passages has been shown and the consistency of different passages were confirmed here. 
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Figure 4.6 Colonoids growth with 50/50 homogenate and Complete media with growth factor 
(CMGF+) culture media after 6 different passages. Full three-dimensional structure was 
observed and enough proliferation and differentiation were attained. Scale bars represent 200 
μm and the magnification is 10X. 
pIgR is responsible for mediating transcytosis of  polymeric immunoglobulins across 
the epithelial layer.(24) This receptor is expressed on the basolateral surface of epithelium and 
it expected to detect it on the outer surface of colonoids. As it is shown on Figure 4.8, this 
receptor is expressed on the outer layer of colonoids. DAPI (blue color) represented the 
epithelial cells of the colonoids and it was surrounded by a layer of pIgR.  
Functionality experiments 
In order to check the functionality and response of colonoids to external stimuli, several 
experiments were designed. In the first group of experiments, FITC-DEX particles (4kDa and 
40 kDa) were added to the media to check the infiltration of the tight junctions. Based on Figure 
4.9, neither 4 kDa nor 40 kDa particles diffused into the lumen via tight junction which was an 
indication of impermeability of tight junctions. 
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Figure 4.7 Hematoxylin and eosin staining of colonoid at first isolation, first and third passage, 
organoid and positive tissue of 129 ASF mice. Cultured colonoid simulate colic epithelium 
structure while organoid resembles small intestinal epithelium. Scale bars represent 50 μm and 
the magnification is 40X. 
Moreover, Rhod123 has been used in a different set of experiment to check the 
efficiency of P-glycoprotein transporters. As it is shown in Figure 4.10, Rhod123 Was 
transported from the basolateral side of colonoids to apical side and gradually accumulated 
inside the lumen of colonoids. This gradual increase happened in a timely manner as it is 
observed here, dye was more pronounced as time increases from 3 h to 24 h. Moreover, in 
order to check the connection of this transportation with P-glycoprotein transporters, verapamil 
was used in the system as an inhibitor of P-glycoprotein transporters. The result has been 
shown in Figure 4.11 and it confirms that the transported Rhod123 was significantly lower 
than what it was reported in Figure 4.10. Verapamil inhibited P-glycoprotein transporter and 
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as a result the green Rhod123 was less pronounced compared to the same experiment without 
verapamil. 
 
Figure 4.8 Confocal laser scanning microscopy of colonoids in order to check the mouse 
Polymeric immunoglobulin receptor (mpIgR) distribution. Blue represents DAPI and Red 
represents Alexa Flour 549. The merged image confirmed the expression of mpIgR on the 
basolateral side of colonoids. Scale bars represent 50 μm and the magnification is 40X. 
The next functionality data was performed using Forskolin as cyclic adenosine 
monophosphate (cAMP) agonist. This agonist is able to activate the cystic fibrosis 
transmembrane conductance regulator (CFTR) chloride channels in intestinal epithelial cells 
which causes colonoid swelling.(25) DMSO was added to some wells as the control. 
Comparing the samples with or without Forskolin treatment in Figure 4.12, the swelling of 
samples was clearly distinguishable. This figure confirms that CFTR was functional in 
colonoids. Moreover, the increase in colonoids surface area were calculated and plotted in 
Figure 4.13. Clearly, the bars related to forskolin-treated samples showed higher average 
compared to DMSO-treated samples in all the time points after pretreatment step. 
Discussion 
3D culture of intestinal organoids and colonoids as an experimental tool facilitated 
research on stem cell biology and intestinal structure. Moreover, it can be applied as an ex vivo 
disease model which accelerates the preliminary experiments with less complications.(9) 
Because of the need to have a comprehensive model that simulate intestinal structure, many 
research groups have focused on finding the best isolation method and culture conditions for 
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organoids and colonoids preservation. Organoids’ culture has already been established and 
because of the Paneth cells that are adjacent to stem cells in freshly isolated crypts and their 
ability to maintain the stem cells’ niche, there are not many complications in their culture.(3, 
11) However, there are many controversies in culture conditions of colonoids due to lack of 
Paneth cells in the colon crypt.(15-23) In this research we have tried to optimize the colonoid 
culture condition to have fully differentiated cells while maintaining stem cell niche. 
 
Figure 4.9 Bright field, DSU-FITC and merged images of 4 kDa and 40 kDa Fluorescein 
isothiocyanate dextran (FITC-DEX) particle interaction with colonoids using confocal 
fluorescent microscope within 2 hours. Lack of 4kDa FITC-DEX transportation inside the 
lumen confirms the integrity of tight junctions of colonoid epithelium. Green area indicates the 
presence of FITC-DEX particles. Scale bars represent 200 μm and the magnification is 10X. 
The first and most acceptable condition was adding exogenous Wnt to the murine small 
intestinal culture media (ENR).(18) As it was shown in Figure 4.1, colonoids could not survive 
even one day with this culture media. It was reported that colonoids cultured with this media 
can proliferate but, due to extra Wnt added to the system, high proliferation and lack of 
differentiation will be the result.(18) However, this was not the case with this experiment. 
There was no indication of growth after adding recombinant Wnt3A to the system. As a second 
strategy, the collected conditioned media with L-WRN cells was used. L-WRN cells are L cells 
that can secrete Wnt3a, R spondin 3, and Noggin in the conditioned media and the media 
collected from these cells have the elements necessary for colonoid growth.(26) Using this 
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media also did not show promising growth of colonoids (Figure 4.1). Colonoids were unable 
to survive after passage using this media. 
 
Figure 4.10 Bright field, DSU-FITC and merged images of 1 μM Rhodamine123 (Rhod123) 
infusion inside the lumen of colonoids in a timely manner using confocal fluorescent 
microscope within 24 hours. Rhod123 was transported into the lumen by the activation of P-
glycoprotein transporter 3h after the beginning of experiment and accumulation increased after 
24h. Green area indicates the presence of Rhod123. Scale bars represent 200 μm and the 
magnification is 10X. 
The next media that was chosen was CMGF+ media that was successfully used for 
canine colonoid culture.(25) Unlike the other two media, CMGF+ showed promising growth 
for the first four days (Figure 4.2) but, long term culture with this media was not achievable. 
Colonoids formed spheroids right after isolation and proliferated into larger structures but, 
differentiation was not achieved after that. In order to give colonoids more space to grow, the 
gel was disrupted, and more gel was added to colonoids pellet after centrifugation (Figure 4.3). 
Even after cleaning the gel and getting rid of apoptosis signal from dead cells, colonoids could 
not grow and started apoptosis three days after cleaning.  
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Figure 4.11 Bright field, DSU-FITC and merged images of Rhodamine123 (Rhod123) infusion 
inside the lumen of colonoids in a timely manner when 40 μM of verapamil was added to the 
system. The images were captured by confocal fluorescent microscope within 24 hours. 
Verapamil by inhibiting the P-glycoprotein activation significantly decreased the 
transportation of Rhod123 into the lumen of colonoids. Green area indicates the presence of 
Rhod123. Scale bars represent 200 μm and the magnification is 10X. 
This result brought up the idea that dead cells inside colonoid structure may send some 
apoptosis signal. This signal may cause colonoids to enter apoptosis phase. To correct this 
phenomenon, different passaging steps were tested to result in the lower number of unbroken 
structures. Two different passaging techniques were testified, physical and chemical 
passaging. In physical technique cells were broken by mechanical disruption while in chemical 
techniques, TrypLEEM Express was used as an enzyme to dissociate mammalian cells.  Table 
4.1 summarized the details of each method. Based on Figure 4.4 mechanical disruption could 
not effectively dissociate the colonoid structure. Neither fine pipette tips nor bigger ones could 
make enough pressure to break the structure into smaller crypts. However, chemical method 
showed better results. After growing colonoids passaged with different incubation time, the 
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lower incubation time (3 minutes) showed colonoids that had enough growth after 6 days. 
Colonoids were broken into crypts, not single cells. Thus, after 6 days, colonoids grew into 
differentiated structures while the maximum incubation time (10 minutes) resulted into 
accumulation of dead cells. Chemical passaging with TrypLEEM Express with 3 minutes 
incubation time was selected as the optimum method. Despite the obvious distinction between 
this groups compared to other groups, there was still some undifferentiated spheroids in Figure 
4.4 even after 6 days. It brought up the conclusion that appropriate culture media is more 
important than modifying passaging techniques. 
As mentioned before, the appropriate culture media for colonoids is the one that can 
mimic stem cells niche in colon tissue. Many researchers have tried to add something to the 
culture media that is already used for small intestinal organoids. As the source of growth factor 
secretion is not completely known yet, in this research we tried to use the exact same media 
the colonic stem cells encounter in colon tissue by making a homogenate of intestinal tissue 
and adding that to the cells. As homogenate includes all the secreted growth factors that are 
already presented in colon tissue, it can effectively create the niche for isolated stem cells. 
Figure 4.5 showed the colonoid structure after adding homogenate to the media in the 
first isolation. The colonoids showed appropriate proliferation at day 4 and made spheroids. 
After 8 days they reached their maximum differentiation with forming a 3D interwoven 
structure. Colonoids preserved their 3D and differentiated structure after multiple passages and 
they even showed a fully differentiated structure after 6 passages (Figure 4.6).  Structurally, 
colonoids are different from organoids as it is expected. Colon tissue has crypt structures which 
are separated by a flat epithelial surface while small intestine has crypts that are separated by 
finger shaped epithelium (villus). This is what was observed with H&E images in Figure 4.7 
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as well. Colonoids had similar structures to colon tissue and organoids showed similarity with 
small intestinal tissue. 
 
Figure 4.12 Colonoids treated with 10 μM Forskolin or Dimethyl sulfoxide (DMSO) over 24h. 
Scale bars represent 200 μm and the magnification is 10X. 7-9 colonoids from different wells 
were tested. 
One other factor to check the structural orientation of colonoids was checking the cell 
surface receptor expression. pIgR expresses on the basolateral surface of epithelium and is 
responsible for transcytosis polymeric immunoglobulins (pIg). Captured pIg by pIgR will be 
transferred from basolateral side to the apical surface. After reaching the apical surface, this 
extracellular section of pIgR will be cleaved and released into the lumen.(24) As it is shown in 
Figure 4.7, Alexa Flour 549 (red color) represents pIgR and it is located at the basolateral 
surface of colonoids. pIgR completely surrounded epithelial cells (DAPI, blue color) and 
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covered the whole area around the colonoids. This showed that colonoid structure was in 
accordance with what was expected. 
 
Figure 4.13 Size increase of colonoids treated with forskolin and Dimethyl sulfoxide (DMSO) 
in 24h. 7-9 colonoids from different wells were tested. 
Functionality experiments 
In order to make sure that the cultured colonoids had required functionality, three 
different experiments were designed. One of the main functionalities of intestinal tissue is 
absorbing nutrient while acting perm-selectively against microbes and toxins. Thus, intestinal 
layer forms a barrier that separates luminal contents including toxins, bacteria, viruses, and 
food allergens from internal fluid. This barrier is sealed by tight junctions (TJs) which 
transports nutrients with the high-capacity pore pathway or low-capacity leak pathway. The 
first pathway is mainly responsible for transporting ions and small molecules (Claudins), while 
the latter relates to transporting large uncharged macromolecules (Zonula Occludens (ZO-1 or 
Tjp1), Occludin (OCLN, Ocln), and Tricellulin (Marveld2)). Adherens junctions and 
desmosomes mostly take care of structural functions.(27) According to previous studies, 4 kDa 
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and 40 kDa FITC-DEX particles were tested to evaluate the leakiness of the tight junctions of 
colonoids.(27, 28) In normal colon the permeability to FITC-DEX should be negligible and if 
high concentration of FITC-DEX in blood serum was detected, the colon would be regarded 
as leaky.(29) In Figure 4.9, none of the probes (4 kDa and 40 kDa FITC-DEX) could permeate 
through the colonoids after 2 hours of incubation. It confirmed that there was no paracellular 
flux of probe and also the colonoids could maintain their epithelial integrity. This result was 
in line with what was previously observed.(30) 
As the second parameter to check the functionality, P-glycoprotein transporter were 
tested. P-glycoprotein is a transmembrane protein that regulates the transportation of lipophilic 
substrates, chemotherapeutic drugs and etc.(31) In intestine, P-glycoprotein is known as a 
secretory transporter because it effluxes drugs from enterocytes to the intestinal lumen.(32) P-
glycoprotein is regarded as an ATP-dependent efflux transporter and its expression on apical 
surface of enterocytes results in limiting influx of substrates into the cells (accumulation into 
the cells) and facilitating efflux from the cells.(33) Rhod123 is shown to be transported by P-
glycoprotein transporters.(30, 34, 35) Figure 4.10 showed that 1μM Rhod123 was transported 
by P-glycoprotein transporters and the dye was accumulated inside the lumen in a timely trend. 
The maximum dye content inside the lumen was observed at 24 hours.  
Moreover, there is a list of Drugs that Modulate the Functional Activity of P-
glycoprotein.(32) Verapamil is one of the drugs that can inhibit P-glycoprotein.(30, 32-35) 
With the same concentration of Rhod123 as in Figure 4.10, adding 40 μM of verapamil to the 
system in Figure 4.11 showed significantly less fluorescent. This figure confirmed that 
Rhod123 was transported by P-glycoprotein transporters and using verapamil modulated P-
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glycoprotein and inhibited transportation. This result showed that cultured colonoids simulated 
colon tissue in this functional assay. 
CFTR is the only member of the ABC transporters that acts as an ion channel.(36) 
CFTR is an anionic channel and the necessity of that is modulating fluid and electrolyte 
homeostasis at epithelial surface. Forskolin increases the amount of intracellular cyclic 
adenosine monophosphate (cAMP) and this will lead to the activation of CFTR. CFTR 
mediates the fluid secretion into the lumen. This method has been used as a functional readout 
of organoids.(37) Activation of CFTR by forskolin leads to swelling and volume increase in 
organoids and this forskolin-induced swelling (FIS) can be quantified.(38) In this study to 
testify the functionality of CFTR, 10 μM forskolin was added to each well. Significant FIS was 
observed in Figure 4.12 for colonoids treated with forskolin compared to control colonoids. 
Moreover, the surface area of the colonoids were compared in Figure 4.13 and the gradual 
increase in area for forskolin treated colonoids were maximum after 24 hours. This data 
showed that cultured colonoids were functional in terms of CFTR. 
To conclude, this study proposed a simple and cost-effective method for isolation and 
culture of colonoids. Intestinal homogenate was used as the prominent factor of culture media 
and the resultant colonoids showed acceptable structure with  proliferation and differentiation 
and similarity to colon tissue. Moreover, colonoids were completely functional after testing 
some of the functionality factors. Despite the promising results that this study showed, it is the 
first step for further studies. Cultured colonoids with this proposed method need to be evaluated 
more for colonic drug development and ex vivo biological studies in the future. Furthermore, 
making homogenate from small piece of human colonic biopsy is straightforward and it would 
be a perfect choice for human colonoid culture. 
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Abstract 
Inflammatory bowel disease (IBD) defines as a group of diseases that result in relapsing 
inflammation of gastrointestinal tract. Regenerative therapy is being developed as a treatment 
method for IBD. It is hypothesized that using organoids can contribute to the resolution of 
lesions characterized by the presence of differentiated stem cells that regenerated a new 
epithelial layer. In this study the dosage and duration of DSS treatment was optimized to 3% 
dextran sodium sulfate (DSS) for 5 days and 1.5% DSS for 2 days to obtain the best lesions in 
the distal colon. Colonoids were transplanted to the inflamed colon and the macroscopic 
appearance of the colon was monitored before and after implantation. Colonoids healed the 
inflammation and regenerate the epithelial tissue relying on colonoscopy images. Moreover, 
the role of interleukin (IL-10) on the regulation of inflammation was investigated using IL-10 
positive and negative colonoids. Mice treated with IL-10 positive colonoids showed to have 
smooth colon mucosa and healed lesion with the lowest tissue friability while mice treated 
with IL-10 negative colonoids showed high granularity and friability and the colon was not 
considered healthy. In the future more experiments need to be performed to quantitate IL-10 
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Introduction 
Inflammatory bowel disease (IBD) is a type of heterogeneous chronic inflammatory 
disorder that occurs due to immune system intervention and affects gastrointestinal tract.(1, 2) 
IBD is a relapsing and life-long inflammation that classifies into two subtypes, Crohn’s disease 
(CD) and ulcerative colitis (UC).(3, 4) Both of these two phenotypes are characterized by 
chronic inflammation in gastrointestinal tract, and recurrent cycles of relapse and remission. 
More than inflammation, they both cause dysregulated immune inflammatory responses.(4) 
UC causes continuous lesions and non-transmural inflammation on the colon mucosa while 
CD causes transmural and intermittent inflammation that can occur in any part of 
gastrointestinal tract. The symptoms for both subtypes includes abdominal pain, diarrhea, 
bloody stool, and malnutrition. (2) The pathogenesis of IBD is not well known but it has been 
related to genetic factors, environmental factors, changes in gut microbiota or immune 
response cells.(3, 4) Pharmacological, nutritional, and surgical therapy have been suggested to 
remit the symptoms, improve the malnutrition and prevent further complications and side 
effects.(2) 
One of the therapeutical method to induce healing is using cell transplantation. 
Intestinal pluripotent stem cells are able to proliferate and differentiate into different type of 
intestinal epithelial cells.(5, 6) Sato in 2009 developed intestinal organoid from G protein-
coupled receptor with leucine rich-extracellular domain (LGR5+) stem cells.(7) This long-
lived structure includes stem cells which will proliferate and maintain the stemness and also 
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differentiate into intestinal epithelial cells.(8) The intestinal stem cells (ISCs) presented in 
organoid structure has shown to heal the lesion area in inflammation site.(9) Moreover, fetal 
enterospheres (FEnS) have also been shown to induce regeneration of adult colonic 
epithelium.(10) ISCs that are grown in transplanted gastric organoids structure have also 
shown regeneration of stomach epithelium and ulcer repair in aged mice.(11) These studies 
suggest that colonic organoids (colonoids) are transplantable and promising results have been 
reported in terms of healing in IBD condition. 
Interleukin-10 (IL-10) deficient mice can be an appropriate model for IBD. Cytokines 
are messengers of immune systems to convey paracrine and autocrine signaling.(12) IL-10 is 
an anti-inflammatory cytokine that was first assumed to be a cytokine synthesis inhibitory 
factor (CSIF) secreted by Th2 T cells and inhibits production of cytokines from Th1 cells. Now 
it has shown that IL-10 can be expressed by different immune cells including macrophages, 
monocytes, dendritic cells (DCs), mast cells, eosinophils, neutrophils, natural killer (NK) cells, 
CD4 + and CD8 + T cells, and B cells. IL-10 is a negative regulator of immune response and 
loss of IL-10 cytokine results in inflammatory diseases Specifically IBD.(13, 14) IL-10 
deficient mice has been shown to be susceptible to IBD.(15) As there are many efforts in 
defining a noninvasive marker for detection of inflammation, detection of IL-10 in IL-10 
Knock out (KO) mouse can be a superior choice. 
Researchers have tried to find noninvasive methods to lessen the number of animals 
that needed to be euthanized for in vivo studies. Franklin group have developed a noninvasive 
method to evaluate epithelial gene expression by  using reverse transcription polymerase chain 
reaction (RT-PCR) and quantitative PCR (q-PCR) of fecal samples.(16-18) One of the other 
noninvasive methods is colonoscopy. Colonoscopy is one of the best methods for evaluation, 
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screening and treating the disease in colon.(19) In the past, direct examination of mouse colon 
was impossible and indirect methods such as weight loss and food or water uptake were the 
only measurements which were inaccurate for some cases. By developing mouse colonoscopy, 
accurate imaging of colon and grading of the disease specifically in case of IBD with minimal 
damage to the animal tissue became possible.(20) 
In this research, the effect of IL-10 on inflammation were studied by transplanting IL-
10 positive colonoid into the colon of IL-10 knockout (KO) mice. IL-10 was measured as the 
biomarker of inflammation to assure the colonoid implantation non-invasively. Other 
noninvasive methods were also proposed to track the transplantation and healing. Moreover, 
effect of proliferation and differentiation of stem cells in colonoid structure on healing were 
studied. Colonoscopy was performed as a noninvasive method before and after implantation 
to monitor the mucosal inflammation and healing after transplantation.    
Materials and methods 
Mice  
Interleukin-10 knockout mice were housed and bred at Iowa State University for this 
experiment. The mice had 129 altered Schaedler flora (ASF) background were used. All animal 
procedures were conducted with the approval of the Iowa State University Institutional Animal 
Care and Use Committee under IACUC-19-166 protocol. All methods and procedures in the 
experiments were performed in full compliance with the committee's guidelines and 
regulations.  
Inflammation 
To induce inflammation in colon and have an experimental model of IBD, mice were 
fed with dextran sodium sulfate (DSS). To optimize the DSS content in order to get enough 
distal colon lesions, 1.5%, 3% , and 5% DSS in water (wt/vol) solution were prepared and 
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provided to mice for 3 or 5 days (higher concentration) and 2, 4, 6 or 8 days (lower 
concentration). The mice were euthanized at the indicated time point. 
For the final colonoscopy experiment, Male and female mice with the age of 6 months 
to 18 months were chosen. 22 IL-10 KO 129 ASF were used and four groups of treatments 
were designed as in Table 5.1. Mice were either fed formula containing DSS or Regular water 
(Control). The control group were fed with Regular water for the whole experiment. The DSS 
treated groups were fed with 3% DSS for 5 days and 1.5% DSS for two more days (Total of 7 
treatment days). Four mice were used as the control and 6 mice were placed in different cages 
for each treatment group. After 7 days of inflammation, mice were ready for colonoscopy and 
colonoid treatment. 









Ctrl 4 Regular water Regular Water No 
Group 1 6 3% DSS for days 0-5 1.5% DSS for days 5-7 No 
Group 2 6 3% DSS for days 0-5 1.5% DSS for days 5-7 129 ASF colonoid 
Group 3 6 3% DSS for days 0-5 1.5% DSS for days 5-7 IL-10 KO colonoid 
 
Colonoid isolation 
Colonoids were isolated from either 129 ASF mice or IL-10 KO 129 ASF mice donated 
by the College of Veterinary Medicine of Iowa State University. All animal procedures were 
conducted with the approval of the Iowa State University Institutional Animal Care and Use 
Committee under IACUC-19-166 protocol. All methods and procedures in the experiments 
were performed in full compliance with the committee's guidelines and regulations. The colon 
of each mouse was cut horizontally and vertically into small pieces and washed with ice-cold 
PBS several times. After several washing steps, the upper PBS was removed and 30 mL of 
164 
Ethylenediaminetetraacetic acid (EDTA) was added to the system. The suspension was left on 
ice while shaking for 30 minutes. After removing EDTA solution from the system and rinsing 
tissue pieces with ice cold PBS, new PBS was added to the system and the suspension was 
pipetted up and down several times to achieve the final solution. The final solution was filtered 
and centrifuged for 5 min at 1400 rpm and 4°C. The final crypts were appeared as a pellet. 
Extracted crypts were suspended with Matrigel and applied on a pre-warmed 24-well plate. 
Colonoscopy 
After 7 days of DSS treatment, mice were ready for colonoscopy. Mice feed were 
pulled the night before the colonoscopy experiment. Ketamine/Xylazine mixture was used as 
the anesthetic. 80 μL of mixture (0.6 ml of ketamine (100 mg/mL) and 0.4 ml of xylazine (2 
mg/mL added to 4 ml of sterile isotonic saline) per 10 g body weight. Almost 200 μl of the 
mixture was injected to each mouse. Mice colons were rinsed with PBS enema before the start 
of the experiment. Colonoscopy was run and images were captured. The experimental 
endoscopy setup, “Coloview system”, consisted of a miniature endoscope (scope 1.9 mm outer 
diameter), a xenon light source, a triple chip camera, and an infusion port for administration of 
saline (all from Karl Storz, Tuttlingen, Germany) to achieve lens cleansing and distention of 
the mouse colon. The endoscopic procedure was viewed on a color monitor and digitally 
recorded via the Storz processor. After the first colonoscopy, treatments were infused into the 
colon while mice were kept on a 45° Angle surface for 10 minutes to overcome loss of 
colonoids due to gravity. The mice tales were fastened by band aid on the surface to avoid any 
damages to mouse skin. After finishing each colonoscopy, mice were kept warm at 37°C on a 
warmer and wait for them to wake up before leaving the barn. Feed and regular water were 
added to each cage after experiment 
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Colonoid enema 
129 ASF and IL-10 KO colonoids were isolated and cultured for 5 days in 1:1 Complete 
media with growth factor (CMGF+) and intestinal homogenate. CMGF+ includes CMGF- (1X 
Advanced DMEM/F12 (Gibco), 2mM Glutamax (Fisher), 10mM HEPES (Fisher), and 
100ug/ml Primocin (InvivoGen)), 1X N2 Supplement (Fisher), 1X B27 supplement (Fisher), 
1 mM N-acetylcysteine (Sigma-Aldrich),  50 ng/mL  EGF  (PeproTech),  100 ng/mL Noggin 
(PeproTech), 500 ng/mL R-spondin-1 (Pepro-Tech), 100 ng/mL Wnt 3a (PeproTech), 10 nM 
Gastrin(Sigma-Aldrich), 10 mM Nicotinamide (Sigma-Aldrich), 5mM A83-01 (TGFβtype I 
receptor inhibitor; Tocris), 50μM SB202190 (P38 inhibitor; Sigma-Aldrich), and 8% FBS  
(Atlanta  Biologicals),  supplemented  with  10μMrho-associated kinase inhibitor (ROCKi) Y-
27632 (Stem-Gent) and 2.5μM glycogen synthase kinase 3β (GSK3β) inhibitor CHIR99021 
(StemGent).  
For making homogenate, small intestine and colon of different mice strains were 
isolated after mice euthanization. Tissues were cut horizontally and washed with ice cold PBS 
three times and cut into small pieces. Basal media was added to the tissue with 1:20 W/V ratio 
and were homogenized with omni blender (OMNI TH (OMNI International)) for 2 minutes. 
The solution was then centrifuged at 4°C and 10000 rpm (15334 rcf) for 30 minutes. The 
supernatant was then sucked up and transferred to a new tube. 10% FBS was added to the 
solution and the solution was filter sterilized with 2.2 μm filter. The solution was frozen at -
20°C until utilization. 
After 5 days, Dome of Matrigel was broken by adding 1 ml of Basal media (1X 
Advanced DMEM/F12, 2mM Glutamax, 10mM HEPES, and 1X Penstrep (Gibco)) to each 
well. The media were collected in a tube and centrifuged at 4°C and 200 rcf for 5 minutes. 
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Each pellet was suspended in 200 μl of new PBS and kept on ice. 1200 colonoids were 
collected for each mouse. 
Making swiss roles and fixation for histopathology 
Mice were sacrificed in CO2 kill box after experiment. For making swiss roles, the 
colon was collected and cut vertically. It was rinsed in PBS and rolled around a cotton tip stick 
(Starting from cecum to rectum and mucosa was the inner part). The rolled tissue was then 
removed from the stick gently and transferred to histology cassettes. For histopathology (H&E) 
and immunohistochemistry (IHC), cassettes were incubated in 10% formalin (Fisher) for 24h 
and then stored in 70% ethanol. Fixed tissues and enteroids were embedded in paraffin blocks 
and were cut into slides. Image were captured by optical microscopy (Olympus BX40). 
Occult blood detection 
To track the severity of inflammation, the occult blood in fecal samples were analyzed. 
Each mouse was kept separately in a sterilized fecal bag for 5-15 minutes and feces were 
collected afterwards. Occult blood was detected by ColoScreen® kit from Helena 
Laboratories. Feces were homogenized with nano-pure water and using the applicator a thin 
smear of fecal material was applied on ColoScreen® slide Box A and B to maintain the 
repeatability. The specimens were left at room temperature to air dry. Two drops of 
ColoScreen® Developer was added to back of the slide and results were read after 30 seconds. 
Traces of blue color was considered as a sign of occult blood.  
Results 
Optimization 
To get the maximum colitis in distal colon, a longer treatment with lower concentration 
of DSS was proposed. In the first round of pilot study, four different groups were evaluated to 
determine the optimum concentration of DSS. Control group (no DSS treatment), 3% DSS 
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treatment for 3 days and 0% DSS afterwards for 4, 6, or 8 days, 3% DSS treatment for 3 days 
and 1.5% DSS afterwards for 4, 6, or 8 days, and 5% DSS treatment for 3 days and 0% DSS 
afterwards for 4, 6, or 8 days. Figure 5.1 showed the weight loss of each group.  Blue curve 
represents control group in each figure. Comparing Figure 5.1 A, B and C showed that weight 
loss was not significant in A while the most loss was observed in C. In order to check for blood 
presented in fecal samples, occult blood in fecal samples was tested (Figure 5.2). Before day 
7, no occult blood has been observed in samples. At day 7, some traces of occult blood were 
detected in Figure 5.2 C for 3% DSS for 3 days and 1.5% DSS afterwards mice. The detection 
of occult blood was not homogenously observed in all samples. At day 11 (Figure 5.2 E), occult 
blood is consistent in fecal samples of mice treated with either 3% DSS for 3 days and 1.5% 
DSS afterwards or 5% DSS for 3 days and 0% DSS afterwards. These two groups showed the 
most blood in their stool. 
One of the other deciding factors in optimizing the colon lesion is the decrease in colon 
length that is correlated with increasing inflammation. The data in Figure 5.3 showed that 
having 0% DSS treatment after treating mice with 3% DSS for 3 days, did not affect the colon 
length. Having 1.5% DSS after feeding mice with 3% DSS for 3 days showed some decrease 
in length compared to control sample and having 5% DSS just for 3 days even without any 
further DSS had effects on decreasing the colon length. 
The images of colons after necropsy has shown in Figure 5.4. Compared to control 
mice, most of the DSS treated mice had shorter colons. Moreover, the colons got less 
transparent (i.e., edematous) while mice were exposed to DSS. Having 1.5% DSS treatment 
after the first high concentration treatment (3% DSS) showed higher inflammation and as a 




Figure 5.1 Body weight loss by mice treated with DSS - optimization study. A) 3% DSS for 3 
days and 0% DSS afterwards. B) 3% DSS for 3 days and 1.5% DSS afterwards. C) 5% DSS 
for 3 days and 0% DSS afterwards. Each group includes three mice. 
Mice treated with 5% DSS showed more severe indicators. The colon length was 
comparably shorter that other groups that was confirmed in Figure 5.3 C as well. The ones 
that lived for 11 days in this group showed blood in colon (Figure 5.4 C, lower right) and 
their cecum was bloody as well.  Moreover, the size of cecum in this group is smaller than 
what is seen in Control mice (Figure 5.4 C, Upper left) Based on the results in this study, it 
was concluded that higher concentration of DSS acts severely inflammation wise. Although 
there was not enough blood in feces and the weight loss was not considerable, still 5% DSS 
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was chosen but for longer times. However, the mice could not survive this condition and they 
died before continuing the rest of the experiments (Data no shown here) 
Thus, it was concluded that 3% DSS followed by 1.5% DSS was the maximum dose 
that could be tolerated. However, the 3% DSS treatment could be longer. In a new set of 
experiment, mice were fed with 3% DSS for minimum of 5 days followed by 1.5% DSS for 2 
days and 4 days.  Figure 5.5 showed the considerable weight loss after 5 days 3% DSS 
treatment and the weight continued to decrease after 1.5% DSS treatment for 2 and 4 days.  
Detecting blood in mouse feces (Figure 5.6) confirmed that after 3 days, inflammation 
started to occur, and occult blood was detected, and it got more pronounced by day5. 
Decreasing the dose to 1.5% DSS still showed bloody fecal samples and confirmed that the 
lesions were not healed. The chance of mice survival for 9 days with DSS treatment was lower 
and the bloody feces confirmed it. In order to have better understanding of the structure, H&E 
images after 5 days, 7 days, and 9 days were captured. As shown in Figure 5.7, distal colon of 
mice has been affected. Tubes of crypts have been completely disrupted and lesion area have 
been formed. Disorganization of the structure that has been detected in Figure 5.7 was 
completely correlated with the inflammation due to DSS administration. Comparing the mice 
treated with 1.5% DSS after 3% DSS for 5 days, red blood cells were observed in their 
structure. Two days treatment with 1.5% DSS after 5 days of treatment with 3% DSS gave 
mice more chance of survival with enough distal colon lesions compared to four days of 1.5% 









Figure 5.2 Occult blood test from fecal samples using ColoScreen® kit for DSS optimization 
at A) Day 0 B) Day 3 C) Day 7 D) Day 9 E) Day 11. Blue boxes indicate samples that showed 
occult blood. 
Colonoscopy experiments 
Different groups in this experiment were shown in Table 5.1. Figure 5.8 has shown the 
mice weight that were recorded for 21 days in each group. DSS treated groups showed a weight 
loss at day 5 and the mice weight continued to decrease until day 7 which granted the maximum 
inflammation and provided some lesions for the rest of the experiments. Moreover, the occult 
blood test (Figure 5.9) showed that most of the mice had traces of blood (Blue color) in their 





Figure 5.3 Assessment of colon length after exposure to varying regimen of DSS treatment - 
optimization study. A) 3% DSS for 3 days and 0% DSS afterwards. B) 3% DSS for 3 days and 
1.5% DSS afterwards. C) 5% DSS for 3 days and 0% DSS afterwards. Each group includes 
three mice. 
At day 7, the colonoids were infused inside the colon after colonoscopy. Basal media 
was infused into the colon of control group and group 2. The images of colonoids at day 5 after 
isolation has been presented in Figure 5.10. The colonoids were not fully differentiated and 
mostly contained stem cells and proliferative cells. After colonoid infusion, mice were moved 
to their cages and weight for 14 more days before next round of colonoscopy. The mice weight 
showed ups and downs in this period of time and did not follow a specific trend but, for almost 
all groups, mice weight increased after 21 days compared to day 7 (Figure 5.8). Unfortunately, 
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some male mice could not survive the inflammation and they have been affected more 
seriously compared to female mice and died quickly after the experiment. 
In order to evaluate the healing at day 13 and 20, occult blood test was performed one 
more time and was shown in Figure 5.11. At day 13, only one of the mice in group 3 showed 
some blood in the stool which seems that healing was not efficient until day 13 for group 3. 
However, at day 20, no blood was detected in DSS treated groups and it confirmed that the 
healing was partly efficient for most groups with or without colonoids. 
The colonoscopy images at day 7 and 21 was recorded and Figure 5.12 represented 
these images. Significant improvement in healing has been observed for samples treated with 
colonoids. Specifically adding 129 ASF colonoids to the mouse colon had a substantial effect 
on healing the colon structure. Friability, Erosion and Granularity has resolved in Group 2 and 
the lesion score has decreased from 3.16 at day-7 to 0.5 at day-21 (Table 5.2). Bleeding was 
minimal in Group 2 and lowest friability and granularity was observed with some mice in 
group 2. The final score of group 2 was similar to control group in table 5.2 which confirmed 
that lesions are mostly healed.  
However, lesions were clearly observed in group 1 after 21 days (Figure 5.12 B) and 
the score of 1.5 in table 5.2 was an indicator of that. Group 3 also showed a high score which 
was mostly due to the high score of granularities. Treatment with IL-10 KO seamed to decrease 







Figure 5.4 Macroscopic appearance of the colon of mice treated with varying DSS treatment 
regimen - Optimization studies. A) 3% DSS for 3 days and 0% DSS afterwards. B) 3% DSS 
for 3 days and 1.5% DSS afterwards. Lack of feces is observable 9 days post treatment. 
Shortening of the length is detectable 11 days post treatment. C) 5% DSS for 3 days and 0% 
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DSS afterwards. Bleeding in colon is detectable 11 days post treatment. Shortening of the 
length is detectable 9 days post treatment. Each group includes three mice. 
Colon length and appearance were shown in Figure 5.13. Control mice have slightly 
longer colons compared to DSS treated samples. Colonoid treated samples had longer colons 
compared to untreated mice and the fecal pellets looked normal while the untreated mice 
showed signs of blood in colon and cecum which showed low healing.   
 
Figure 5.5 Assessment of weight loss of mice exposed varying treatment regimen of DSS. 
Mice showed weight loss after 7- and 9-days post treatment. Each group includes three mice. 
Discussion 
 IBD results in relapsing inflammation in any part of gastrointestinal tract.(3) Different 
methods of treatments have been suggested(2) and one of which is regenerative therapy using 
cells. Intestinal stem cells with their ability to self-renewal and multi-potent differentiation 
seems to be a  good choice.(21) Sato developed organoid structure from small intestinal crypts 
by simulating the niche of the stem cells.(7) Organoids contain stem cells that proliferate and 
finally differentiate into epithelial cells.(22) These cells seem to be a perfect choice for 
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regeneration of lesions in the case of IBD. Researchers have used colonoids as a transplant in 
case of IBD before and enough coverage and adherence of colonoids to the damaged tissue 
was observed.(9) Transplantation of Fetal Enterospheres (FEnS), that was isolated from mouse 
fetal intestine and cultured in vitro, has shown to regenerate injured colonic epithelium by 
forming crypt-like structure and some signs of differentiation.(10) Gastric organoids in a 
different study has also shown promising regeneration of gastric epithelium.(11) These studies 
suggest that colonoids can be an ideal choice for transplantation. As IL-10 deficient mice was 
shown to be an IBD mouse model(15),  it seems that IL-10 is necessary to inhibit inflammation 
and this cytokine may be necessary for healing the inflamed region. In order to test this 
hypothesis, this research has focused on transplanting colonoids isolated from IL-10 
expressing mice to the inflamed region of IL-10 KO mice and evaluate the healing process. 
Moreover, to assess the effect of stem cells in colonoids without considering IL-10, colonoids 
isolated from IL-10 KO mice has also transplanted as a different group. 
 
Figure 5.6 Occult blood test from fecal samples using ColoScreen® kit for mice treated with 
3% DSS for 5 days and 1.5% DSS afterwards. The bleeding was severe after Day 7 and the 
chance of mice survival was lower. Blue boxes indicate samples that showed occult blood. 
IL-10 KO mice with 129 ASF background was selected. ASF is a model community 
including eight bacterial species isolated from mouse gut. IL-10 KO (IL-10(−/−)) mice lack IL-
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10 and can readily develop inflammation.(23) In order to develop inflammation DSS was fed 
in drinking water. DSS is considered to be toxic to the epithelial cells of basal crypts and 
damages epithelial barrier. This barrier injury results in exposing mucosal and submucosal 
immune cells to luminal antigens and results in rapid and intense inflammatory response.(24, 
25) As the transplantation aim was 2-3 cm from the rectum in distal colon, the DSS dosage 
and duration needed to be optimized. Literature have used different dosage and duration of 
DSS but, mostly used 3% to 5%.(26-29) In the optimization experiment it was shown that 
feeding mice for 3 days with water containing 3% DSS did not develop enough inflammation. 
Weight loss of the mice were minimal (even after 11 days) and the colon length (Figure 5.3 A) 
was not changed significantly compared to the control group. Mice started healing the minimal 
damage and the weight loss was compensated (Figure 5.1 A). No blood was observed in the 
fecal sample (Figure 5.2) and it seems that the epithelial layer was intact. Thus the 3% DSS 
for 3 days was excluded from the options.  
 
Figure 5.7 Hematoxylin and Eosin staining of IL-10 KO mice colon treated with A) 3% DSS 
for 5 days B) 3% DSS for 5 days and 1.5% DSS treatment for 2 days afterwards C) 3% DSS 
for 5 days and 1.5% DSS for 4 days afterwards. Tubes of crypts have disrupted after treatment 
and lesion areas are visible. Red blood cells are detectable in B and C. Complete 
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disorganization of the structure and thus lower chance of mice survival is shown in C.  The 
magnification of upper images is 10X and scale bars represent 200 μm. The magnification of 
upper images is 40X and scale bars represent 50 μm. Each group includes three mice. 
3% DSS for 3 days followed by 1.5% DSS seemed to develop more inflammation. The 
weight loss was more significant, and the colon length decreased compared to the control 
sample. (Figure 5.1 B and Figure 5.3 B) Occult blood was observed (Figure 5.2) which was a 
sign of epithelial lesion. Moreover, 5% DSS for 3 days also showed a higher weight loss 
compared to the latter group even when mice were fed just for 3 days. (Figure 5.1 C). Colon 
length decreased significantly (Figure 5.3 C) and blood was observed in feces after 11 days 
(Figure 5.2 E). Comparing the appearance of colon from different samples in Figure 5.4, by 
increasing the dosage of DSS and duration of treatment, colons got shorter and less transparent. 
Colons are thicker and fecal pellets were not formed in distal colon, especially for mice treated 
with 1.5 % DSS after the initial 3% and mice treated with 5% DSS (Figure 5.4 C, D). 5% DSS 
after 11 days showed considerable blood in colon and cecum and cecum of the mice were 
comparably smaller than control (this happened in all DSS treated mice but, still less than what 
was observed in 5% DSS) (Figure 5.4 D). This confirmed that inflammation in the colon of 
mice treated with 5% DSS was probably irreversible and considerable weight loss confirmed 
this hypothesis. Thus, 3% DSS followed by 1.5% DSS was selected as the gold optimization. 
However, the number of days that mice were treated with 3% DSS was not enough for getting 
distal colon lesion and high weight loss. Hence, the duration of treatment with 3% DSS was 





Figure 5.8 Mice weight over 21 days. Each group contains 4-6 mice. Control group was 
treated with regular water. Group 1 was treated with 3% DSS for 5 days followed by 1.5% 
DSS for two days. Group 2 was treated with 3% DSS for 5 days followed by 1.5% DSS for 
two days and 129 WT ASF colonoid was infused in distal colon at day 7. Group 3 treated 
with 3% DSS for 5 days followed by 1.5% DSS for two days and 129 IL-10 KO colonoid 
was infused in distal colon at day 7. 
Significant weight loss of the mice treated with 3% DSS started after day 4-5 (Figure 
5.5) and the dose of DSS decreased to 1.5% to prevent excessive inflammation. The experiment 
ran for 2 and 4 days after decreasing the dosage and the trend of weight loss observed even 
after that. Blood was detected in fecal samples of the mice after day 3 and at day 5 and 7 
(Figure 5.6) that confirmed inflammation.  H&E images of distal colon has been shown in 
Figure 5.7 and confirmed the lack of integrity in intestinal epithelium. The tubular structure of 
colon was completely disrupted, and lesions was observed in epithelial structure. Longer 
duration of DSS treatment (for 7 and 9 days) even showed red blood cells in the epithelial 
structure. The loss of surface epithelium and reaching epithelial defect to the underneath layer 
as well as cell infiltration underneath was a sign of colitis. The outside erosion of the colon 
tissue was evident in Figure 5.7. The changes reached deeper than the surface epithelial cell 
layer and altered all overall mucosal architecture. Considering all the results, 3% DSS for 5 
days followed by 1.5% DSS for 2 days develop enough lesion for colonoid engraftment.  
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Figure 5.9 Occult blood test from fecal samples using ColoScreen® kit at day 6 for A) Control 
B) Group 1 C) Group 2 D) Group 3. Group 1 was treated with 3% DSS for 5 days followed by 
1.5% DSS for two days. Group 2 was treated with 3% DSS for 5 days followed by 1.5% DSS 
for two days and 129 WT ASF colonoid was infused in distal colon at day 7. Group 3 treated 
with 3% DSS for 5 days followed by 1.5% DSS for two days and 129 IL-10 KO colonoid was 
infused in distal colon at day 7. Blue boxes indicate samples that showed occult blood. 
Using optimized dosage and duration of DSS treatment, colonoscopy and colonoid 
transplantation experiment started. The weight loss at day 7 and traces of occult blood in their 
feces were the detected signs of inflammation and lesion formation before colonoid 
engraftment (Figure 5.8 and Figure 5.9). Colonoids were deliberately collected and infused at 
day 5 after isolation (Figure 5.10). colonoids were used at early stages as the stem cells are 
necessary component for healing. Stem cells are proliferating at early stages and self-renew 
themselves. As it is shown in Figure 5.10, colonoids formed spheroids and did not have more 
time to differentiate into epithelial cells and form the inter woven structure. Thus, it mainly is 
a sphere full of stem cells and it is expected to engraft to injured epithelium after transplantation 




Figure 5.10 Colonoids isolated from A)129 WT ASF B) IL-10 KO 129 ASF mice 5 days after 
isolation. The magnification is 5X and scale bars represent 500 μm. 
Before colonoid infusion, mice were monitored by colonoscopy at day 7 (Figure 5.12). 
Control mice have shown no trace of inflammation. The surface of epithelial layer was smooth, 
enough vascularization could be observed, and the tissue did not show friability. The detected 
score of inflammation was 0.25 from 12 (Table 5.2) and it was considered as no inflammation. 
Mice treated with DSS, all showed lesions and bleeding in epithelial layer. Group 2 and 3 
(Figure 5.12 C and D) both showed cobblestone structure instead of a smooth epithelial surface 
which showed granularity. Lesions and irregular vascularity were completely evident in Figure 
5.12 C and D. The tissue was friable and started bleeding when the scope probe entered the 
colon. The score of groups 2, 3 and 4 were all significantly more than control mice (Table 5.2). 
The colons were then ready for colonoid attachment. 
After colonoid infusion, the occult blood of mice feces were measured a week after the 
experiment and except for one mouse, blood was not detected in other mice’s feces which was 
a sign of healing (Figure 5.11 A, B, C, D). The mice weight was decreased right after 
colonoscopy which was because of cage moving to the colonoscopy room and environmental 
factors and it started to increase again while they stayed stable for a while (Figure 5.8). After 
21 days, none of the mice treated with DSS showed blood in their feces (Figure 5.11 F, G, H) 
but one of the control mice started to develop inflammation and blood was observed in its 
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feces. (Figure 5.11 E). It can be due to the strain of these mice (IL-10 KO) that are susceptible 
to inflammation and could easily develop signs of that.  
 
Figure 5.11 Occult blood test from fecal samples using ColoScreen® kit for A) Control at 
day 13 B) Group 1 at day 13 C) Group 2 at day 13 D) Group 3 at day 13 E) Control at day 20 
F) Group 1 at day 20 G) Group 2 at day 20 H) Group 3 at day 20. Control samples developed 
inflammation over time due to susceptibility of 129 IL-10 KO to inflammation (E). Healing 
takes time for samples that were treated with DSS (D). At the final stage of experiments none 
of the groups showed traces of occult blood in fecal samples (F, G, and H) Group 1 was 
treated with 3% DSS for 5 days followed by 1.5% DSS for two days. Group 2 was treated 
with 3% DSS for 5 days followed by 1.5% DSS for two days and 129 WT ASF colonoid was 
infused in distal colon at day 7. Group 3 treated with 3% DSS for 5 days followed by 1.5% 
DSS for two days and 129 IL-10 KO colonoid was infused in distal colon at day 7. Blue 
boxes indicate samples that showed occult blood. 
The second colonoscopy was performed 14 days after the colonoid infusion, at day 21. 
As can be observed in Figure 5.12, control samples still looked normal with a little more 
granularity compared to day 7. It confirmed the idea that colon of IL-10 KO mice is more prone 
to inflammation. The recorded colonoscopy score was 0.5. It was a little more than the control 
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score at day 7 but, it was still low in terms of inflammation. The DSS treated group without 
any colonoid infusion (group 1) still had signs of inflammation in the epithelial layer. High 
friability and erosion were reported for this tissue and the overall score was 1.5 that was 
considered high. In colonoscopy images, blood was visible, and it related to the high friability 
of the tissue. DSS treated group that had 129 ASF colonoid infusion, interestingly showed the 
highest degree of healing. Some healed regions have been captured in colonoscopy images. 
The epithelial surface was smooth with lowest granularity and friability. The vascular structure 
was completely normal, and bleeding was minimal. The recorded score was 0.5 that was 
similar to control group. Comparing group 1 and 2 showed that transplantation was successful, 
and regeneration of epithelial layer was satisfying.  
Figure 5.13 showed the colon structure after euthanasia and comparing different groups 
showed that there was not a high difference in the overall appearance of colon for different 
groups but in two out of four mice in group 1 (no colonoid) (Figure 5.13 B) showed short 
bloody colons that confirmed the importance of colonoid infusion in healing. 
To evaluate the effect of IL-10 on the healing, group 2 and 3 should be compared. In 
group 3 images, no bleeding was observed but granularity was maximum. The cobblestone 
structure could not be fixed, and smooth epithelial layer have not attained with this group. 
Moreover, friability and erosion scored high in this model and the overall score was 2.5 which 
was the highest. Comparing group 2 and 3 showed that IL-10 plays a significant role in healing 






Figure 5.12 Endoscopy images of mice colon before (day-7) and after (day-21) colonoid 
infusion A) Control B) Group 1 C) Group 2 D) Group 3. Group 1 was treated with 3% DSS 
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for 5 days followed by 1.5% DSS for two days. Group 2 was treated with 3% DSS for 5 days 
followed by 1.5% DSS for two days and 129 WT ASF colonoid was infused in distal colon at 
day 7. Group 3 treated with 3% DSS for 5 days followed by 1.5% DSS for two days and 129 
IL-10 KO colonoid was infused in distal colon at day 7. 
To conclude, this study worked on evaluation of colonoid transplantation with a focus 
of IL-10 on inflammation healing in IBD condition. In the first step, optimization of DSS 
dosage and duration for developing distal colon lesions showed that 3% DSS for 5 days 
followed by 2 days of 1.5% DSS treatment presented inflammation. Moreover, 
transplantation showed that colonoids regenerated epithelial damage and decreased the 
inflammation signs. Moreover, infusion of IL-10 positive colonoids into the colon of IL-10 
deficient mice, significantly healed the lesions after inflammation while healing was not 
observed for IL-10 negative colonoid transplantation. This research was the first step in 
developing this idea and to obtain more accurate results, quantitative data needs to be 
analyzed in the future. Measuring IL-10 expression in fecal samples using q-PCR and 







Table 5.2 Colon score after each colonoscopy. Mice colon were scored 0 (healty) to 3 (maximum of each factor). 4-6 mice were evaluated 
in each group and the scores are the average of total scores. Each criterion can score 0 (no trace) to 3 (high trace). Sum represents the 
total score of each group. 
Group Day-7 Day-21 
Blood Erosion Friability Granularity Sum Blood Erosion Friability Granularity Sum 
Control 0 0.25 0 0 0.25 0 0.25 0 0.25 0.5 
Group 1 0.167 1.167 0.833 0 2.167 0 1 0.5 0 1.5 
Group 2 0.167 1.167 1.167 0.667 3.167 0 0 0.25 0.25 0.5 
Group 3 0.833 1.5 1.167 1.333 4.833 0 0.75 0.5 1.25 2.5 
*Group 1 was treated with 3% DSS for 5 days followed by 1.5% DSS for two days.  
*Group 2 was treated with 3% DSS for 5 days followed by 1.5% DSS for two days and 129 WT ASF colonoid was infused in distal colon at day 7. 




Figure 5.13 Macroscopic appearance of the colon of mice - colonoscopy experiment. A) 
Control B) Group 1 C) Group 2 D) Group 3. Each group includes 4-6 mice. Shortening of 
colon length is detectable in B and bloody colon is a confirmation of inflammation. C and D 
showed comparably longer colon length. has Group 1 was treated with 3% DSS for 5 days 
followed by 1.5% DSS for two days. Group 2 was treated with 3% DSS for 5 days followed 
by 1.5% DSS for two days and 129 WT ASF colonoid was infused in distal colon at day 7. 
Group 3 treated with 3% DSS for 5 days followed by 1.5% DSS for two days and 129 IL-10 
KO colonoid was infused in distal colon at day 7. 
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 GENERAL CONCLUSION AND FUTURE PLAN 
In chapter 2 and 3 it was shown that nanoparticles containing active agents can be 
entrapped inside the organoids. It was first shown that negatively charged alginate coated 
PLGA nanoparticle containing RhodB with the size of around 250 nm, could not diffuse the 
Matrigel and get entrapped inside the organoid when they were added to the culture medium. 
Thus, PLGA nanoparticles were mixed with the combination of Matrigel and organoid. It was 
shown that nanoparticles could be absorbed inside the lumen of organoids after they were 
mixed with Matrigel and organoid suspension. Organoids started absorbing nanoparticles right 
after they were in contact and the maximum dye was detected 2-3 days after the first contact. 
It was shown that nanoparticles were desorbed from the lumen of organoids at day 4-5, the dye 
was not pronounced inside the lumen after that and finally disappeared. It was shown that 
nanoparticles did not impose any harmful effect on the growth rate of the organoids. The 
organoids had their normal growth rate with a high viability while in contact with 
nanoparticles. Thus, they can be a good candidate for drug delivery. 
Due to the affinity of epithelial cells to absorb positively charged nanoparticles, it was 
proposed that different particle charges may affect the particle absorption inside the lumen. 
Thus, nanoparticles coated with alginate and chitosan as negatively and positively charged 
nanoparticles were designed to check the effect of particle charge on nanoparticle absorption. 
The nanoparticles were mixed with Matrigel and organoid suspension and applied on the well 
plate afterward. It was shown that positively charged nanoparticles were highly absorbed inside 
the organoid lumen compared to the negatively charged particles. Moreover, none of the 
particles imposed any negative effect on the growth rate of the organoids. It was shown that 
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organoids grew healthy and the viability of the cells were high while in contact with alginate 
coated or chitosan coated nanoparticles. 
Based on the results that was observed, the next step was evaluating the effect of the 
system in vivo. The system needed to be used in mouse models to obtain the effect of the 
system on drug delivery as well as tissue regeneration. IBD mouse models needed to get 
involved and the ability of the system using IBD models needed to be evaluated. The system 
needed to be administered rectally via anus. Based on the literature(1), the organoid has the 
ability to target the inflamed area and regenerate the tissue. As the system is administered 
rectally, colon is in contact with organoids. Organoids cannot travel far enough to reach small 
intestine. As organoid is a representative of small intestine, after absorption in the colon, it will 
regenerate into the small intestine in colon tissue which is not an ideal treatment. Colon and 
small intestine have different functions. To avoid this phenomenon, we started culturing 
colonoids from 129 ASF mouse colons. Due to the lack of Paneth cells in the crypts of colon, 
colonoids do not have enough Wnt-3A to maintain the structure. In chapter 4, different reported 
media were tested and could not provide necessary elements for proliferation and 
differentiation. Intestinal homogenate including the host growth factors showed superior 
support for colonoids. Colonoids showed considerable levels of proliferation and 
differentiation while in contact with homogenate growth factors. Moreover, they could survive 
for more than 6 passages while still were functional. Checking the functionality of this system, 
it was observed that colonoids lack leakiness in their tight junctions, P-glycoprotein transporter 
was active and ion channel worked perfectly. Thus, an optimized and novel method of isolation 
and culture of colonoids were proposed in this chapter. 
193 
 
In vivo study using cultured colonoids were delineated in chapter 5. IL-10 KO mice 
model were selected as a susceptible model to induce IBD. Moreover, by infusion of IL-10 
positive and IL-10 negative colonoids to IL-10 KO mice, the effect of IL-10 on healing and 
regeneration were studied. Optimization of DSS in IL-10 KO mice to develop IBD was 
performed and mice treated with 3% DSS for 5 days and 1.5% DSS for 2 days showed distal 
colon lesion, blood in their feces and weight loss as the signs of IBD. Colonoscopy before and 
after colonoid infusion was the main method of detection. Colonoids indicated significant 
effect on tissue regeneration and healing. Friability, Granularity, bleeding, and erosion of 129 
ASF colonoid treated colons were minimized and comparable to control mice. However, 
infusion of IL-110 KO colonoids to IL-10 KO mice colon was not as successful. Level of 
granularity was high, and it was a sign of inflammation. DSS treated mice that were not infused 
with colonoids were shorter in length and showed high blood content in their cecum and colon. 
In conclusion, colonoids can regenerate the inflamed tissue with the aid of stem cells in their 
structure but, IL-10 had considerable effect in healing and repair of colon tissue and without 
IL-10 complete repair will not happen.  
Despite the promising results that were obtained in this study, there are still many steps 
missing that needs to be considered in future. First, colonoids that were developed in chapter 
4 needs to be characterized in detail via phenotypic and quantitative measurements. IHC for 
detecting different cell markers and q-PCR for determination of each marker expression and 
comparing those to colon tissue will be a huge step in characterizing colonoids. Moreover, IL-
10 has been introduced as a noninvasive marker to detect the inflammation and healing in 
tissue in chapter 5. Thus, IL-10 should be characterized in fecal samples of mice in different 
days and comparisons of different expression levels can provide a huge amount of data for 
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confirming the hypothesis in chapter 5. Furthermore, detection of IL-10 in necropsied tissue 
of IL-10 KO mice infused with 129 ASF colonoids by IHC can be as a massive confirmation 
to the story above. Finally, chapter 5 was the beginning of a huge step in determining the effect 
of colonoids in IBD healing. The next steps in far future will be performing methods in chapter 
2 and 3 with colonoids and using a combination of colonoids, nanoparticle and active agents 
in inflamed colon. 
 
 
